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In   recent   years   there   has   been   a   considerable   focus   on   the   development   of   subunit  
vaccines,  preferred  over  traditional  vaccines  for  reasons  of  safety  and  purity.  However,  
subunit   vaccines   are   less   immunogenic   than   attenuated   vaccines   and   need   therefor  
multiple  administrations  in  combination  with  immunostimulatory  adjuvants,  in  order  
to  induce  immunity.  The  sustained  release  of  a  vaccine  together  with  the  release  of  an  
adjuvant  is  a  potential  alternative  to  giving  multiple  doses.  The  aim  of  this  thesis  was  
to  manufacture   lipid   implants   for  vaccine  delivery  by   twin-­‐‑screw   (tsc)   extrusion  and  
evaluate  the  potency  of  these  lipid  systems  to  stimulate  an  immune  response  in  vivo.    
To   accomplish   this,   lipid   implants   consisting   of   cholesterol,   soybean   lecithin,   and  
Dynasan   114   (D114)   were   prepared.   Different   formulations  were   evaluated   for   their  
extrudability   before   adding   the   model   antigen   ovalbumin   (OVA)   and   the   adjuvant  
Quil-­‐‑A   (QA)   to   the   formulation.   Investigating   the   release  behaviour  of  OVA  and  QA  
showed   that  mainly   cholesterol   influences   the   release   behaviour   of   OVA,   increasing  
the   fraction  of  cholesterol  slows  down  the  release  of  OVA.  To  further  slow  down  the  
release  of  OVA  from  the  implants,  they  were  cured  at  different  temperature  resulting  
in   an   even   longer   OVA   release.   Furthermore,   the   addition   of   QA   to   the   implants  
influenced   the   release   behaviour   of   OVA   and   vice   versa.   The   investigation   of   the  
implant  polymorphism  after   the   extrusion  process   as  well   as  during   storage   showed  
good  stability.  To  combine  the  advantage  of  particulate  delivery  and  sustained  release,  
preformed   liposomes  were   incorporated   into   the   implants  prior   to   extrusion.   For   the  
analysis   of   the   immune   response,   two   sets   of   animal   experiments   in   mice   were  
performed,   one   evaluating   the   kinetics   of   the   release   of   the  model   antigen   in   vivo,   a  
second  one  to  evaluate  the  immune  response  in  vivo.  Evaluation  of  these  data  indicated  
a  correlation  between  the   in  vitro  and   in  vivo  release  behaviour  of  OVA.  Furthermore,  
immune   responses   similar   to   those   induced   by   two   booster   injections,   consisting   of  
OVA  and  alum  could  be   achieved  using   implant   formulations   containing  QA.  These  
results   further   emphasized   the   importance   of   adjuvant   in   the   formulation.   The  
incorporation  of  preformed  liposomes  into  the  implants  on  the  other  hand  did  not  lead  
to  an   improved  outcome.   In  a  second  part  of   this  work,  an   in  vivo   tumour  study  was  
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prepared,  using  the  TRP2  peptide  as  active  ingredient.  Due  to  the  use  of  this  expensive  
peptide,  a  transfer  to  a  different  extruder  was  necessary.  The  influence  that  a  change  of  
the  production  device  has  on   the   implants   characteristics  was   investigated.  Once   the  
formulation  was  adapted  to  the  new  extruder,  implants  containing  TRP2  and  QA  were  
produced.  The  in  vitro  release  of  TRP2  proved  to  be  very  slow,  much  different  from  the  
OVA  release.  Furthermore,  the  preparation  of  vesicular  phospholipid  gels  (VPGs)  as  an  
alternative  lipid  delivery  system  for  TRP2  was  investigated.  The  TRP2  release  from  the  
VPGs  was  also  slow  and  incomplete.  Both  formulations  were  used  in  an  in  vivo  tumour  
growth   study.   Mice   were   injected   with   B16F10luc2   melanoma   cells,   6   days   later  
formulations  were  administered.  VPGs  showed  adverse  reactions  in  the  mouse  and  are  
therefore   not   s   suitable   delivery   system.   TRP2   implants   showed   a   slow   delay   in   the  
start  of  tumour  growth,  but  were  not  more  potent  that  TRP2  in  PBS  injections  given  to  
the  mice.  The  very   slow   in   vitro   release  data  of  TRP2  brought  up   the  question  about  
interactions   between   the   lipid   implants   and   the   peptide   influencing   the   release.  
Choosing  peptides   of  different   size   and  hydropathy,   an   investigation  of   their   release  
behaviour  and  interaction  with  the  implants  was  conducted.    
In   conclusion,   lipid   implants   were   well   tolerated   and   offer   a   great   potential   as  
sustained   release   delivery   system   for   vaccines.   They   allow   releasing   the   active  
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1 General  Introduction  
1.1 Introduction  
The  world’s   first   vaccination  was   performed   by   Edward   Jenner   in   1796.   Vaccination  
represents   the   most   effective   approach   to   prevent   diseases   [1].   According   to   Louis  
Pasteur,  a  vaccine  is  defined  as  a  “suspension  of  live  (usually  attenuated)  or  inactivated  
microorganisms   (e.g.   viruses   or   bacteria)   or   fractions   thereof   administered   to   induce  
immunity  and  prevent  infectious  disease”  [2].  Spreading  of  infectious  diseases  such  as  
diphtheria,   measles,   mumps,   pertussis   and   smallpox   have   been   reduced   due   to   the  
development  of  safe  and  effective  vaccines  and  their  widespread  distribution  in  many  
countries.  Even  though  a  lot  of  vaccines  are  commercially  available,  vaccines  for  many  
diseases,  including  two  of  the  world´s  leading  killers,  Malaria  and  HIV,  remain  elusive  
[2,3].   In   addition,   there   is   an   increasing   awareness   that   vaccines   might   also   be  
considered  as  therapies  against  chronic  infections  or  cancer  [4].  Conventional  vaccines  
are  based  on  entire  live  attenuated  or  inactivated  pathogens,  or  their  inactivated  toxins,  
that  do  not  lead  to  an  infection,  but  are  capable  of  inducing  protective  immunity.  These  
vaccines   are   very   effective   in   terms   of   protection,   but   there   are   several   drawbacks  
arising   from   their   preparation.   On   the   one   hand,   there   are   safety   considerations,  
namely   the   difficulty   of   being   able   to   ensure   adequate   attenuation   or   killing   of   the  
pathogen   [5].  This  possible   risk   can  be  of  particular   consequences   in   the   case  of   fatal  
incurable   diseases   such   as   AIDS   [5].   Conventional   vaccines   can   additionally   induce  
vaccine  related  diseases   in  people  with   immune  deficiencies.  Between  1969  and  1982,  
94  cases  of  paralytic  poliomyelitis  were  reported  in  the  US  due  to  the  use  of  live,  oral  
polio   vaccines   [6,7].   Apart   from   safety   considerations,   it   is   sometimes   difficult   to  
prepare  sufficient  material  for  vaccine  production,  for  example  for  viruses  that  cannot  
be  cultivated   in  vitro.  Therefore,  new  approaches   for  vaccine  development,  not  based  
on  the  entire  organism,  are  being  considered.  
To   overcome   the   negative   side   effects   associated   with   the   use   of   whole  
microorganisms,   purified   antigens   instead   of   whole   pathogens   are   used   for  
vaccination.   The   identification   and   production   of   the   antigens   of   pathogens   able   to  





identification,   production,   isolation   and   characterization   of   relevant   antigens.   These  
non-­‐‑replicating  subunit  vaccines  are  based  on  the  targeted  delivery  of  specific  antigens  
(proteins,  peptides  or  DNA)   to   cells   of   the   immune   system   [8].  Even   though   subunit  
vaccines   are   safer,   they   pose   new   challenges,   because   the   immune   response   against  
purified  antigens  alone  is  often  insufficient  to  stimulate  protective  immunity  [6,9].  This  
is   because   subunit   antigens   do   not   provide   any   of   the   necessary   signals   to   activate  
innate   immunity   [8]   and  are  often  degraded  before   activation  of   the   immune   system  
can   occur.   Therefore,   subunit   vaccines   are   often   given   together   with  
immunostimulatory   adjuvants   to   enhance   their   immunogenicity   [10]   and   multiple  
doses   of   subunit   vaccines   are   given   in   order   to   stimulate   protective   immunity.   This  
renders  subunit  vaccines  unattractive   in   terms  of  cost  and  patient  compliance  as  well  
as  from  a  logistics  point  of  view  especially,  in  developing  countries  [4].    
Ramon  was  the  first  to  describe  vaccine  adjuvants  about  80  years  ago  [4,11].  According  
to   the  definition,  an  adjuvant   (Latin  “adjuvare”  which  means  to  help)   is  any  material  
that  helps  to  increase  the  humoral  or  cellular  immune  response  to  an  antigen  [12].  The  
use  of  an  appropriate  adjuvant  component  in  subunit  vaccines  can  turn  an  ineffective  
vaccine  into  an  effective  vaccine  [13].    
Single  shot   formulations,  able   to   release   the  antigen   in  a  sustained  manner  or  able   to  
mimic  giving  two  or  several  booster  injections,  would  have  a  major  impact  on  vaccine  
compliance  [14]  and  would  reduce  costs.  A  huge  number  of  different  delivery  systems  
for  vaccination,  made  of  different  materials,  have  been  tested,  such  as  particles  [15-­‐‑19],  
liposomes  [20-­‐‑22],  ISCOMs  [6,23],  gels  [24]  and  implants  [25-­‐‑29].  This  review  will  focus  
on  sustained   release   systems   (Figure  1-­‐‑1).  Different   release  profiles  will  be   compared  







Figure  1-­‐‑1:  Different  release  systems  described  in  this  review.  Nanoparticles  and  gels  in  the  nm  
range,  microparticles,   liposomes   and  microneedles   in   the   µμm   range   and   implants   in   the  mm  
range.  Between  each  group  is  a  difference  in  size  of  the  order  of  magnitude  of  1000.  
1.2 Sustained  release  delivery  systems  for  vaccination  
The  goal  of  research  in  this  area  is  to  improve  existing  vaccines  and  to  allow  the  use  of  
novel  vaccines  by  presenting  the  antigens  to  the  immune  system  in  a  way  that  induces  
strong,   long-­‐‑lasting   immunity.   Delivery   systems   should   closely   imitate   the  
composition   and   characteristics   of   actual   pathogens   and   should   protect   the   antigens  
from   degradation   upon   delivery.   Different   release   kinetics   have   been   evaluated,   to  
determine  whether  continuous  or  pulse  release  is  preferable  (Figure  1-­‐‑2),  since  antigen  






Figure  1-­‐‑2:  Release  profile:  (a)  zero-­‐‑order  release  profile,  (b)  first-­‐‑order  release  profile  with  burst  
release  during  the  beginning  of  the  release,  (c)  first-­‐‑order  release  profile,  (d)  dual-­‐‑pulsed  release  
profile  with  two  pulses.  Schematic  representation  modified  after  Engert  [31].  
1.2.1 Particles  
There  has  been  a  major  focus  on  the  development  of  particulate  vaccines  and  adjuvants  
over   the   past   years   [32].   An   antigen-­‐‑loaded   particle   may   act   as   an   antigen   depot,  
slowly   releasing   the   antigen   to   prolong   its   availability.   But   compared   to   other  
sustained  release  systems,  particles  are  particularly  interesting  as   it   is  known  that  the  
uptake  of  vaccine  antigen  by  antigen  presenting  cells  (APC’s)  is  enhanced  if  the  antigen  
is  presented   in  particulate  rather   than   its  soluble   form  [33].  A  vast  number  of  studies  
investigating  particles  for  vaccine  delivery  have  been  conducted.    
1.2.1.1 PLGA  particles  
The  most  commonly  described  material   for  particles   is  poly(lactide-­‐‑co-­‐‑glycolide)  acid  
(PLGA).  The  immune  response  to  ovalbumin  (OVA)  entrapped  in  PLGA  microparticles  
(5.32  µμm)  was  compared  to   that  stimulated  by  emulsified  OVA  in  Freunds’  complete  
adjuvant  (FCA)  by  O’Hagan  et  al  (1991)  [34].  The  immune  response  to  the  OVA-­‐‑loaded  
particles  was  higher  than  to  OVA  in  FCA.  The  PLGA  microparticles  have  potential  as  a  
system   for   controlled   vaccine   delivery   due   to   their   ability   to   slowly   degrade   and  
release  the  entrapped  antigen.  In  a  second  study,  O’  Hagan  et  al  (1993)  [35]  showed  that  
mice   immunized   with   OVA-­‐‑loaded   PLGA   particles   are   able   to   induce   strong   IgG  





effect   of   particle   size   on   immunogenicity   and   found   that   smaller   particles   (1.5   µμm)  
were   more   immunogenic   than   microparticles   of   72.6   µμm.   Joshi   et   al   (2013)   also  
investigated   the   influence   of   particle   size   on   immune   responses   and   confirmed   the  
previous   results   [17].   PLGA   particles   loaded   with   OVA   and   CpG  
oligodeoxynucleotides   sized   between   17   µμm   and   200   nm   were   administered   to  
C57BL/6  mice.  The  particles  showed  a  release  between  48  h  (300  nm  particles)  and  350  
h  in  PBS  at  37  °C.  In  vivo  the  highest  antigen-­‐‑specific  cytotoxic  T  cell  responses  as  well  
as   the  highest  OVA-­‐‑specific   antibody   titres  were   found   in  mice   immunized  with   the  
300   nm   sized   particles.   These   results   suggest   that   smaller   particles   induce   and  
stimulate   a   stronger   immune   response.   But   not   only   is   the   size   of   the   particles  
important,  but  also  the  duration  during  which  the  antigen  is  presented  to  the  immune  
system.  OVA-­‐‑loaded  PLGA  particles  showing  a  slower  OVA  release,  resulted  in  higher  
and  constant  antibody  levels  over  the  duration  of  a  year,  compared  to  faster  releasing  
particles  [36].  These  results   imply  that  the  particulate  nature  alone  is  not  enough,  but  
that   also   a   sustained   presentation   of   the   antigen   is   necessary   to   induce   a   long-­‐‑term  
immunity.   These   results   were   confirmed   by   investigating   the   immune   response   of  
lactic/glycolic  acid  polymer  microcapsules  in  mice  using  bovine  serum  albumin  (BSA)  
as  a  model  antigen  [37]  where  a    higher  antibody  titre  and  persisting  immune  response  
were  measured  up  to  142  days.  The  adjuvant  effect  was  comparable  to  that  of  FCA  and  
stronger   than   that  of  aluminum  hydroxide.  To   investigate   if   the  presence  of  particles  
alone   was   enough   to   stimulate   an   immune   response,   one   group   was   injected   with  
blank   microcapsules   and   antigen.   The   immune   response   from   this   group   was   no  
greater  than  that  induced  by  BSA  in  saline.  These  results  show  that  blank  particles  do  
not   possess   adjuvanticity,   but   that   the   sustained   release   of   the   model   protein   is  
necessary  [37].  In  a  different  study  Sah  et  al  (1996)  [38]  confirmed  this  by  testing  BSA-­‐‑
loaded  poly(d,l-­‐‑lactide-­‐‑co-­‐‑glycolide)  (PLCG)  and  poly(d,l-­‐‑lactide)  (PLA)  microparticles  
(with  an   in  vitro   release  of  up   to  18  days)   in  mice  where   immune  responses  up   to  27  
weeks  were  measured.  BSA-­‐‑loaded  particles  stimulated  a  better  immune  response  than  
BSA  dissolved  in  saline  or  adsorbed  to  alum.  All  these  studies  show  the  importance  of  





Many  other  groups  investigated  particles  for  tetanus  toxoid  (TT)  vaccines.  Sasiak  et  al  
(2001)   [39]   investigated   the   stability   of   experimental   vaccines   containing   TT   within  
PLGA  microspheres  by  incubating  them  at  37  °C.  Changes  in  structure  of  TT  could  be  
detected  and  were  related  to   the  breakdown  of   the  encapsulating  polymers   into   their  
acid   components.   This   polymer   breakdown   can   lead   to   an   increased   acidity   of   the  
vaccine  surroundings  once  released  from  the  particles.  Similar  changes  occurred  when  
incubating   un-­‐‑encapsulated   TT   in   low   pH   solutions.   Protective   immunity,   equal   to  
freshly  prepared  vaccines,  was  induced  by  microparticles  that  retained  their  spherical  
shape   after   incubation.   This   indicates   that   as   long   as   the   particles   stay   intact,   TT  
remains   stable   and   immunogenic.   Raghuvanshi   et   al   (1993)   [40]   successfully  
immunized   rats  with  TT-­‐‑loaded  PLGA  microparticles,   finding  a   comparable   immune  
response  over  5  month  compared  to  alum  TT  injections.  Singh  et  al  (1997)  [41]  used  TT-­‐‑
loaded   PLCG   microparticles   to   immunize   Sprague-­‐‑Dawley   rats.   The   antibody  
responses  were  monitored  for  1  year  and  compared  to  rats  that  were  immunized  with  
TT  adsorbed  to  alum  at  0,  1  and  2  months.  The  best  antibody  responses  were  achieved  
by   TT   adsorbed   to   alum   and   also   entrapped   in   microparticles,   indicating   the  
importance  of  the  adjuvant.  Esparza  and  Kissel  (1992)  [42]  also  studied  the  parameters  
that  affect  the  immunogenicity  of  microencapsulated  TT.  TT-­‐‑loaded  PLA:PGA  particles  
in  water  and  TT-­‐‑microparticles  in  an  water-­‐‑in-­‐‑oil  emulsion,  using  either  peanut  oil  or  
IFA,   were   compared   to   alum-­‐‑TT.   Whereas   similar   primary   IgG   responses   were  
observed   for   the  different   formulations,  TT-­‐‑loaded  microparticles   induced   a   stronger  
and   longer   lasting   secondary   antibody   response   than   alum-­‐‑TT,   proving   that   TT  
antigenicity   is  maintained   after  microencapsulation.   Furthermore,   it  was   shown   that  
the   choice   of   carrier   is   important.   The   strongest   secondary   antibody   response   was  
obtained   when   TT   microparticles   were   given   in   water-­‐‑in-­‐‑oil   emulsions,   where   IFA  
proved   to   be  more   potent   adjuvant   than   peanut   oil.   All   these   particles   released   the  
antigen  in  a  sustained  manner.    
1.2.1.2 Particles  releasing  antigen  pulses  
Sanchez  et  al  (1996)  [43]  tried  to  develop  a  release  system  that  mimicked  a  conventional  





that  release  the  antigen  in  a  pulsed  manner.  TT  was  entrapped  in  an  oil-­‐‑based  core  and  
the  outer   shell  was   formed  by  PLCG.  These  particles   release  TT  after  21  days  and  49  
days,  which  was  made   possible   by   carefully   selecting   the   copolymer   composition   of  
these   two   types  of  particles.  Cleland   et   al   (1998)   [44]   investigated   the  use  of  pulsatile  
release   of   a   subunit   vaccine   for  HIV-­‐‑1,   recombinant   glycoprotein   120   (rGP120),   from  
PLGA  microspheres.  Depending  on  the  polymer  rGP120  was  released  at  1  and  6  month  
after  administration.  In  guinea  pigs,  neutralizing  antibody  titres  that  were  comparable  
to   titers   obtained   from   two   immunizations   of   rGP120   and  QS-­‐‑21  were   induced   by   a  
single  immunization  with  rGP  120-­‐‑loaded  PLGA  microspheres  resuspended  in  soluble  
rgp120   and   QS-­‐‑21.   In   baboons,   immunization   with   rGP120-­‐‑loaded   microspheres  
resulted   in   long-­‐‑lasting   neutralizing   antibody   titres   that   were   greater   than   repeated  
immunizations   with   soluble   rgp120   and   QS-­‐‑21.   Continuous   release   of   rGP120   from  
PLGA  microspheres  induced  a  lower  humoral  response  than  the  repeated  pulses.  This  
is   in   contrast   to   the  previously  mentioned  TT   studies.  These   results   show   that   either  
continuous  or  pulsatile   release  might   lead   to  a  stronger   immune  response  depending  
on  the  vaccine  in  questions.    
1.2.1.3 Particles  for  influenza  vaccination  
Sustained   release   microparticles   are   an   interesting   alternative   to   current   vaccines   to  
enhance  antibody  titres  against  the  major  surface  glycoprotein  hemagglutinin.  To  this  
end,  PLGA  particles  loaded  with  influenza  vaccine  were  investigated  [45].  In  vitro  this  
system   released   the  vaccine   in   a  pulsatile  manner   and   in  mice  a  higher  primary   IgG  
antibody   response  was   stimulated  by   the  PLGA-­‐‑microsphere  vaccine.  These   findings  
show  the  potential  for  single  dose  influenza  vaccination  using  particles  as  the  delivery  
system.   Oral   and   subcutaneous   administration   routes   of   the   influenza   PLG   and  
poly(isobutylcyanoacrylate)   microparticles   were   compared   by   Chattaraj   et   al   (1998)  
[46].   The   best   results   were   obtained   when   the   vaccine   was   administered  
subcutaneously   follow   by   oral   boosting.   These   are   very   promising   results,   making  
vaccination   more   effective   and   easier   accessible   when   only   one   visit   to   a   medical  





1.2.1.4 Microparticles  for  hepatitis  B  vaccines  
Microparticles  were  also  studied  for  the  controlled  release  of  a  single  dose  hepatitis  B  
vaccine.  CD1  mice  were  immunized  with  30  µμg  of  Hepatits  B  surface  antigen  (HBsAg)  
in  PLG  and  PLA  particles  [47].  Control  mice  received  three  injections  of  HBsAg  in  alum  
at   0,   1   and   6  months.   Antibody   levels   stimulated   by   a   single  microparticle   injection  
appeared  comparable  to  the  three  alum  injections  for  at  least  1  year.    
1.2.1.5 Solid  lipid  nanoparticles  for  vaccine  delivery  
Mishra   et   al   (2010)   [48]  used  solid   lipids  nanoparticles   (SLN,)  made  of   tristearin,  as  a  
potential  delivery  system  for  HBsAg.  They  explored  the  effect  of  surface  modifications  
of   the  SLN  on   loading  efficiency  as  well  as   cellular  uptake.  A  greater   cellular  uptake  
and  a  greater  Th1  immune  response  was  induced  by  SLN  particles  compared  to  soluble  
HBsAg.  Particularly,  mannosylated  formulations  showed  great  potential  by  producing  
sustained  antibody  titers.    
1.2.1.6 Chitosan  particles  
Jaganathan   et   al   (2004)   [49]   compared   TT-­‐‑loaded   PLGA   particles   with   chitosan  
particles.  Both  particles  provided  sustained  antigen  release  in  vitro  (TT  release  up  to  35  
days)  and  in  guinea  pigs  PLGA  and  chitosan  TT-­‐‑loaded  particles  stimulated  equivalent  
immune  responses,  comparable  to  a  prime-­‐‑boost  alum-­‐‑TT  vaccine.  This   indicates  that  
the  expensive  PLGA  polymer  might  be  replaced  by  other,  cheaper  materials.    
1.2.1.7 Liposomes  
Another  well-­‐‑studied   particulate   carrier   for   vaccines   are   liposomes.   Liposomal   drug  
formulations   are   already  being  used   in   the   clinic   (Doxil®,  Ambisome®),  making   this  
formulation   even   more   attractive.   As   early   as   1974,   liposomes   were   investigated   as  
antigen   carriers,   using   Diphtheria   toxoid,   and   were   found   to   increase   antibody  
response  [20].  Ever  since,  they  have  been  widely  studied  to  increase  vaccine  efficiency  
[21,50-­‐‑52].  Demento  et  al   (2012)  [53]  compared  the  efficacy  of  OVA-­‐‑  loaded  liposomes  
and   PLGA   particles   in   inducing   long-­‐‑term   immunity   in   mice.   The   in   vitro   release  
indicated  a  difference  between  the  two  carrier  systems,  with  OVA  being  released  much  





immune  responses.  This  study  showed  that  the  difference  in  performance  was  not  due  
to  the  different  materials,  but  due  to  the  release  kinetics  of  the  antigen,  indicating  once  
more  the  importance  of  a  sustained  antigen  release.    
In  order  to  develop  a  sustained  release  liposome,  Tiwari  et  al  (2009)  [54]  manufactured  
gel   core   liposomes.   BSA-­‐‑loaded   gel   core   liposomes   were   compared   to   conventional  
liposomes   as   well   as   alum   absorbed   BSA   and   BSA   alone   given   by   intramuscular  
injection   to   Balb/c   mice.   Gel   core   liposomes   induced   efficient   systemic   antibody  
responses,  justifying  the  potential  use  for  vaccine  delivery.  In  a  second  paper  Tawari  et  
al   (2009)   [55]   used   the   gel   core   liposomes   as   a   delivery   system   for      Pfs25   malaria  
antigen     with   or  without   the   CpG  ODN   adjuvant.   The   authors   showed   that   in   vitro  
antigen  is  released  from  gel  core  liposomes  for  up  to  20  days,  whereas  for  conventional  
liposomes   the   release   stopped   after   5   days.   Immunizations   with   gel   core   liposomes  
induced   a   significant   and   durable   immune   response   compared   to   conventional  
liposomes.  Moreover  including  the  CpG  ODN  adjuvant  further  enhanced  the  immune  
response  to  the  vaccine.  
1.2.2   Gels,  patches  and  microneedles  
1.2.2.1 Thermosensitive  gels  
Gordon  et  al   (2008)  [56]   investigated  the  use  of   thermosensitive  chitosan  hydrogels  as  
sustained  vaccine  delivery  devices  for  chitosan  nanoparticles  (CNPs).  By  adding  polyol  
salts   to   chitosan   solutions,   gels   are   formed   upon   increasing   temperature   [57,58].  
Nanoparticles   and   gels   were   loaded   with   OVA   and   the   immune   response   was  
examined   in  mice.  Chitosan  hydrogels   loaded  with  OVA  were   able   to   induce  both   a  
cell-­‐‑mediated  and  humoral  immunity,  whereas  OVA-­‐‑loaded  CNPs  did  not  exhibit  any  
significant   immunogenicity.   In   vitro   it   could   be   shown   that   the   release   of   FITC-­‐‑OVA  
from  the  gels  was  more  sustained  than  from  CNPs,  with  less  than  10%  released  OVA  
after  10  days.  CNPs  on  the  other  hand,  released  over  50%  FITC-­‐‑OVA  within  the  same  
time.   In  a   following  study,  silica  nanoparticles   (SNPs),  of  a  size  of  approximately  300  
nm,  were   included  into  thermosensitive  chitosan  hydrogels  as  a  particulate  sustained  
release   vaccine   delivery   system   [59].   Gel-­‐‑based   systems   containing   SNP-­‐‑associated  





proliferation  was   induced   by   chitosan   gels   containing  OVA-­‐‑loaded   SNP   and  Quil-­‐‑A  
(QA)  than  chitosan  gels  containing  soluble  QA  and  OVA,  indicating  the  importance  of  
the  SNP  in  this  system.  
Kojarunchitt   et   al.   (2011   and   2014)   [60,61]   investigated   thermoresponsive   Poloxamer  
407   (P407)   –   Pluronic-­‐‑R   (25R4)   gels   chitosan-­‐‑methyl   cellulose   (MC)   formulations   as  
single-­‐‑dose,  sustained  release  vaccines.  The  gels  were  liquids  at  room  temperature  and  
formed   stable   gels   at   physiological   temperatures.   The  model   antigen  OVA  was  used  
and  Quil  A   and  monophosphoryl   lipid  A   as   adjuvants.   Chitosan-­‐‑MC   gels   showed   a  
sustained   antigen   release   of   at   least   up   to   14   days   in   mice,   whereas   the   release   of  
antigen   was   not   sustained   from   the   P407–25R4   gels.   Both   cellular   and   humoral  
responses  were  stimulated  by  the  chitosan-­‐‑MC  gels.  It  appeared  that  the  incorporation  
of  a  particulate  vaccine  (cubosomes)  did  not  facilitate  synchronous  vaccine  release  [60].  
The   chitosan-­‐‑MC   gels   though   showed   great   potential   as   sustained   release   delivery  
systems.  
1.2.2.2 Microneedle  patches  
Other  interesting  systems  for  sustained  transdermal  antigen  delivery  are  microneedles.  
Lee  et  al  (2008)  [62]  achieved  a  sustained  delivery  of  sulforhodamine  over  hours  to  days  
out  of  dissolving     microneedles  made  of     carboxymethylcellulose  (CMC).  To  quantify  
the   release,   microneedle   patches   were   inserted   into   human   cadaver   skin   and   the  
transdermal  flux  was  measured.  In  2010  Raphael  et  al  [63]  introduced  a  densely  packed  
dissolving  microprojection  array  made  out  of  CMC  for  vaccine  delivery.  The  authors  
reported   stimulation   of   a   systemic   immune   response   when   administering   the  
dissolving   patches   containing   either   OVA   or   Fluvax2008   (a   commercial   trivalent  
influenza  vaccine)  to  a  mouse  model.  
Chen   et   al   (2012)   [64]   reported   that   chitosan   microneedles   loaded   with   BSA,   could  
achieve  an  in  vitro  drug  release  of  up  to  8  days.  The  gentle  fabrication  process  did  not  
alter  the  secondary  structure  of  BSA.  In  vivo,  when  applying  Alexa  Fluor  488  labelled  
BSA-­‐‑loaded  microneedles  to  rat  skin,  it  could  be  shown  that  the  BSA  diffuses  gradually  





chitosan   microneedle   array   whereby   the   needles   were   attached   to   a   mechanically  
strong   support   made   of   poly(L-­‐‑lactide-­‐‑co-­‐‑D,L-­‐‑lactide).   The   microneedles   successful  
separated   from   the   supporting   array   when   inserted   into   rat   skin,   penetrating  
approximately  600  nm  into  the  skin  and  gradually  delivering  the  antigen  (OVA)  for  up  
to   14   days.   OVA   immunization   in   rats   using   these   microneedles   resulted   in  
significantly   higher   antibody   responses   than   those   stimulated   by   traditional  
intramuscular  immunization.  Subsequent  studies  found  that  the  immune  response  was  
mostly   dependent   on   the   dose,   rather   than   on   the   depth   of   delivery,   microneedle  
density  or  the  area  of  application  [66].  
Numerous   studies   have   been   conducted   to   investigate   the   use   of   microneedles   for  
influenza   vaccination.   Immunogenic   responses   using   low-­‐‑dose   influenza   vaccines  
delivered   intradermally  by  microneedles  where   found   to  be   similar   to   those   induced  
by  the  full-­‐‑dose  intramuscular  vaccination  [67].  The  trial  was  conducted  in  180  healthy  
adults  and  a  marketed  inﬂuenza  vaccine  for  the  2006/2007  inﬂuenza  season  (RIX  ®  by  
GSK   Biologicals)   was   used   for   all   injections.   Protective   efficacy   and   long-­‐‑term  
sustained   immunogenicity   were   the   result   of   using   microneedle   patches   for  
vaccination  [68].  Patches  were  left  on  the  back  of  the  mice  for  10  minutes.  A  caveat  to  
all  the  mouse  studies  is  that  the  differences  between  rodent  and  human  skin  (thickness,  
number  of  hairs)  likely  over  estimates  the  efficacy  of  the  transdermal  formulations.    
Vaccine  stability  is  a  problem  when  using  microneedles.  Studies  have  been  conducted  
to  determine  the  effects  of  drying  and  of  storage  time  on  antigen  stability  and   in  vivo  
immunogenicity  of   influenza  microneedle  vaccines   [69,70].  Choi  et  al   (2012)   [70]  were  
interested   in   long-­‐‑term   stability   of   microneedles   coated   with   whole   inactivated  
influenza  vaccine.  They  were  guided  by   the  hypothesis   that  damage  can  occur   to   the  
influenza  vaccine  coated  onto  microneedles  due  to  crystallization  or  phase  separation  
of   the   microneedle   coating   matrix.   Vaccine   stability   was   measured   in   vitro   by  
hemagglutination   activity.   Studies   showed   that   the   vaccine   lost   stability   and   had  
reduced  immunogenicity  in  proportion  to  the  degree  of  phase  separation  and  coating  





as   well   as   the   hemagglutination   activity   could   be   improved   after   storage   when   the  
vaccine  was  coated  on  microneedles  together  with  trehalose  [69].    
1.2.3 Implants  
A   very   interesting   and   not   yet   fully   investigated   system   for   vaccine   delivery   are  
implants.   Different   types   of   implants   for   vaccine   delivery   have   been   investigated,  
including  both  continuous  as  well  as  pulsatile  release  systems  [71-­‐‑73].    
1.2.3.1 Implants  made  from  polymers  
Preis  and  Langer  (1979)  described  the  use  of  an  inert  pellet,  less  than  1  mm  in  diameter,  
made   out   of   ethylene-­‐‑vinyl   acetate   copolymer   for   vaccine   delivery.   Antigens   over   a  
wide   range   of   molecular   weights   were   tested   (ribonuclease   MW   14’000,   BSA   MW  
68’000,  and  gamma-­‐‑globulin  MW  158’000)  and  released  continuously  from  the  pellets.  
The  implants  were  administered  subcutaneously  to  mice  and  were  able  to  stimulate  an  
immune  response  comparable  those  induced  by  two  injections  [71].  These  results  show  
that   implants   are   a   promising   system   for   single-­‐‑step   immunization.   However,   these  
implants   had   to   be   surgically   removed   once   the   antigen   was   released,   which   limits  
their  use  in  terms  of  patience  acceptability.  Furthermore,  their  manufacturing  requires  
the  use  of  organic  solvents  and  exposure  to  heat  [74]  which  will  likely  compromise  the  
integrity  of  protein  antigen,  limiting  the  practical  application  of  these  systems.    
Kohn  et  al  (1986)  investigated  the  use  of  a  biodegradable  polymer  for  antigen  delivery  
based   on   poly(CTTH-­‐‑iminocarbonate)   [75].   This   polymer’s   primary   degradation  
product,   N-­‐‑benzyloxycarbonyl-­‐‑L-­‐‑tyrosyl-­‐‑L-­‐‑tyrosine   hexyl   ester   was   found   to   be   as  
potent  an  adjuvant  as  FCA.  The  produced   implants,   transparent,   slightly  brittle   films  
containing  10%  w/w  of  BSA,  were  implanted  subcutaneously  in  the  back  of  mice.  BSA  
released  from  these  implants  induced  significant  levels  of  anti-­‐‑BSA  antibodies  over  56  
weeks.   Even   though   these   implants   were   made   of   a   biodegradable   material,   the  





1.2.3.2 Implants  made  from  lipids  
Lipids  such  as  triglycerides  [44],  mixtures  of  triglycerides  with  cholesterol  (CHOL)  and  
phospholipids   [30],   and   phospholipids   or   blends   of   phospholipids   and   CHOL,   [45]  
have  been  investigated  as   interesting  alternatives  to  polymers  for  the  development  of  
controlled-­‐‑release   systems.   Lipids   are   generally   biocompatible   and   biodegradable  
[28,76-­‐‑78].  In  addition,  harsh  condition  during  manufacturing,  such  as  heat  or  the  use  
of  organic  solvents,  can  be  avoided.    
Khan   (1991)   [79]   studied   implantable   matrix   systems   prepared   from   CHOL   and  
lecithin  using  BSA  as  antigen.  Antibody  responses  to  BSA  in  mice  implanted  with  these  
matrixes  were  studied,  as  well  as  the  effects  of  the  CHOL-­‐‑lecithin  ratio  on  the  erosion  
and  the  release  of  BSA  in  vitro.  It  was  shown  that  the  release  rate,  as  well  as  the  erosion  
of  the  pellets,  was  dependent  on  the  CHOL-­‐‑lecithin  ratio.  In  addition,  gelatin  proved  to  
be   useful   as   filler   and   release   modifier.   Antibody   levels   were   higher   in   mice  
immunized  with   implants   compared   to  mice   immunized  with   a   single   or   three   BSA  
injections   given   in   phosphate-­‐‑buffered   saline   (PBS).   An   immune   response   could   be  
induced   and   maintained   in   mice   for   at   least   10   month   following   implant  
administration  [80].  
Opdebeeck   et   al   (1993)   also   produced   CHOL   pellets   by   direct   compression   for   the  
delivery  of  BSA.  Pellets  were  implanted  under  the  skin  of  mice  and  released  BSA,  after  
an   initial   burst,   slowly   over   77   days.   Comparing   to   mice   receiving   a   single   or   3  
injections  of  the  same  dose  of  BSA,  mice  immunized  with  pellets  had  higher  antibody  
levels.   A   control   group   receiving   injections   as   well   as   blank   implants   demonstrated  
that   the  slow  release  of   the  BSA  was  responsible   for   the  higher  antibody   titers   rather  
than  the  presence  of  the  pellet  itself  [81].  
Walduck  et  al  (1998)  [82]  tested  CHOL  and  lecithin  implants  delivering  a  recombinant  
antigen   (recombinant   Dichelobacter   nodosus   pili)   and   the   adjuvant   Quil   A   (QA)   in  
sheep.   In  vitro,   the  presence  of  QA   in   the   implants  enhanced  antigen  release  and  QA  
was  required   in  vivo   to   induce   immune  responses,  however  minor  skin   irritation  was  





induced  by   two   injections  given   4  weeks   apart.   Even   though   sheep   immunized  with  
implants  produced  antibodies,  significantly  higher  levels  of  antibodies  were  observed  
in   sheep   immunized  with   two   injections.   In   order   to   delay   antigen   release,   implants  
were   coated   either  with  CHOL  and   lecithin  using   a  manually  operated   single  punch  
tablet   press   or   with   an   enteric   coating   polymer   (hydroxyl   propyl   methylcellulose  
phthalate)   by   spraying   onto   the   implants   using   compressed   air.   Also   double   coated  
implants   were   tested,   being   first   coated   with   polymer   and   then   with   CHOL   and  
lecithin.  Coated  implants  were  given  together  with  simple  implants  to  deliver  a  prime  
and   a   boosting   dose   of   antigen.   The   double   implant   system   was   able   to   achieve  
equivalent   antibody   titres   to   those  detected   in   animals   receiving   injections.  However  
antibody   levels  were   not   sustained   past   6  weeks.  Walduck   further   reported   that   the  
period  of  delivery  rather  than  the  delivery  profile  was  important.  This  was  confirmed  
by  another  study  performed  by  Walduck  and  Opdebeeck  (1997)  [83]  investigating  the  
effect   of   antigen   delivery   profiles   on   antibody   responses   in  mice.   They   showed   that  
continuous   BSA   delivery   is   as   effective   as   giving   injections   over   the   same   period   of  
time,   showing   how   promising   sustained   release   devices   might   be   for   single-­‐‑step  
vaccination  programs.  
Myschik  et  al  (2007)  [28]  investigated  the  release  kinetics,  the  morphology  of  structures  
released   from   implants   as  well   as   the  morphology   of   the   implant   itself   for   different  
formulations  consisting  of  varying  ratios  of  QA:CHOL:L-­‐‑α-­‐‑Phosphaditylcholine   (PC).  
It   was   shown   in   vitro,   that   the   formulation   of   lipid   implants   for   sustained   release  
delivery   of   subunit   antigens   in   combination  with   colloidal   particles   is   possible.   In   a  
second   study   Myschik   et   al   (2008)   [29]   demonstrated   in   vivo   that   lipid   implants  
containing   the  adjuvant  QA  were  able   to  stimulate   immune  responses  comparable   to  
two  immunizations  with  an  immediate-­‐‑release  vaccine,  containing  equivalent  amounts  
of  QA  and  antigen,      administrated  by   injection.   It  was  also   shown   that   stronger   cell-­‐‑
mediated   and   humoral   immunity   was   induced   by   QA-­‐‑containing   sustained-­‐‑release  
implants  as  compared  to   lipid   implants  without  adjuvant.  This  result  emphasizes   the  
importance   of   the   adjuvant   in   this   kind   of   implants.   Tantipolphan   (2009)   [84]  





suggested  that  the  incorporation  of  salts  into  the  lecithin  system  could  delay  the  initial  
release.    
In  spite  of  all  the  enumerated  advantages,  using  lipids  in  pharmaceutical  formulations  
holds   a   few   challenges   to   overcome.   The   major   problem   is   the   instability   of   lipids  
during  storage.  An  increase  of  melting  ranges  or  of  melting  enthalpy,  the  formation  of  
pores  in  the  surface,  changes  in  rheological  properties  or  a  decrease  in  tensile  strength  
might  result  from  aging  of  lipids  [48].  These  changes  associated  with  the  aging  of  lipids  
are   of   great   significance   for   sustained   release   dosage   forms.   Storage   and   long   term  
stability  are  therefore  issues  that  must  be  kept  in  mind.  
1.2.3.3 Implants  made  from  silicone  
Kemp  et  al  (2002)  [73]  manufactured  injectable  implants  for  single-­‐‑shot  vaccine  delivery  
consisting  of  mannitol,  sodium  citrate  and  non-­‐‑biodegradable  silicon.  The  production  
process   of   these   implants   did   not   require   the   use   of   organic   solvents   or   high  
temperatures,  rendering  it  attractive  for  antigen  incorporation.  Two  different  types  of  
implants   were   produced,   releasing   the   antigen   avidin   over   1  month   or   over   several  
months.  Because  of   its   lipophilic  nature,   silicone   is   impermeable   to  water  and  bodily  
fluids,  allowing  the  possibility  of  such  a  release  system.  Immune  responses  induced  by  
these   two   types   of   implants   were   compared   to   AlzetTM   mini-­‐‑osmotic   pumps   and  
conventional   antigen   delivery   in   sheep.   IL-­‐‑1   or   alum   were   used   as   adjuvants.   The  
authors   showed   that   the   presence   of   an   adjuvant   was   important   and   that   implants  
releasing  the  antigen  together  with  adjuvant  over  several  months  were  able  to  result  in  
higher  antibody  titers  than  the  injections  and  the  other  type  of  implants.  
Lofthouse  et  al  (2002)  [27]  investigated  a  similar  system  for  vaccination  in  sheep  using  
either   the  model   antigen   avidin   or  Clostridium   tetani   and  Clostridium   novyi   toxoids.   A  
matrix   type   implant,   delivering   antigen   in   vitro   over   approximately   1  month,   and   a  
coated   rod   type,   that   delivers   antigen   for   several  months,   were   compared.   Implants  
were  produced  by  extrusion  and  cured  for  3-­‐‑4  days  at  25  °C.  Coated  rod  implants  were  
co-­‐‑extruded  with   an   outer   covering   of   silicone.   The   antibody   response   to   the  matrix  





adjuvant   (alum).   The   slow   releasing   rod   implants   stimulated   higher   antibody   titres  
than   the   alum   injection   group.   Moreover,   following   vaccination   with   coated   rod  
implants,  a  prolonged  antibody  response  was  observed.    
1.3 Adjuvants  
A  number  of  the  studies  reviewed  above  have  demonstrated  the  crucial  role  adjuvants  
play   in   sustained   release   vaccine   formulations.   Adjuvants   (Table   1-­‐‑1)   can   satisfy  
several   purposes:   1)   increase   the   immunogenicity   of   highly   purified   or   recombinant  
antigens;  2)  minimize  the  number  of  immunizations  or  the  amount  of  antigen  needed  
to   acquire   protective   immunity;   3)   improve   the   efficacy   of   vaccines;   or   4)   operate   as  
antigen   delivery   system   [13].   An   ideal   adjuvant   should   be   non-­‐‑toxic,   provide   good  
immunological  memory,  not   induce  autoimmunity,  be   stable  under  a  broad   range  of  
storage  conditions  (time,  temperature  and  pH)  and  should  stimulate  a  strong  humoral  
and/or   T   cell   immune   response   [85].   The   immune   system   is   activated   by   adjuvants  
because   they   represent   pathogen   associated   molecular   patterns   (PAMPS).   PAMPS  
assist  the  immune  system  to  differentiate  between  self  and  foreign  substance  [86].  The  
growing   understanding   that   adjuvants   represent   PAMPS,   which   are   recognized   by  
pathogen   recognition   receptors   constitutes   the   bone   of   contention   for   the   research   of  
optimal  synthetic  adjuvants  from  diverse  sources,  including  small  molecules  [4,32].  
There  are  different  classifications  for  adjuvants.  Moyle  and  Toth  [9]  distinguished  two  
classes  of  adjuvants,   immunopotentiators  and  delivery  systems.   Immunopotentiators,  
as   indicated   by   their   name,   activate   the   innate   immune   system.  Antigen   uptake   and  
presentation  can  be  improved  by  particulate  vaccine  delivery  systems  [9],  modulating  
or   enhancing   immune   responses   [87].   The   effect   of   adjuvants   on   the   nature   of   the  
immune   response   can   be   profound.   Adjuvants   can   influence   the   immune   system  
toward   either   a   Th1   or   Th2   type   response   [88].   Protective   immunity   against  
intracellular   infection   agents,   as   for   example   bacteria   or   certain   viruses,   and  
presumably  against  cancer  cells,  requires  a  Th1  response.  Contrariwise,  Th2  immunity  
is   efficient   for   protection   against   certain   viral   infections   as   well   as   most   bacterial  
infections  [89].  According  to  Marciani  (2000)  [89],  a  Th1  immune  response,  mediated  by  





produces  the  cytokines  interleukin-­‐‑2  (IL-­‐‑2),  tumour  necrosis  factor-­‐‑β  and  interferon-­‐‑ϒ.  
In  mice   a   Th1   immune   response   is   characterized   by   enhanced   production   of   IgG2a,  
IgG2b  and   IgG3,  whereas  a  Th2   response   is   identified  by  an  enhanced  production  of  
IgG1  and  secretory  IgA  as  well  as  by  the  production  of  cytokines  IL-­‐‑4,  IL-­‐‑5  and  IL-­‐‑10.  
Water/oil  emulsions  and  alum  represent  the  most  commonly  used  adjuvants,  but  they  
are  only  capable  of   inducing  a  Th2  immune  response.  Most  of   the  currently  available  
adjuvants   (water/oil   emulsions   and   alum)   mainly   stimulate   a   Th2   type   immune  
response   which   is   most   of   the   time   ineffective   against   intracellular   pathogens   [89].  
There   is  a  wide  range  of  different  adjuvants  such  as  monophosphoryl   lipid  A  (MPL),  
liposomes,   ISCOMs,   saponins,   and  many  more   [1].  The   classical,   and   for  many  years  
only  FDA-­‐‑approved,  adjuvant   for  vaccines   is  alum,  which  provides  a  depot  releasing  
the   vaccine   in   a   sustained  manner   [3,88].  Aluminium  based   adjuvants   induce   a  Th2-­‐‑
type   antibody   dominated   response.   However   vaccines   for   intracellular   infections   or  
cancer,  require  cellular  immunity  and  need  both  a  CD8  as  well  as  CD4  T  cell  response  
[12].   In  recent  years,  much  research  has  been  conducted  to   identify  and  develop  new  
adjuvants  for  use  in  humans  [90,91].  Monophosphoryl  lipid  A  (MPL)  is  for  example  of  
a   newer   Toll-­‐‑like   receptor   (TLR)-­‐‑dependent   adjuvant   that   is   approved   for   use   in  
human  vaccines  [3].  Adjuvants  must  fulfil  three  requirements  to  be  licensed  for  use  in  
humans:  safety,  immunogenicity  and  clinical  efficacy  [12].  Many  have  failed  to  satisfy  
all  three  conditions.    





Table  1-­‐‑1:  Overview  of  the  adjuvants  used  in  studies  described  in  this  review  
Adjuvant   Source      Systems  
Alum   Aluminium  slats     
  
• PLGC  particles  (Singh  et  al  1997)  







containing   unmethylated  
CpG  motifs  
  • Liposomes  (Tawari  et  al  2009)  
Quil-­‐‑A   Quillaja   saponaria,   Molina  
Tree  
  • Chitosan  hydrogels  (Gordon  et  al  2010)  
• CHOL/Lecithin  implants  (Walduck  et  al  
1998)  
• CHOL/PC  pellets  (Myschik  et  al  2008)  
• CHOL/Lecithin/D114  implants  (Even  et  al  
2014)  
  
QS-­‐‑21   Purified  fraction  of  Quil-­‐‑A     • PLGA  microparticles  (Tawari  et  al  1998)  
1.3.1 Adjuvants  approved  for  human  use  in  sustained  vaccine  delivery  
The   challenge   is   to   identify   an   adjuvant   suitable   for   human   use   that   is   capable   of  
inducing   cellular   and   antibody   immune   responses.   For   a   long   time   aluminium   salt  
based   adjuvants   were   the   only   ones   approved   for   human   use   (diphtheria-­‐‑pertussis-­‐‑
tetanus,   dipheteria-­‐‑tetanus,   Hepatitis   A)   [92].   Oil-­‐‑in-­‐‑water   emulsions   have   also   been  
successfully  used  in  different  vaccines.  MF59TM  is  an  oil-­‐‑in-­‐‑water  nano-­‐‑emulsion  that  is  
used  in  Europe  as  an  adjuvant  for  influenza  vaccines  [93],  and  was  the  first  adjuvant  to  
receive  approval  for  human  use  after  alum  [94].  But  like  alum,  MF59TM  cannot  induce  a  
Th1  immune  response  and  also  acts  through  a  depot  effect  [94,95].  AS03  is  another  oil-­‐‑
in-­‐‑water  emulsion  that  is  used  in  influenza  vaccines  [91].  Another  licensed  adjuvant  is  
AS04,  an  aqueous  formulation  of  MPL  and  alum  [96].  Able  to  induce  a  Th1  response,  
MPL   is   a   non-­‐‑toxic  derivative   from   lipopolysaccharide   of  Salmonella  Minnesota   and   a  
component  of  a   licensed  HBV  vaccine   [97].  Another   licensed  adjuvant  are  virosomes,  
used   in   influenza   (Inflexal)   and   HBV   (Epaxal)   vaccination,   they   are   composed   of  





1.3.2 Adjuvants  in  research  for  sustained  vaccine  delivery  
Many  other  adjuvants  are  not  approved  for  human  use  yet,  but  have  been  investigated  
in  preclinical   research   and   in  human   clinical   trials,   among   them   the   saponins.   In   the  
1930s  Quillaja   saponaria   extracts  were   first   identified   to  have  adjuvant  properties   [98].  
Dalsgaard  (1974)  [99]  used  a  defined  Quillaja  saponin,  QA,  showed  an  increase  in  the  
immune  response  in  cattle  to  a  food-­‐‑and-­‐‑mouth  disease  (FMD)  vaccine.  QA  as  well  as  
QS21,  a  purified   fraction  of  QA,  are  widely  used   in   research,  but  are   relatively   toxic.    
Incorporation  of  QA  into  liposomes  is  order  to  reduce  toxicity  [90].  QA  and  QS21  can  
perforate   lipid  membranes  by  binding   to  CHOL.  The  CHOL  present   in   liposomes  or  
ISCOMs   interacts   with   the   saponin,   thereby   blocking   it   from   interacting   with  
cholesterol  in  cell  membranes.  Different  studies  have  been  conducted  on  this  adjuvant  
[6,20,21,51,100-­‐‑102]  but  so  far  it  has  not  been  licensed  for  human  use.    
1.4 Immune  System  
The  activity  of  white  blood  cells  called  leukocytes  play  a  crucial  role  in  both  innate  and  
adaptive  immunity.  All  cellular  elements  of  the  blood  are  derived  from  hematopoietic  
stem  cells  of   the  bone  marrow.  Once  mature  they  circulate   in  the  bloodstream  and  in  
the   lymphatic   system   [86].  The   lymphatic   system   is  a  key  component  of   the   immune  
system  and  is  composed  of  lymph  vessels  and  lymphoid  organs.  Lymphoid  organs  are  
divided  into  primary  and  secondary  lymphoid  organs.  Lymphocytes  are  generated  in  
the  primary  lymphoid  organs,  the  bone  marrow  and  the  thymus.  Mature  lymphocytes  
then   circulate   through   and   reside   in   the   secondary   lymphoid   organs   (lymph   nodes,  
spleen   and  mucosal   lymphoid   tissues)   and   adaptive   immune   responses   are   initiated  
here.  A  system  of  lymphatic  vessels  drains  the  extracellular  fluid  from  tissue  through  
the  lymph  nodes.  In  this  manner  macrophages  as  well  as  mature  dendritic  cells  migrate  
to   the   lymph   nodes   and   lymphocytes   residing   in   the   lymph   nodes   are   taken   to   the  
blood  [86].  
1.4.1 Immune  response  
The   immune   response   is   divided   into   two   different   parts   differing   by   the   specificity  





we  can  divide   the   immune   response   into   two  parts,   both   types  of   immune   functions  
interact  closely.    
1.4.2 Innate  immune  response  
The   innate   immunity   is   the   first   line   of   defence,   responding   quickly   and   non-­‐‑
specifically.   The   innate   immune   response   is   responsible   for   the      recruitment   and  
activation  of  neutrophils  at  the  site  of  infection  to  kill  pathogens  [103].  Neutrophils  are  
the  most  numerous  and  important  cells  of  the  innate  immune  response.  Although  the  
innate   immune   response   is   not   antigen-­‐‑specific,   pattern   recognition   receptors   (PRRs)  
allow   discrimination   of   self   from   non-­‐‑self.      Pathogen-­‐‑associated   molecular   patterns  
(PAMPs)  are  molecular  structures  in  pathogens  that  are  recognised  by    PRRs  found  on  
macrophages,   neutrophils   and  dendritic   cells   [104].  Macrophages   also  provide   a   first  
line   of   defence.  Once   activated   by   the   cytokine   interferon-­‐‑ɣ   (IFN-­‐‑ɣ),   they   engulf   and  
kill   invading   microorganisms   and   dispose   of   pathogens   (such   as   mycobacteria,  
protozoa   and   fungi)   and   infected   cells   [86,103].   Absence   or   mutation   of   the   IFN-­‐‑ɣ  
receptor  leads  to  severe  mycobacterial  infections  [105].  A  cytokine  is  a  general  name  for  
any   protein   secreted   by   a   cell   that   affects   the   behaviour   of   nearby   cells   bearing  
appropriate  receptors  [86].    
Dendritic  cells  (DCs)  are  the  main  class  of   innate  antigen  presenting  cells  (APCs)  and  
act   as   sentinel   cells   of   the   innate   immune   system  and  as   the   link  between   the   innate  
and   acquired   immune   systems.   DCs   are  widely   distributed   in   the   body   and   are   the  
most  capable  of   initiating  acquired   immune  responses   [106].  They  do   this   though  the  
cell   surface   expression  of  peptide-­‐‑  major  histocompatibility   complex   (MHC)  or   lipid-­‐‑
CD1  complexes  [107,108].  Additional  stimulatory  signals  produced  by  DC  are  required  
for  full  activation  of  the  acquired  immune  response  and  these  are  produced  following  
binding  of  PRR  to  PAMPs  [86].  
1.4.3 Adaptive  immune  response    
The   adaptive   immune   response   is   antigen   specific   and   less   rapid   than   innate  
immunity.  The  reason  for  this  is  that  the  pathogen  first  needs  to  be  taken  up  by  DC  and  





bound   to   proteins   of   the   MHC   T   cell   activation   can   take   place,   resulting   in   the  
generation  of  effector  T  cells.  This    process  occurs  over  2-­‐‑3  days  once  the  T  cell  meets  
an  antigen-­‐‑presenting  cell  bearing   its   specific  antigen   [86,103].  Dendritic  cells  possess  
pathways  to  process  non-­‐‑protein  antigens  (such  as  lipids)  which  are  loaded  onto  CD1  
molecules   [108].   The   adaptive   immune   response,   through   the   processes   of   clonal  
expansion   and   affinity   maturation   [86],   is   able   to   develop   populations   of   memory  
lymphocytes  so  that  in  case  of  a  secondary  infection  responses  occur  much  faster  and  
more   efficiently.   The   development   of   populations   of   memory   cells   is   what   many  
vaccines  aim  to  achieve.  
The   hematopoietic   stem   cells   of   the   bone   marrow   amongst   others   give   rise   to   two  
different  categories  of  white  blood  cells,   the  myeloid  and   the   lymphoid   lineages.  The  
later  one   compromises   the   lymphocytes  of   the   adaptive   immune   response.  There   are  
two  types  of  lymphocytes,  T  and  B  lymphocytes  (or  cells).  
1.4.3.1 T  Lymphocytes  
T   cells   mature   and   differentiate   in   the   thymus   and   have   antigen   receptors   on   their  
surface   (T-­‐‑cell   receptors).  There  are   two  different   types  of  effector  T  cells,  one  carries  
the  cell-­‐‑surface  protein  CD8  on   its  surface,   the  other  one  the  cell-­‐‑surface  protein  CD4  
[86].   T-­‐‑cells   are   only   able   to   recognize   antigens   that   have   been   processed   and   are  
displayed   as   peptides   or   lipids   bound   to   particular   cell   surface   glycoproteins   called  
MHC  [86].  CD4+  lymphocytes  only  recognize  antigen  presented  by  MHC  class  II  and  
CD8+   cells   by   MHC   I   class   molecules   [103].   MHC   I   class   molecules   complex   with  
antigens   derived   from   proteins   synthesized   within   the   cell,   and   can   stimulate  
responses   to   viruses,   intracellular   pathogens   or   abnormal   tumour   antigens.   MHC   II  
class  molecules  binds  to  antigens  derived  from  extracellular  pathogens.    
CD8+  T  cells  
Upon  activation,  CD8+  T  cells  become  cytotoxic  effector  or  memory  T  cells.  They  are  
able   to  destroy   cancer   cells   and   cells   infected   by   intracellular   pathogens   through   the  
release   of   three   types   of   cytotoxic  proteins;   granzymes,  perforin   and  granulysin   [86].  





apoptosis.   Furthermore,   CD8   cytotoxic   T   cells   contribute   to   the   host   defence   by  
releasing  different  cytokines  (  IFN-­‐‑  ɣ,  TNF-­‐‑α  and  LT-­‐‑α),  inducing  increased  expression  
of  MHC  class  I  molecules  in  infected  cells  and  directly  inhibiting  viral  replication  [86].  
CD4+  T  cells  
CD4+  T  cells  can  differentiate  into  a  number  of  different  T  helper  cell  subsets,  Th1,  Th2,  
Th9,  Th17,  Th22  and  follicular  helper  T  cells  (Tfh  cells)[86,108-­‐‑110].  Dependent  on  the  
type  of  infection,  these  subsets  promote  different  types  of  responses.  Th1  and  Th2  cells  
have  been  investigated  most  fully  and  are  distinguished  by  the  cytokines  they  secrete  
[33]   and   the   types   of   responses   they   induce.   Upon   activation,   Th1   cells   secrete  
interferon-­‐‑ɣ,   IL-­‐‑2   and   the   tumour-­‐‑necrosis   factor-­‐‑β.   IL-­‐‑2   induces   T-­‐‑cell   proliferation,  
stimulates  not  only  CD4+  production  but  also   increases  CD8+  T-­‐‑cell  proliferation  and  
cytotoxicity.  TH2  cells  on  the  other  hand  favour  antibody  production  by  secreting  IL-­‐‑4,  
IL-­‐‑5,   and   IL-­‐‑6.   Furthermore   they   inhibit   macrophage   function   by   secreting   IL-­‐‑10.  
Additionally  IL-­‐‑4  down-­‐‑regulates  TH1  on  responses  and  induces  further  Th2  responses  
[103].  
1.4.3.2 B  Lymphocytes  
B-­‐‑lymphocytes  mature   in   the  bone  marrow  and  utilise  membrane-­‐‑bound  antibody  as  
antigen   receptors.      Around   105   antibodies   are   attached   to   the   surface   of   each   B-­‐‑
lymphocyte   [111].   After   an   antigen   binds   to   a   B-­‐‑cell   receptor,   the   lymphocyte  
differentiates  into  an  antibody-­‐‑secreting  plasma  cell  or  memory  B  cell  [86].  In  contrast  
to  T  cells,  naïve  B  cells  are  able  to  recognize  native  antigen.  Upon  activation  B  cells  can  
differentiate  into  plasma  cells  which  secrete  large  amounts  of    antibody  [111].  
1.4.3.3 Antigen  presenting  cells  
B   and   T   lymphocytes   are   the  mediators   of   immunity,   but   the   presence   of   these   two  
parties   does   not   always   lead   to   immunity.   In   addition,   the   presence   of   antigen  






Figure   1-­‐‑3:   Antigens,   APCs,   different   MHC   molecules   and   resulting   immune   responses.  
Schematic  representation  modified  after  Beck  et  al  [113].  
1.5 Conclusion  
All  the  mentioned  studies  clearly  show  that  there  has  been  a  focus  on  the  development  
of  sustained  release  vaccine  delivery  systems  over  the  last  30  years.  There  is  no  doubt  
that   new   delivery   strategies   are   required   to   advance   the   field   and   to   facilitate   the  
development   of   new   vaccines   to   treat   both   communicable   and   non-­‐‑communicable  
diseases.  All  the  studies  agree  on  the  fact  that  adjuvants  are  needed  to  induce  a  strong  
and  durable  immune  response.  The  search  for  and  investigation  of  new  adjuvants  is  as  
important   as   the   development   of   new   delivery   systems.   Most   studies   investigating  
antigen  release  systems  confirm  that  slow,  sustained  antigen  release  is  able  to  induce  a  
stronger  immune  response  than  repeated  injections.  However,  there  are  a  few  studies  
that   show   that   pulsatile   administration   achieves   better   immunity.   This   suggests   that  
the  optimal  type  of  delivery  may  be  antigen  and  adjuvant  dependent.    
Substantial   progress  has   been  made,   especially   in   the   field   of   polymeric  particles   for  
vaccine  delivery.  But  unfortunately  the  manufacture  of  most  of  these  particles  requires  
harsh   conditions   [17,34,36].  Heating,   high   shear   forces,   exposure   to   organic   solvents,  
increased   osmotic   pressure   as   well   as   acylating   degradation   products   can   lead   to  
irreversible   changes   in   structure  and  activity  of  proteins   [114].  Furthermore,  polymer  





protein   based   drugs   [26]   [115].   Even   though   some   promising   results   have   been  
reported,  more  research  has  to  be  performed  before  these  systems  are  ready  for  human  
use.  Microneedle  delivery  of  vaccines  is  a  particularly  interesting  area  showing  much  
promise,   although   the   issue  of  antigen   stability  must  be  addressed.  Stability   is   also  a  
major  challenge  with  lipid  implants  or  particles,  as  upon  storage  the  lipids  themselves  
might  be  subject  to  polymorphic  changes.  Review  of  all  the  literature  in  this  area  does  
not   point   to   any   particular   optimal   system   or   material.   There   have   been   major  
achievements  made  in  the  development  of  sustained  release  vaccine  delivery  systems  
as  well  as  in  the  development  of  new  adjuvants.  However  there  are  still  many  barriers  
to  be  overcome  before  such  systems  are  widely  used  in  man.    
1.6 Aim  of  the  Thesis  
From  a  review  of   the   literature   it  becomes  clear   that   there   is  a  need   for  new  delivery  
systems  to  improve  existing  vaccines  and  to  allow  the  use  of  novel  vaccines.  Sustained  
vaccine  release  seems  to  be  the  key  to  achieve  strong,  long  lasting  immune  responses.  
Lipid  implants  are  a  promising  alternative  to  other  sustained  deliver  systems  described  
in   literature.  Since   lipids  are  biodegradable  as  well  as  biocompatible   they  provide  an  
interesting   platform.   Some   research   on   lipid   implants   for   sustained   vaccine   delivery  
has   been   carried   out   and   published.   However,   the   production   of   such   lipid   vaccine  
delivery  systems  by  twin-­‐‑screw  extrusion  has  not  previously  been  investigated  and  is  
therefore  the  subject  of  this  thesis.    
The   aim  was   to   produce   lipid   implants   by   twin-­‐‑screw   extrusion   and   investigate   the  
sustained   release   from   these   implants   in   vitro   and   in   vivo.   In   a   first   step,   the  model  
antigen  ovalbumin   (OVA)  was   incorporated  and   the   immune   response  was   tested   in  
vivo  using  murine  models.   In  a  second  step,   the   long  peptide  TRP2  was   incorporated  
into  the  implants  and  an  in  vivo  tumour  growth  study  was  performed.  
Chapter  Two  describes  the  preparation  and  characterisation  of  the  release  behaviour  of  
OVA   and   Quil   A   (QA)   from   the   implants.   The   influence   of   the   formulation   and  
adjuvant  on  the  release  of  OVA  is  investigated.  Furthermore  the  influence  on  the  OVA  





Chapter   Three   investigates   the   occurrence   of   unstable   polymorphs   due   to   the  
extrusion  process  as  well  as  during  storage.  Furthermore  the  OVA  release  in  vitro  was  
compared  to  the  OVA  release  in  vivo  in  a  murine  model.  The  ability  of  the  implants  to  
induce   an   immune   response   was   tested   in   vivo   and   the   importance   of   QA   in   the  
formulation  was  studied.  
Chapter   Four   describes   the   production   of   twin-­‐‑screw   extruded   lipid   implants  
containing  the  TRP-­‐‑2  peptide  for  tumour  therapy.    The  consequences  of  a  change  of  the  
production   device   on   the   implant   characteristics   are   shown.   Furthermore,   the  
preparation   of   vesicular   phospholipid   gels   (VPGs)   as   an   alternative   lipid   delivery  
system  is  described.  VPGs  as  well  as  implants  containing  TRP-­‐‑2  were  analysed  in  an  in  
vivo  tumour  study.    
Chapter   Five   examines   the   interactions   between   peptides   and   the   lipid   implants.  
Chapter  Four  suggested  that  the  release  of  the  TRP-­‐‑2  peptide  from  the  implants  is  very  
slow.   The   reason   for   this   behaviour   was   investigated   by   choosing   molecules   of  
different   size   and   hydropathy,   and   investigating   their   release   behaviour   and  





Impact  of  implant  composition  of  twin-­‐‑screw  extruded  
lipid  implants  on  the  release  behaviour    
Parts   of   this   chapter   have   been   submitted   as   a   manuscript   to   the   International  
Journal  of  Pharmaceutics  and  are  in  revision:  
Even  MP,  Bobbala  S,  Kok  Liang  Kooi,  Hook  S,  Winter  G,  Engert   J.   Impact  of   implant  
composition  of  twin  screw  extruded  lipid  implants  on  the  release  behaviour.  





2 Impact  of  implant  composition  of  twin-­‐‑screw  extruded  lipid  
implants  on  the  release  behaviour  
The  following  chapter  deals  with  the  production  of  lipid  implants  for  vaccine  delivery  
produced   by   twin-­‐‑screw   extrusion.   The   general   introduction   highlights   the   fact   that  
there   is   a   need   for   novel   vaccine   delivery   systems   in   order   to   optimize   the   use   of  
existing   vaccines   and   make   the   use   of   new   vaccines   possible.   Lipid   implants   have  
shown  great   prospect   as   sustained   release   vaccine   delivery   devices.  However,   so   far  
they  have  always  been  produced  by  direct  compression  or  similar  procedures,  making  
the   production   of   big   batch   sizes   a   time   consuming   act.   The   use   of   a   twin-­‐‑screw  
extruder  as  production  device  is  investigated.  The  use  of  twin-­‐‑screw  extrusion  would  
be   a   process   that   is   easy   to   scale   up.   The   impact   of   the   formulation   on   the   release  
behaviour   of   the  model   antigen   is   discussed,   as  well   as   its   stability   after   release.  An  
adjuvant   is   incorporated   into   the   implants.   The   influence   the   adjuvant   had   on   the  
antigen   release   is   investigated  as  well   as   the   release  behaviour  of   the   adjuvant   itself.  
Furthermore,   the   possibility   to   influence   the   antigen   release   by   curing   the   implants  
after  extrusion  is  examined.  
In  the  following,  the  text  of  the  manuscript  as  submitted  is  reprinted.  Sharan  Bobbala  
performed   the   Quil   A   release   study   and   Christian  Minke   helped  with   the   SEM.   All  
other  work  was  done  by  myself.  
  






The  development  of  vaccine  delivery  systems  that  will  remove  or  reduce  the  need  for  
repeated   dosing   has   led   to   the   investigation   of   sustained   release   systems.   In   this  
context,  the  duration  of  antigen  release  is  of  great  importance  as  is  the  requirement  for  
concomitant   adjuvant   release.   In   this   work,   lipid   implants   consisting   of   cholesterol  
(CHOL),   soybean   lecithin,  Dynasan  114   (D114),   the  model   antigen  ovalbumin   (OVA)  
and  the  adjuvant  Quil-­‐‑A  (QA)  were  produced  by  twin-­‐‑screw  extrusion.  The  release  of  
antigen  and  adjuvant  was  investigated  in  vitro  and  we  observed  complete  OVA  release  
over  a  period  of  7  days  while  QA  was  released  in  a  linear  fashion  over  a  period  of  up  to  
12   days.   In   order   to   extend   the  OVA   release,   lipid   implants  were   subjected   to   post-­‐‑
extrusion   curing   at   45-­‐‑55°C.   The   OVA   release   could   be   extended   to   up   to   14   days.  
Furthermore,   the   influence   of   the   implant   composition   on   the   release   of   the   model  
antigen  was  investigated.  It  was  shown,  that  the  percentage  of  cholesterol  in  particular  
plays  an  important  role  in  modulating  release.  
Key  words:  lipid  implants,  twin-­‐‑screw  extrusion,  vaccine  delivery,  sustained  release  of  
antigen,  ovalbumin,  Quil-­‐‑A  
  






Vaccination  often  requires  the  administration  of  a  prime  and  booster  immunisation  to  
induce   a   strong  memory   immune   response   and   long-­‐‑term   protection.   Often   subunit  
antigens   such   as   proteins   or   peptides   are   used   in  modern   vaccines,   replacing  whole  
pathogens,   for   purity   and   safety   considerations   [5].   In   order   to   induce   immunity,  
multiple   doses   of   these   subunit   antigens,   in   combination   with   immunostimulatory  
adjuvants,   are   required   as   they   are   less   immunogenic   than  whole-­‐‑pathogen   vaccines  
[6].   However,   repeated   administration   of   vaccines   often   compromises   patient  
compliance.   Therefore,   a   delivery   system,   which   is   able   to   release   antigen   in   a  
sustained   manner,   could   be   a   major   advance   in   the   development   of   vaccines.   The  
general  concept  of  sustained  release  of  vaccines  has  already  been  investigated  by  Preis  
and  Langer  [71]  using  ethylene-­‐‑vinyl  acetate  copolymer  pellets  and  by  Lofthouse  et  al.  
[27]  using  silicone  based  implants.  The  sustained  antigen  from  both  types  of  implants  
proved   effective   in   eliciting   prolonged   antibody   formation.   It   should   be   noted   that  
such  systems  made  from  non-­‐‑biodegradable  polymers  would  require  surgical  removal  
[116].    
For  this  reason  biodegradable  polymers  such  as  polylactic  acid  (PLA)  and  poly(lactic-­‐‑
co-­‐‑glycolic   acid)   (PLGA),   which   can   release   drug   continuously   after   parenteral  
administration   [114,117,118],   are   increasingly   being   investigated   today   for   drug   and  
vaccine   delivery   as   injectable   or   implantable   depot   formulations.  However,   an   issue  
with   these   formulations   is   polymer   degradation   to   smaller   chain   acids   upon   contact  
with   water,   leading   to   significant   drops   in   the   micro-­‐‑environmental   pH,   which   can  
result   in   a   loss   of   activity   with   protein-­‐‑based   drugs   [26,119].   The   use   of   synthetic  
polymer   matrix   materials   has   the   additional   problem   that   during   manufacture  
irreversible   changes   in   structure   and   activity   of   proteins   can   be   induced   by   heating,  
high  shear  forces,  exposure  to  organic  solvents  and  increased  osmotic  pressure  [114].  
An  interesting  alternative   is   to  utilize   lipid   implants  as  parenteral  controlled  delivery  
systems.   Lipids   are   considered   to   be   safe   for   diverse   types   of   applications   and   are  
widely   used   in   the   food   and   cosmetic   industry.   Lipids   such   as   triglycerides   [114],  





phospholipids   or   blends   of   phospholipids   and  CHOL   [120]   have   been   considered   as  
alternatives  to  polymers  for  the  development  of  controlled-­‐‑release  systems.  Lipids  are  
generally   biocompatible   and   biodegradable   and   are   normally   not   inherently  
immunogenic   [76,121,122].   Lipid   implants   have   been   thoroughly   investigated   as  
sustained   delivery   systems   for   protein   and   to   a   lesser   extent   for   vaccine   delivery  
[26,29,78,123-­‐‑127].  
Recently,  we  reported  that  lipid  implants  for  vaccine  delivery  can  be  prepared  by  twin-­‐‑
screw  extrusion   [127].  Administration  of   these   implants   to  mice  resulted   in  enhanced  
antigen-­‐‑specific   IgG   titers   when   both   an   adjuvant   (Quil   A,   QA)   and   antigen  
(ovalbumin,  OVA)  were  present  in  the  implants.  The  release  behavior  of  adjuvant  used  
in   sustained   release   implants  will   be   an   important   aspect   to   consider   as   it   has   been  
reported  that  antigen  and  adjuvant  must  be  released  synchronously  in  order  to  obtain  
an   optimal   immune   response   [128].   Therefore   the   release   of   QA,   a   saponin   derived  
from   the   tree  Quillaia   saponaria,   and  OVA   from  different   implant   formulations  was  
examined.  Both  release  behaviors  were  compared  to  ensure  the  release  of  adjuvant  and  
antigen  was  simultaneous.    
It  has  been  reported  that  implants  releasing  OVA  over  a  period  of  7  days  could  induce  
immune   responses   similar   in   magnitude   to   two   injections   [127],   this   led   to   the  
hypothesis  that  longer  antigen  release  may  induce  even  stronger  immune  responses.  In  
order   to   tune   the   release   of   antigen   and   adjuvant   the   effect   of   curing   implants   post-­‐‑
production  was   examined.   Kreye   et   al   [129]   had   reported   that   curing   lipid   implants  
composed   of   Dynasan   120   sustained   the   release   of   propranolol   hydrochloride.   We  
wanted   to   investigate   if   similar   results   could  be   achieved   for   antigen   release.  Curing  
temperatures   ranging   from   45°C   to   55°C   were   chosen   for   our   implants.   The   curing  
temperatures  were  slightly  below  the  melting  temperature  of  the  lipids  in  order  to  melt  
the   outer   surface   of   the   implants   and   change   the   size   of   pores   at   the   surface   of   the  





2.2 Materials  and  methods  
2.2.1 Materials  
Ovalbumin   from   chicken   egg   white   (OVA)   grade   V   was   purchased   from   Sigma-­‐‑
Aldrich.  Cholesterol   (CHOL),  purity  95%,  was  purchased   from  AlfaAesar   (Karlsruhe,  
Germany).   Soybean   Lecithin   (approx.   90%   phosphatidylcholin)   was   purchased   from  
APPLICHEM  LIFESCIENCE   (Darmstadt,  Germany).   PBS   tablets   from  Oxoid  Limited  
(Basingstoke,   England).   Puriﬁed   Quil-­‐‑A   (QA)   was   sourced   from   Brenntag   Biosector  
(Frederikssund,  Denmark)  as  a  lyophilised  powder  and  used  as  supplied.  Dynasan  114  
(D114)  was  kindly  provided  by  SASOL  Germany  GmbH  (Witten,  Germany).Ultrapure  
deionized   water   having   a   conductivity   of   less   than   0.055   µμS/cm   (Milli-­‐‑Q   Water  
systems,   Millipore,   MA,   USA)   was   used   throughout   the   study.   All   other   chemicals  
were  of  analytical  grade.  
2.2.2 Preparation  of  lipid  implants  by  twin-­‐‑screw  extrusion  
Mixtures   of   soybean   lecithin,  CHOL,  D114,  with   and  without  OVA   and/or  QA  were  
used  to  prepare  the  implants.  High  grade  stainless  steel  beakers  for  milling  in  a  swing  
mill,  Retsch®  CryoMill  (Retsch  Technology,  Haan,  Germany)  were  filled  with  soybean  
lecithin  and  D114.  The  system  was  precooled  with  liquid  nitrogen  for  10  minutes  at  5  
Hz,   the  mixture  was   then  ground   for  1  minute  at  25  Hz.  A  plastic  mortar  and  pestle  
were  used  to  mix  the  obtained  powder  by  hand  with  the  remaining  components.  QA  
and  OVA  were   then   gradually   blended  with   the   lipid  mixture   and   subsequently   fed  
into   a   twin-­‐‑screw  extruder   (Haake  MiniLab®  Micro  Rheology  Compounder,  Thermo  
Haake,   Germany).   The   implants   were   extruded   at   a   rotation   speed   of   40   rpm   at   an  
extrusion   temperature   of   45°C  with   closed   bypass   channel   using   an   outlet   of   2  mm  
diameter.  The  resulting   implants  had  a  diameter  of  2  mm  and  were  subsequently  cut  
into  lengths  of  2.5  cm,  resulting  in  an  implant  mass  of  about  0.08  g.    
2.2.3 Curing  of  lipid  implants  prepared  by  twin-­‐‑screw  extrusion  
Implants  were  cured  using  an  oven  (UM  400,  Memmert  GmbH  +  Co.KG,  Schwabach,  
Germany)  at  55°C   for  15  minutes   (min),  or  at  40,  45  or  50°C   for  60  min,   respectively.  





horizontally  placed  into  the  heating  cupboard.  To  ensure  that  the  complete  surface  of  
the  implants  was  heated  equally,  implants  were  turned  by  turning  the  Eppendorf  tube  
(every   5  minutes   for   incubation   time   of   15  min,   every   15  min   for   60  min   incubation  
time).  At  55°C  a  curing  time  of  15  min  instead  of  60  min  was  chosen  to  avoid  implant  
deformation.    
2.2.4 Differential  scanning  calorimetry  (DSC)  
A  DSC   204   Phoenix   (Netsch,   Selb,   Germany)   was   used   to   analyse   each   lipid   before  
extrusion.  Thermograms  of  implants  were  recorded  directly  after  the  extrusion  as  well  
as  after  the  post-­‐‑treatment.  Samples  of  about  4  mg  were  each  weighed  into  aluminium  
crucibles.  A  heating  and  cooling  rate  of  5  K/min  was  used  as  between  20°C  and  160°C.  
An  empty  crucible  served  as  reference.  
2.2.5 In  vitro  release  of  OVA  from  implants  
The  release  of  the  model  antigen  OVA  was  investigated  over  a  period  of  up  to  15  days.  
Lipid  implants  of  a  length  of  2.5  cm  (n=3)  were  incubated  at  37°C  in  a  Heidolph  1000  
Incubator   in  vials   containing  1.8  ml  phosphate  buffered  saline   (PBS)   (pH  7.4,  0.01  M,  
0.05%  NaN3).  At  defined  time  points  samples  were  taken  and  the  release  medium  was  
exchanged   completely.   All   samples   were   centrifuged   at   14000  rpm  
(Mikroliterzentrifuge   Z   160   M,   Hermle   Labortechnik,   Wehingen,   Germany)   for   5  
minutes   to   remove   lipid   particulates.  OVA  was  measured   in   the   supernatant   by  UV  
(Agilent   Technologies   8453)   at   a  wavelengths   of   280   nm.   For   each   tested  mixture   an  
implant   containing   neither   OVA   nor   QA   was   used   as   a   blank   for   the   UV  
measurements.  Measurements  were  performed  as  long  as  OVA  was  released  from  the  
implants.   Each   implant   was   weighted   before   the   release   and   the   total   amount   of  
protein   present   in   each   implant   was   calculated   individually   using   a   standard   curve  
prepared  by  an  11-­‐‑fold  1:1  dilution  starting  from  a  sample  of  3  mg  OVA  in  1  mL  PBS.  






2.2.6 In  vitro  release  of  Quil  A  from  implants  
Implants   were   cut   in   3.5   cm   lengths   and   weighed.   All   implants   contained   55%  
cholesterol,  340  –  750  µμg  of  QA  and  145  –  2240  µμg  of  OVA.  Implants  were  placed  into  5  
mL   tubes   filled   with   1.8   mL   PBS   buffer   (pH   7.3)   and   incubated   at   37°C   (Clayson  
incubator,  New  Zealand).  At  defined  time  points  samples  were   taken  and  the  release  
medium  was  exchanged  completely.  Samples  were  centrifuged  for  30  minutes  at  14000  
rpm   in   a   bench   top   centrifuge   (Prism   R,   Labnet   International   Inc.,   Edison,   USA)   to  
pellet  the  lipid  fractions.  The  supernatant  was  transferred  into  an  Eppendorf  tube  and  
stored  at  -­‐‑20°C  until  high  performance  liquid  chromatography  with  evaporating  light  
scattering  detector  (HPLC-­‐‑ELSD)  analysis  was  carried  out.  
2.2.7 Size  exclusion  chromatography  
Protein   integrity   was   determined   by   size   exclusion   chromatography   (SEC)   using   a  
Dinoex  HPLC  system  (Dionex,  Softron  GmbH,  Germering,  Germany).  A  TSKgel  G300  
SWXL   size-­‐‑exclusion   column   (7.8   mm   x   30.0   mm,   Tosoh   Bioscience,   Stuttgart,  
Germany)  was  kept   at   25°C   and   an   injection  volume  of   100  µμL  of   each   sample  were  
used.  The  running  buffer  consisted  of  50  mM  PBS  (pH  7.0,  0.05%  NaN3),  with  a   flow  
rate  set  to  0.5  mL/min.    
2.2.8 Scanning  electron  microscopy  (SEM)  
A  Jeol  JSM-­‐‑6500  F  (Jeol  JSM-­‐‑6500F,  Tokyao,  Japan)  was  used  at  an  acceleration  voltage  
of  2  kV  and  a  magnification  of  150  was  used.  After   release,   implants  were  dried   in  a  
vacuum   dryer   (Memmert,   Schwabach,   Germany)   at   20°C   and   50  mbar   for   24   hours.  
Implants  were   cut   and   attached   to   aluminum  blocks  with   double   adhesive   tape   and  
were  analyzed  without  further  treatment.    
2.2.9 High  performance  liquid  chromatography  with  evaporating  light  scattering  
detector  (HPLC-­‐‑ELSD)  
Analysis   was   carried   out   as   described   by   Bobbala   et   al.   [130].   The   HPLC   system  
consisted   of   1200   Series   evaporating   light   scattering   detector   (ELSD)   system   from  
Agilent   Technologies   (Santa  Clara,  USA)   equipped  with   a   ZORBAX  Eclipse   XDB-­‐‑C8  





temperature  of  25°C.  A  guard  column  (2.1  x  12.5  mm,  Agilent  Technologies)  was  used  
to  prevent  contamination  of  the  column  and  was  also  maintained  at  25°C.  The  injection  
volume   was   20   µμL.   The   mobile   phase   consisted   of   water/acetonitrile   (75:25%   v/v)  
containing   0.01%  v/v   formic   acid.  A   flow   rate   of   0.25  mL  per  minute  was   used.   The  
ELSD  settings  were  as  follows:  nebulizing  temperature  of  30°C,  nitrogen  gas  pressure  
at  3.5  bar,  gain  at  10.    
2.3 Results  and  discussion  
2.3.1 Preparation  of  implants  
Compared   to   lipid   implant   preparation   methods   often   seen   in   the   literature,   for  
example   compression  or  melting  methods,   twin-­‐‑screw  extrusion   is   a   faster   and  more  
easily   scaled  up  production  procedure.  However,   the   extrusion   conditions   as  well   as  
the   lipid   composition   need   to   be   chosen   with   great   care.   After   an   extrudable  
formulation  has  been  identified,  the  extrusion  temperature  has  to  be  optimized  so  as  to  
allow   the   lipid  mass   to   be   uniformly   extruded   through   the   outlet   die,   which   is   not  
possible   if   the   temperature   is   either   too   high   or   too   low.   In   our   study,   a   number   of  
different   formulations   were   tested   applying   different   extrusion   temperatures.   All  
formulations   consisted   of   a   mixture   of   CHOL,   soybean   lecithin   and   D114   with   or  
without   antigen   (OVA)   and/or   adjuvant   (QA)   (Table   2-­‐‑1).   The   percentage   of   CHOL  
was  varied  from  40%  to  60%  while  at   the  same  time  the  percentage  of  D114   (the   low  
melting  point   lipid)  was  decreased   from  45%   to   25%.  An   increase   of  CHOL   to  more  
than  60%  resulted  in  blockage  of  the  extruder,  indicating  the  importance  of  the  low  to  
high  melting   lipid   ratio   for   the  extrusion  process.  The  percentage  of   soybean   lecithin  
was   kept   constant   at   15%   in   all   formulations   as   increasing   it   above   15%   resulted   in  
lipid  mixtures  that  were  too  soft  for  extrusion.  
The  amount  of  protein  antigen  (0.13%  OVA)  and  adjuvant  (0.66%  QA)  included  in  the  
implants,  was  based  on  the  amounts  required  to   induce   immune  responses  [127].  For  
the  measurement  of  the  quantity  of  released  antigen,  2%  of  OVA  were  loaded  into  the  
implants   to  be  able   to  detect  OVA  release.  Two  concentrations  of  QA  were  examined  






Table  2-­‐‑1:  Different  formulations  extruded  in  this  study  










1   40   45   15   2   -­‐‑  
2   50   35   15   2   -­‐‑  
3   55   30   15   -­‐‑   -­‐‑  
4   55   30   15   2   -­‐‑  
5   55   30   15   2   0.3  
6   60   25   15   2   -­‐‑  
7   60   25   15   2   0.3  
8   55   30   15   -­‐‑   0.3  
9   55   30   15   -­‐‑   0.66  
10   55   30   15   0.13   0.66  
11   55   30   15   2   0.66  
2.3.2 Antigen  and  adjuvant  release  from  tsc-­‐‑extruded  lipid  implants    
Formulations  consisting  of  different  ratios  of  CHOL:  D114:  soybean  lecithin  (Table  2-­‐‑1)  
were   prepared   and   the   release   of   OVA   was   investigated   in   vitro.   Each   sample   was  
loaded  with  on  average  1.5  mg  of  OVA,  corresponding  to  2%  OVA  in  the  formulation.  
A   comparison   of   the   different   formulations   (Table   2-­‐‑1,   formulations   1,   2,   4   and   6)  
revealed  that  increasing  the  percentage  of  CHOL  from  40  to  60%  retarded  the  release  of  
OVA   from   the   implant   (Figure   2-­‐‑1).   This   behaviour   is   in   accordance   with   previous  
reports  by  Demana  et  al.   [120]   that  showed   that   the  release  of   the  model  antigen  PE-­‐‑
FITC-­‐‑OVA   could   be   slowed   down   by   over   50%   by   adding   an   additional   72%   of  
cholesterol   to  the  formulation.  Furthermore  we  can  see  that  release  discontinues  after  
100   hours,   except   for   the   formulation   containing   60%   of   cholesterol.   The   release   is  
either   too   low   to   be   detected   or   the   remaining  OVA   stays   inside   the   lipid  matrix.  A  
difference   in   release   between   implants   containing   40%,   50%,   55%,   or   60%   CHOL  
respectively,  can  already  be  observed  at  6  hours.  Roughly  20%  of  OVA  were  released  
from   all   the   formulations,   however   implants   containing   60%   CHOL   released  







Figure  2-­‐‑1:  Cumulative  release  of  OVA  from  implants  containing  40%,  50%,  55%,  or  60%  CHOL  
(Table  2-­‐‑1,  formulations  1,  2,  4  and  6).  Data  are  the  mean  and  SD  of  3  independent  replicates.  
The   effect   of   QA   in   the   implant   formulations   was   then   investigated.   Implants  
contained   0.3%  or   0.66%  QA,   and  2%  of  OVA,   respectively.  The   amount   of   adjuvant  
found   to   induce   immune   responses   corresponds   to   0.66%   [127].   The   addition   of  QA  
may  impact  on  OVA  release  as  QA  is  a  water-­‐‑soluble  saponin  and  upon  incubation  QA  
may   be   released   into   the   media.   This   could   enhance   the   formation   of   pores   in   the  
implant  matrix   and  as   a   consequence  diffusion  of   the   antigen  may  be  accelerated.   In  
Figure  2-­‐‑2  release  of  OVA  in  presence  of  QA  in  the  formulation  is  shown.  For  the  two  
different   percentages   of   QA   tested   in   this   experiment   (0.3%   and   0.66%),   the   OVA  
release  was  independent  of  the  amount  of  QA  incorporated  in  the  implants  (Figure  2-­‐‑2  
A).  Therefore,  in  the  following  experiments  we  investigated  the  influence  of  QA  on  the  
OVA   release   in   implants   containing   0.3%   QA   and   either   55%   and   60%   CHOL   and  
compared   them   to   formulations  without  QA   (Figure   2-­‐‑2   B).   Formulations   containing  
QA   showed   a   faster   release   of   antigen   compared   to   the   same   formulations   without  
adjuvant.   After   48   hours   approximately   20%   more   OVA   were   released   from   the  
formulations  containing  QA.  Formulations  with  QA  containing  55%  CHOL  showed  a  
difference  in  the  release  of  OVA  after  48  hours  opposed  to  the  formulations  containing  





hours).   This   confirms   previous   findings   of  Myschik   et   al.   [28]  who   showed   that   the  
presence  of  QA  in  the  formulation  enhances  the  release  of  OVA  through  the  creation  of  
pores  in  the  lipid  matrix.    
  
Figure   2-­‐‑2:   (A)   Cumulative   release   of   OVA   from   implants   containing   55%   CHOL,   0.3%  
respectively  0.66%  of  QA  and  2%  of  OVA   (Table  2-­‐‑1,   formulations  5  and  11).   (B)  Cumulative  
release   of  OVA   from   55%  CHOL   and   60%  CHOL   implants  with   and  without  QA   (Table   2-­‐‑1,  
formulations  4-­‐‑7).  Data  are  the  mean  and  SD  of  3  independent  replicates.  
The   release   of   QA   from   implants   was   quantified   using   HPLC   with   an   ELSD.   The  
implants  were  all   composed  of  55%  CHOL,  but   contained  different  amounts  of  OVA  
and  QA   (Table  2-­‐‑1,   formulations  5  and  8-­‐‑11).   It  was  observed   that   in   the  presence  of  
OVA   the   release   of  QA  was   faster   for   both  QA   concentrations   (0.66%  and   0.3%  QA)  
(Figure  2-­‐‑3).  This  is  likely  due  to  pore  formation  facilitating  the  release  of  QA  from  the  
lipid   matrix.   Interestingly,   in   contrast   to   antigen   release,   there   was   no   initial   burst  
release   of   the   adjuvant   and   instead   linear   release  was   observed   for   all   formulations  
tested   (Figure   2-­‐‑3).   QA   is   released   over   a   longer   period   of   time   (1-­‐‑3   extra   days)  
compared   to   the   model   antigen   (see   Figure   2-­‐‑2   and   2-­‐‑3),   meaning   that   QA   should  
always   be   present   when   OVA   is   being   released,   increasing   the   likelihood   that   an  
effective   immune   response   will   be   generated.   After   analysing   both,   antigen   and  
adjuvant  release,  it  can  be  concluded  that  both  are  released  faster  in  the  presence  of  the  






Figure  2-­‐‑3:  Cumulative  release  of  QA  from  implants  (55%  CHOL)  with  different  ratios  of  OVA  
and   QA   (Table   2-­‐‑1,   formulations   5   and   8-­‐‑11).   Data   are   the   mean   and   SD   of   3   independent  
replicates.  
2.3.3 Integrity  of  OVA  after  extrusion  and  upon  release  
As  well  as  investigating  the  overall  release  of  the  model  antigen,  the  integrity  of  OVA  
after   extrusion  and   release  was   investigated  using  SEC-­‐‑HPLC.  This   technique  allows  
quantification  of  the  amount  of  monomeric  protein  as  well  as  dimers  or  oligomers.  In  
general,  protein  aggregation  can  occur  due  to  different  stress  factors  (pH,  temperature,  
shear   or   mechanical   stress)   during   manufacturing   but   also   upon   incubation   [131].  
Changes  in  the  tertiary  and  quaternary  structure  of  the  protein  should  be  investigated,  
as   these   may   cause   problems   in   terms   of   product   quality   such   as   efficacy   or   safety  
[132].  On   the   other   hand,   protein   aggregates   are   able,   in   some   cases,   to   enhance   the  
immune  response   [133].  As  a  reference,  OVA  was   incubated   in  PBS  at  37°C  with  and  
without   QA   over   a   period   of   15   days   to   ensure   that   the   incubation   does   not  
compromise  the  integrity  of  OVA.  The  OVA  used  was  composed  of  90%  monomer  as  
raw  material.  The  percentage  of  monomer  present  during   the   incubation   in  PBS  with  
and  without  QA  was   around   90%   and   remained   constant   over   15   days   (Figure   2-­‐‑4).  
Figure   2-­‐‑4   shows   the   percentage   of   OVA   monomer   and   dimer   present   after   it   was  
released   from   the   implants.   It   can   therefore   be   concluded   that   the   extrusion   process  
itself   did   not   cause   any  protein  denaturation.  After   one  week   the   amount   of   protein  





formation  took  place  during  the  incubation.  As  this  increase  in  dimer  is  only  observed  
in  the  OVA  released  from  the  implants,  it  is  likely  that  while  incorporated  in  the  lipid  
matrix,  changes  in  protein  structure  occur.  In  general  Van  der  Waals  and  hydrophobic  
attractions   between   side   chains   and   backbone   atoms   are   responsible   for   folding   of  
proteins   [132].  The   inclusion  of  QA   into   the  PBS  had  no   effect   on  OVA  stability   and  
only  a  minor  effect  on  protein  stability  was  detectable  when  QA  was   included   in   the  
implants.    
  
Figure   2-­‐‑4:   Percentage   of   OVA  monomer   and   dimer   released   over   a   period   of   9   days   from  
implants  with  and  without  QA  (Table  1,   formulations  4  and  5).  Percentage  of  OVA  monomer  
for  OVA  and  OVA+QA  incubated  in  PBS  at  37°C.  Data  are  the  mean    and  SD  of  3  independent  
replicates.  
2.3.4 Surface  characteristics  of  implants  before  and  after  72  hours  of  release  
The  surface  of  the  implants  after  the  extrusion  process  and  following  an  incubation  of  
72  hours   in  media  at  37°C  was   investigated  using  SEM  (Figure  2-­‐‑5).     Blank   implants,  
implants  without  OVA  and  QA  (Table  2-­‐‑1,  formulation  3),  were  compared  to  implants  
containing  OVA  only  or  a  combination  of  OVA  and  QA  (Table  2-­‐‑1,  formulations  4  and  
5).  Directly  after  extrusion,   there  were  no  visible  differences   in   the  appearance  of   the  
three   formulations   with   the   implant   surfaces   appearing   relatively   smooth.   After   72  
hours  incubation  in  media,  differences  in  the  surface  appearance  were  visible  and  were  





pores  were  observed   for   the  blank   implants   (Figure   2-­‐‑5  B)  while   the   surface  of  OVA  
implants   contained   some   larger   pores   (20-­‐‑30   µμm)   and   the   entire   implant   surface  
appeared  rougher  (Figure  2-­‐‑5  D).  Implants  containing  OVA  and  QA  also  had  a  rough  
surface  with  many  small  pores  (less  than  10  µμm  in  size)  and  a  few  larger  ones  (Figure  
2-­‐‑5  F).  This  high  number  of  small  pores  on  the  surface  might  explain  the  difference  in  
release  between  implants  with  and  without  QA.  
  
Figure   2-­‐‑5:   Scanning   electron   micrographs   obtained   from   lipid   implants   after   extrusion   and  
after   the   72   hours   in   PBS   buffer   (pH   7.4)   at   37°C.   Formulations   contained   55%   CHOL,   15%  
soybean   lecithin  and  30%  D114   (Table  1,   formulation  3-­‐‑5).   (A)  and   (B)  blank   implant.   (C)  and  
(D)  contained  2%  OVA.  (E)  and  (F)  2%  OVA  and  0.3%  QA.  White  arrows  indicating  the  pores.  
Scale  bar  =  100  µμm.  Magnification  150  x.  
2.3.5 Release  of  OVA  from  cured  implants  
The  extruded   implants  described  above   released  antigen  and  adjuvant  over  a  7   to  12  





stimulation   required   to   induce   protective   effector   and   memory   immune   responses,  
therefore   studies  were   carried  out   to  determine   if   antigen   release   could  be   sustained  
longer.  One  potential  mechanism  for  achieving  a  more  sustained  release  is  to  cure  the  
implants,   thereby   creating   a   denser   lipid   matrix   on   the   outer   surface   and   as   a  
consequence  slowing  antigen  release  [129].  Curing  temperatures  between  40  and  55°C  
were   used   as   these   are   below   the   melting   temperature   of   the   low   melting   lipid  
Dynasan  114   (55-­‐‑58°C).   Implants  were  cured  for  60  min  except   for  curing  at  55°C.  At  
55°C   a   curing   time   of   15   min   instead   of   60   min   was   chosen   to   avoid   implant  
deformation.  The  melting   temperature  of  D114   is   close   to  55°C  and   the   implants   lost  
their  shape  when  curing  them  longer  than  15  min  at  this  temperature.    
Curing  of  the  implants  (Table  2-­‐‑1,  formulations  4  and  5)  extended  release  of  antigen  to  
14  days,  which  was  twice  as  long  as  release  from  the  non-­‐‑cured  implants  (Figure  2-­‐‑6  A  
and  B).   Incomplete  OVA  release  was  again  observed   from   implants  without  QA  and  
this  was  in  most  cases  further  reduced  (to  less  than  60%)  by  curing  compared  to  non-­‐‑
cured   implants.  Also   for   implants   containing  QA,   curing   slowed   the   release   (around  
60%  at  4  days  as  compared  to  90%  release  for  the  non-­‐‑cured  implants),  extending  the  
release  to  14  days  (Figure  2-­‐‑6  B).  Interestingly,  from  day  seven  on  increased  release  was  
observed   from   implants   cured   at   higher   temperatures.   This   is   in   agreement   with  
studies  reporting  that  the  use  of  curing  temperatures  closer  to  the  melting  temperature  
of  the  lipid  results  in  the  formation  of  larger  pores  and  channels  compared  to  curing  at  






Figure   2-­‐‑6:   Cumulative   release   of   OVA   from   cured   implants   containing   55%   CHOL.   (A)  
Without  QA.  (B)  With  QA.  Data  are  the  mean  and  SD  of  3  independent  replicates.  
These   results   show   that   curing   does   slow   down   antigen   release,   but   among   cured  
implants   there   are   differences   in   release   depending   on   the   curing   temperature.  
Depending  on  the  curing  temperature,  pores  of  different  sizes  could  have  been  formed  
on  the  implant  surface.  If  there  are  larger  or  more  pores  it  is  easier  for  the  release  buffer  
to  penetrate  into  the  implants  and  higher  amounts  of  drug  can  be  dissolved  in  buffer  
and  become  available   for  diffusion.  Buffer  movement   into   implants  has  an   important  
influence   on   the   release   duration   [134].   To   confirm   these   assumptions,   scanning  
electron  micrographs  of  implant  surfaces  were  recorded  after  curing  and  after  14  days  
of   release.  After   curing  no  difference   in   surface   structure   resulting   from   the  different  
curing   temperatures   could   be   observed   (data   not   shown).   Figure   2-­‐‑7   shows   the  
micrographs   taken   for   implants   containing   OVA   after   14   days   incubation   in   release  
buffer.   The  micrographs   show   that   implants   cured   at   temperature   higher   than   40°C  
have   pores   on   their   surface   after   14   days   of   incubation.   The   same  was   observed   for  
implants   containing  QA+OVA.  On   the  other  hand,  blank   implants  did  not   show  any  







Figure   2-­‐‑7:  Scanning   electron  micrographs   obtained   from   lipid   implants   after   14  days   in  PBS  
buffer  (pH  7.4)  at  37°C.  Implants  were  cured  at  40°C,  45°C,  50°C  respectively  55°C.  Scale  bar  =  
10  µμm.  Magnification  500  x.    
2.3.6 Investigation  of  lipid  stability  using  differential  scanning  calorimetry  (DSC)  
The   thermal   stress   induced   by   the   curing   step   may   lead   to   transitions   to   unstable  
polymorphs   which   subsequently,   upon   storage,   may   transform   to   a   more   stable  
polymorph  [135].  Changes  in  the  matrix  structure  of  implants  can  be  the  consequence  
of  such  rearrangements  and  might  have  an  influence  on  release  behaviour.  Therefore,  
polymorphic   modifications   were   investigated   directly   after   the   curing   process   by  
differential   scanning   calorimetry.   Prior   to   thermal   analysis,   melting   points   and  
polymorphic   behaviour   of   the   individual   lipids   (D114,   CHOL   and   soybean   lecithin)  
were  measured   as   reference   values   (Figure   2-­‐‑8   A).   One   single   endothermic   event   at  
59°C  (n=3,  SD=0.8)  can  be   identified   in  the  thermogram  of  D114.  This   is  characteristic  
for  the  melting  of  the  stable  β-­‐‑modification  of  pure  D114  at  around  56°C  [136].  CHOL  
showed   a   sharp  melting  peak   at   149°C   (n=3,   SD=0.5)   as  well   as   a   small   endothermic  
event   at   38.4°C   (n=3,   SD=0.2)   characteristic   for   impurities   in   cholesterol.   Soybean  
lecithin   did   not   show   a   distinct  melting   peak   but   the   thermogram   indicated   that   an  





implants   undergo   thermal   and   mechanical   stress,   therefore   a   thermogram   of   the  
extrudates  immediately  after  the  extrusion  was  recorded  to  investigate  if  any  changes  
to   the  polymorphism  of   the   lipids   took  place   (Figure  2-­‐‑8  B  no   curing).  The  extrusion  
process  did  not  affect  the  crystalline  state  of  the  material  as  no  re-­‐‑crystallization  events  
or  unstable  modifications  after  extrusion  could  be   identified.  Two  endothermic  peaks  
were  detected   in   the   thermograms  of   the  extrudates   (Figure  2-­‐‑8  B  no  post-­‐‑treatment)  
corresponding  to  the  melting  endotherms  of  D114  and  CHOL.  It  can  be  assumed  that  
D114   crystallized   in   the   stable   β-­‐‑modification,   as   the   first   peak   is   observed   at   59°C,  
corresponding   to   the   melting   endotherm   of   D114   also   observed   for   the   pure   D114  
(Figure  2-­‐‑8  A).  In  contrast  to  the  endotherm  observed  for  pure  CHOL,  the  intensity  and  
shape  of  the  endothermic  event  associated  with  melting  of  CHOL  changed.  Decreased  
peak   intensity  as  well  as  a  shift   from  149°C   to  117°C  was  apparent.  Vogelhuber  et  al.  
(2003)   [115]   described   the   same   behaviour   when   studying   glyceryl  
trimyristate/cholesterol   mixtures   and   this   was   interpreted   as   a   melting   point  
depression.   These   results   let   to   the   assumption   that   small   amounts   of   triglycerides  
dissolve  in  the  cholesterol  phase.    
Thermograms  of  cured  implants  are  shown  in  Figure  2-­‐‑8  B.  No  re-­‐‑crystallizations  took  
place  and  no  unstable  modifications  appeared  except   for   the   implants   cured  at   55°C.  
For   these   implants   the   thermogram   showed   two   smaller   peaks   and   one  major   peak.  
The  temperatures  of  the  two  smaller  peaks,  38.9°C  (n=3,  SD  =  0.19)  and  47.7°C  (n=3,  SD  
=   0.05)   correspond   to   the   values   found   in   literature   for   the   unstable   α   and   β᾽  
modifications   of  D114   [137].   The  major  peak   at   58.1°C   (n=3,   SD=0.92)   corresponds   to  
the  stable  β  modification.  In  conclusion,  curing  too  close  to  the  melting  temperature  of  
D114   is   not   recommended   as   unstable   polymorphs   occurred  due   to   this   curing   step.  
However,  storing  these  implants  for  1  week  at  25°C  was  enough  time  for  the  instable  
form  to  shift  back  into  the  stable  β  modification  (Figure  2-­‐‑8  B).  This  shows  that  higher  
curing   temperatures   can  be  used,   if   tempering   the   implants  post-­‐‑manufacture  allows  






Figure  2-­‐‑8:  DSC   thermograms  of:   (A)  pure   components,  D114   (         ),  CHOL   (-­‐‑   -­‐‑   -­‐‑)   and  soybean  
lecithin  (·∙·∙·∙),  (B)  implants  right  after  extrusion  (-­‐‑·∙-­‐‑·∙)  and  after  post  treatment  at  45°C  (·∙·∙·∙),  50°C  (-­‐‑  -­‐‑  
-­‐‑)  ,55°C  (      )  and  55°C  (-­‐‑-­‐‑-­‐‑)  after  1  week  storage  at  room  temperature  (n  =  3).  (Formulations  4  and  
5  Table  2-­‐‑1)  
2.4 Conclusion  
This  study  showed  that  the  formulation  of  the  implant  as  well  as  the  addition  of  actives  
to   the   formulation   have   an   impact   on   release   behaviour   of   the   model   antigen.  
Importantly  the  adjuvant  QA  was  released  over  approximately  the  same  period  of  time  
as  the  model  antigen,  which  is  an  important  feature  for  vaccine  delivery.  Furthermore,  
post-­‐‑extrusion   curing   of   the   implants   slowed   the   release   of   the   model   antigen.  
However   the   curing   temperature   itself   is   of   great   importance   as   it   influences   the  
antigen   release   and   can   lead   to   unstable   polymorphs   and   therefore  must   be   chosen  
carefully.  
2.5 Data  additional  to  the  publication  







In  vivo  investigation  of  twin-­‐‑screw  extruded  lipid  implants  
for  vaccine  delivery  
Parts  of  this  chapter  have  been  published  as  peer-­‐‑reviewed  article:  
Even  MP,  Young  K,  Winter  G,  Hook   S,   Engert   J.   In   vivo   investigation  of   twin-­‐‑screw  
extruded  lipid  implants  for  vaccine  delivery.  Eur  J  Pharm  Biopharm.  2014  Jul;87(2):338-­‐‑
46  





3 In  vivo  investigation  of  twin-­‐‑screw  extruded  lipid  implants  for  
vaccine  delivery  
In   the   last   chapter   the  use   of   twin-­‐‑screw   extrusion   as  possible  production  device   for  
lipid  sustained  vaccine  delivery  systems  was  investigated.  It  was  shown  that  implants  
were   successfully   produced   by   tsc   extrusion.   A   simultaneous   adjuvant   and   antigen  
release  behaviour  was  observed.  Now  the  stability  of  the  implants  was  analysed.  First  
the  effect  the  mechanical  and  thermal  stress  that  the  extrusion  process  itself  has  on  the  
lipids  was  examined.  As  they  easily  undergo  polymorph  changes  thermograms  of  the  
lipids  before  and  after  extrusion  were  recorded.  The   influence  storage  might  have  on  
the   mechanical   properties   and   polymorph   state   of   implants   was   investigated.  
Furthermore,   the  potential   advantage   of  particulate  delivery  was   studied.  Preformed  
liposomes  were  incorporated  into  the  lipid  implants  during  the  extrusion  process.  The  
main  part  of  this  chapter  revolves  around  an  in  vivo  study  in  a  mouse  model.  Implants  
with   and   without   preformed   liposomes   were   compared   to   an   antigen   +   adjuvant  
injection.  In  a  first  study,  the  in  vivo  release  of  the  model  antigen  was  investigated  and  
compared  to  the  in  vitro  release.  In  a  second  study,  the  induced  immune  response  was  
analysed.  Cytokine  secretion  was  measured   to   identify   if  a  Th1  or  Th2   type  response  
was   triggered.   Moreover,   CD4   and   CD8   OVA-­‐‑specific   T-­‐‑cell   proliferation   was  
measured  as  well  as  antibody  titres.  These  studies  should  evaluate  if  the  lipid  implant  
systems  are  well  tolerated  in  vivo  and  are  able  induce  an  immune  answer  in  vivo.    
In  the  following  parts  of  this  chapter  the  published  text  is  reprinted.  All  the  work  was  
conducted  by  me.  The  two   in  vivo  studies  were  led  with  the  help  of  Katie  Young  and  
Julia   Engert   under   the   supervision   of   Sarah   Hook   at   the   School   of   Pharmacy,  
University  of  Otago.  Richard  Easingwood,  Otago  Centre   for  Electron  Microscopy,   for  
assisted  with  TEM.  






Sustained   release   systems   have   become   the   focus   of   attention   in   vaccine   delivery   as  
they  may  reduce  or  prevent  the  need  for  repeated  dosing.  In  this  work,  lipid  implants  
were  prepared  by  twin-­‐‑screw  extrusion  and  investigated  as  vaccine  delivery  systems  in  
vivo.  The   lipid   implants   consisted  of   cholesterol,   soybean   lecithin,   and  Dynasan   114.  
Ovalbumin  (OVA)  was  employed  as  a  model  antigen  and  Quil-­‐‑A  (QA)  as  an  adjuvant.  
In  addition,  OVA  and  QA  loaded  liposomes  were  prepared  by  the  lipid-­‐‑film  hydration  
method,   freeze-­‐‑dried  and   then  added   to   the   lipid  matrix  prior   to   extrusion.   Implants  
were   administered   subcutaneously   and   the   kinetics   of   antigen   release   as  well   as   the  
overall   immune  response  stimulated  were  analysed  by  measuring  CD4+  and  CD8+  T  
cell   proliferation,   OVA-­‐‑specific   IgG   production   as   well   as   cytokine   (IFN-­‐‑γ   and   IL4)  
secretion.  Vaccine   release   from   the   implants  was   completed   by   14  days.   Inclusion   of  
adjuvant   into   the   implants   was   required   for   the   generation   of   cellular   and   humoral  
immune   responses.   Inclusion   of   liposomes   into   the   implant   did   not   enhance   the  
resulting  immune  responses  generated  
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Modern  vaccines  often  utilise  subunit  antigens  such  as  peptides  or  proteins  instead  of  
the  whole  pathogen  for  safety  and  purity  reasons  [5].  However,  subunit  vaccines  need  
to  be  administered  multiple  times  in  combination  with  immunostimulatory  adjuvants  
in  order  to  induce  immunity  [5].  This  is  because  subunit  vaccines  are  less  immunogenic  
than   whole-­‐‑pathogen   vaccines   as   they   lack   secondary   signals   required   for   the  
stimulation  of  immune  responses  [6].    
The   most   commonly   used   and   licensed   adjuvant   is   alum.   While   the   exact   mode   of  
action   of   alum   is   still   point   of   discussion   in   the   research   community,   a   prolonged  
release   from   an   antigen   depot   has   been   proposed   to   be   important   [138,139].   Thus,  
single-­‐‑shot   administration   of   a   vaccine  with   sustained   (7-­‐‑10   days)   and   synchronised  
release  of  the  antigen  and  adjuvant  is  a  potential  alternative  to  giving  multiple  vaccine  
doses  and  one  which  will  potentially  induce  superior  immune  responses.    
Different  systems  for  the  controlled  release  of  vaccines  have  been  evaluated,  including  
controlled   release  particles,   implants   and  depot   systems.  A  variety   of  materials   have  
been   analysed,  with   early   studies  using  non-­‐‑degradable  polymers,   requiring   surgical  
removal   of   the   system   after   the   drug   has   been   released,   and   more   recent   studies  
utilising   biodegradable   systems   [116].   Biodegradable   PLGA   nanoparticles   have   been  
investigated   for   the   controlled   release   of   protein   antigens   such   as   OVA   and   have  
shown  great  potential  [34].  Systems  can  be  developed  to  release  antigen  for  a  range  of  
times  from  days  up  to  months  [34].  
Implants   as   vaccine   delivery   systems   have   been   investigated   since   the   early   1970s.  
These   implants   consisted   either   of   silicone,   ethylene-­‐‑vinyl-­‐‑acetate   copolymer,   or  
collagen.  
Later,  lipid  implant  systems  for  sustained  release  of  drug  or  antigen  were  investigated  
[28,79,126].   The   majority   of   the   implants   were   prepared   by   direct   compression,   a  
technique  that  can  be  applied  in  the  laboratory  setting,  but  is  challenging  for  scale-­‐‑up  
to  larger  batch  sizes  and  the  resulting  disk-­‐‑shaped  implants  are  not  feasible  for  human  





Myschik   (2008)   [28]   was   able   to   show   that   lipid   implants   manufactured   by   direct  
compression   were   able   to   stimulate   immune   responses   comparable   to   two  
immunizations   with   an   equivalent   liquid   vaccine   [29].   Importantly,   these   implants  
stimulated  CD8  immune  responses  –  the  type  required  for  therapeutic  cancer  vaccines.  
Unfortunately,  efficacy  of   cancer  vaccines   is   low  even  with  multiple  doses  of  vaccine  
being  given,  demonstrating  the  need  for  new  vaccine  formulations  [140].  
The  aim  of  the  current  work  was  to  manufacture  lipid  implants  for  vaccine  delivery  by  
twin-­‐‑screw   extrusion   and   evaluate   the   efficacy   of   this   implant   system   in   stimulating  
immune   responses   in   vivo.   Twin-­‐‑screw   extrusion   has   been   used   successfully   for   the  
preparation   of   implants   from   triglycerides   and   mixtures   of   triglycerides   for   the  
sustained  delivery  of  proteins  [124],  however,  it  has  not  been  used  to  produce  implants  
for   vaccine   delivery  where   the   amount   of   active   ingredient   included   is  much   lower.  
The   extrusion   process   easily   converts   the   raw   materials   into   a   product   of   uniform  
density  and  shape  in  a  one-­‐‑step  production  process  by  pushing  it  through  a  die  under  
controlled   conditions.   Lipid   implants   consisting   of   cholesterol,   soybean   lecithin,   and  
Dynasan   114   were   prepared  with   a   load   of   20   µμg   antigen   and   100   µμg   adjuvant.   To  
combine   the   advantages   of   particulate   delivery   and   sustained   release,   preformed  
liposomes  were  incorporated  into  the  implants  prior  to  extrusion.    
After   preparation,   the   implants   were   administered   through   a   trocar   into   the  
subcutaneous  tissue.  For  the  analysis  of  the  immune  response,  two  sets  of  experiments  
were  performed,  one  evaluating  the  kinetics  of  the  release  of  the  model  antigen  in  vivo,  
a   second   one   to   evaluate   the   immune   response   in   vivo.   Ovalbumin   in   a   liquid   alum  
dispersion  served  as  control.  
3.2 Materials  and  methods  
3.2.1 Materials  
Ovalbumin   from   chicken   egg   white   (OVA)   grade   V   was   purchased   from   Sigma-­‐‑
Aldrich.  Ovalbumin,  Fluorescein  CO  (FITC-­‐‑OVA)  from  Life  Technologies  (Darmstadt,  
Germany).   Cholesterol   (CHOL),   purity   95%,   was   purchased   from   AlfaAesar  





purchased   from  APPLICHEM  LIFESCIENCE   (Darmstadt,  Germany).  Puriﬁed  Quil-­‐‑A  
(QA)  was  sourced  from  Brenntag  Biosector  (Frederikssund,  Denmark),  as  a  lyophilised,  
powder,   and   was   used   as   supplied.   Dynasan   114   (D114)   was   kindly   provided   by  
SASOL  Germany  GmbH  (Witten,  Germany).  Chloroform  (HPLC  grade)  was  purchased  
from   Fisher   Scientific.   Ultrapure   deionised  water   having   a   conductivity   of   less   than  
0.055   µμS/cm   (Milli-­‐‑Q  Water   systems,  Millipore,  MA,  USA)  was   used   throughout   the  
study.  All  other  chemicals  were  of  analytical  grade.  
The   following   agents   were   used   for   the   immunological   study:   anti-­‐‑CD16/CD32  
antibody  (2.4G2  Fc  block),  CD4-­‐‑FITC,  CD4-­‐‑biotin,  CD4  V500,  CD8-­‐‑APC,  CD8-­‐‑PE,  CD8  
PE-­‐‑Cy  7,  Va2-­‐‑PE,  Vb5.1-­‐‑biotin,  PI,  CD122  FITC,  CD44  APC,  CD127  V450  and  anti-­‐‑CD3e  
(BD  Biosciences).  5,  6-­‐‑carboxy-­‐‑fluoresceine  diacetate  succinimidyl  ester  was  purchased  
Molecular   Probes.   All   single-­‐‑cell   suspensions   were   prepared   in   sterile   complete  
Iscove’s  Modiﬁed  Dulbecco’s  Medium  [cIMDM;   IMDM  supplemented  with  5%  foetal  
bovine  serum,  1%  penicillin/streptomycin,  1%  glutamax  and  0.01%  2-­‐‑mercaptoethanol  
all  from  Gibco  Life  Technologies  (New-­‐‑York,  USA)].  
3.2.2 Preparation  of  lipid  implants  by  twin-­‐‑screw  (tsc)  extrusion  
Implants   were   prepared   from   mixtures   of   soybean   lecithin,   CHOL,   D114,   with   and  
without  OVA  and/or  QA.  Soybean  lecithin  and  D114  were  transferred  into  high  grade  
stainless   steel   beakers   for   milling   in   a   swing   mill   Retsch®   CryoMill   (Retsch  
Technology,  Haan,  Germany).  After  precooling  the  system  with  liquid  nitrogen  for  10  
minutes  at  5  Hz,   soybean   lecithin  and  D114  were  ground   for  1  minute  at  25  Hz.  The  
obtained   powder   was   mixed   by   hand,   using   a   plastic   mortar   and   pestle,   with   the  
remaining   ingredients.   The   final  mixture  was   then   gradually   blended  with   a  mix   of  
OVA   and   QA   and   subsequently   fed   into   a   twin-­‐‑screw   extruder   (Haake   MiniLab®  
Micro  Rheology  Compounder,  Thermo  Haake,  Germany).  The  implants  were  extruded  
with  closed  bypass  channel  and  a  rotation  speed  of  40  rpm  at  an  extrusion  temperature  
of   45°C.   The   resulting   implants   had   a   diameter   of   2  mm  and  were   subsequently   cut  





3.2.3 Preparation  of  implants  by  twin-­‐‑screw  extrusion  containing  preformed  
liposomes  
Liposomes  consisting  of  soybean  lecithin  and  cholesterol  were  prepared  using  the  lipid  
film   hydration   method   as   described   previously   [141].   Briefly,   0.9   mg   of   soybean  
lecithin   and   0.23  mg   of   cholesterol  were   dissolved   in   70  mL   of   chloroform   [28].   The  
organic   solvent  was   evaporated   under   reduced   pressure   in   a  water   bath   at   45°C   for  
approximately  1  hour  using  a  rotary  evaporator  (Laborota  4001,  Heidolph,  Germany).  
Residual   chloroform  was   removed   by   flushing   of   the   flasks   with   nitrogen.   The   thin  
lipid   film  was   rehydrated   by   an   aqueous   solution   (70  mL)   containing   OVA  with   or  
without  QA.  Glass   beads  were   added   to   the   flasks   that  were   rotated   for   1   h   and   an  
additional   rehydration   time   of   approximately   3   h   was   given   for   the   samples   to  
equilibrate.   The   liposome   size   and   size   distribution   were   determined   using   a   Laser  
Scattering   Particle   Size   Distribution   Analyzer   (LA-­‐‑950,   HORIBA   Scientific).   The  
obtained  dispersion  was  then  freeze  dried  in  a  Christ  Epsilon  2-­‐‑6D  freeze-­‐‑drier  (Christ,  
Germany)   for   a   total   duration   of   44   hours   employing   a   conventional   freeze-­‐‑drying  
protocol.    
Lyophilized   powders  were  mixed   to  D114   and   additional   CHOL   in   a   plastic  mortar  
and   subsequently   fed   into   the   twin-­‐‑screw   extruder.   The   extrusion  was   performed   at  
45°C.    
3.2.4 Applicability  of  tsc  extrudates  through  trocar  into  cadaver  pig  skin  
Extrudates  of  a  length  of  1  cm  and  a  diameter  of  2  mm  were  introduced  into  cadaver  
pig  skin  using  a  trocar  with  an  inner  diameter  of  2  mm.  After  application  into  the  pig  
skin,  the  skin  was  carefully  cut  open  and  the  extrudates  were  retrieved.  Pictures  of  the  
implants  were  taken  before  and  after  the  application.  
3.2.5 Texture  analysis  of  implants  
The  mechanical  stability,  the  hardness/softness  of  the  lipid  implants,  was  tested  using  a  
TA.XT  Plus  Texture  Analyser  (Stable  Micro  Systems).  A  stainless  steel  cylinder  with  a  
diameter  of  5  mm  was  attached  to  the  machine  and  used  to  compress  the  implants  and  





3.2.6 Differential  scanning  calorimetry  (DSC)  
All   lipids  were  analysed  by  DSC   (204  Phoenix,  Netsch,  Selb,  Germany)  prior   to   their  
use,   to   obtain   a   reference   to   identify   eventual   polymorph   changes   induced   by  
processing  or  subsequent  storage.  Samples  of  approximately  4  mg  were  weighed  into  
aluminium  crucibles.  Heating  and  cooling  rates  were  set  to  5  K/min  between  20°C  and  
160°C.  An  empty  crucible  was  used  as  the  reference.  
3.2.7 In  vitro  release  of  FITC-­‐‑OVA  from  implants  
FITC-­‐‑OVA  was  incorporated  into  the  implants  to  investigate  the  in  vitro  release  of  the  
model   antigen.   The   extruded   strand   was   cut   into   pieces   of   a   length   of   2.5   cm.   The  
implants   (n=3)   were   placed   into   vials   containing   1.8   mL   PBS   (pH   7.4,   0.01M,   0.05%  
NaN3)  and  incubated  at  37°C  in  a  Heidolph  Inkubator  1000.  At  defined  time  intervals  
samples   were   taken   and   the   release   medium  was   exchanged   completely.   The   taken  
samples  were  centrifuged  for  5  minutes  at  14000  rpm  to  remove  potential  lipid  pieces.  
Protein   content   was   determined   via   size   exclusion   chromatography   (SEC)(Dionex  
GmbH,   Idstein,  Germany)  The   flow  rate  was  0.5  mL/min  and  100  µμL  of   each   sample  
were   injected  onto  a  TSKgel  G3000  SWXL  size-­‐‑exclusion  column  (7.8  mm  x  30.0  mm,  
Tosoh   Bioscience,   Stuttgart,   Germany).   The   running   buffer   consisted   of   50  mM   PBS  
(pH  7.0,  0.05%  NaN3).  
3.2.8 Animals  
Female  C57Bl/6  and  OT-­‐‑I  and  OT-­‐‑II  transgenic  mice  were  bred  and  maintained  under  
specific   pathogen-­‐‑free   (SPF)   conditions   at   the   HTRU,   Dunedin,   New   Zealand.   Mice  
were   between   6   and   8  weeks   of   age   and   had   access   to  water   and   food   available   ad  
libitum.   All   experiments   were   approved   by   the   University   of   Otago   Animal   Ethics  
Committee,  AEC-­‐‑Code:  D64/12.  
3.2.9 Preparation  of  OVA-­‐‑specific  TCR  transgenic  T  cells  
Spleen,  axial  and  brachial  lymph  nodes  were  harvested  from  OT-­‐‑I  and  OT-­‐‑II  transgenic  
mice.  These  mice  contain  high  proportions  of  CD4  (OT-­‐‑I)  and  CD8  (OT-­‐‑II)  T  cells  that  
specifically  recognise  peptides  derived  from  chicken  ovalbumin  [142].  Red  blood  cells  





(ratio   9:1),   pH   7.65)   (5   mL/spleen).   Single-­‐‑cell   suspensions   were   prepared   in   sterile  
complete   IMDM.  After   centrifugation   (1100   rpm,   8  min),   the   cells  were   resuspended  
and   counted   by   phase-­‐‑contrast   microscopy   using   trypan   blue   stain   to   exclude   dead  
cells.   The   cells   were   then   either   stained   with   5,   6-­‐‑carboxy-­‐‑fluoresceine   diacetate  
succinimidyl  ester   (CFSE)   [143,144]  or   left  unstained.  After   several  washing  steps   the  
cells  were  resuspended  in  sterile  PBS  at  required  concentrations,  and  were  injected  via  
the  tail  vein  into  C57Bl/6.  
3.2.10 Immunisation  protocol  to  determine  the  kinetics  of  antigen  release  
This  set  of  experiments  determined  the  duration  of  antigen  release  from  the  implants.  
Six  different  formulations  were  analysed  (Table  3-­‐‑1).  
On  day  0  the  C57Bl/6  mice  were  immunised  with  the  vaccines.  The  vaccines  (implants  
or   aqueous   control   vaccine)   were   given   subcutaneously   into   the   neck   of   the   mice.  
Aqueous   vaccines  were   given   in   a   volume   of   200   µμl.   For   insertion   of   implants  mice  
were  anaesthetized  with  isoflurane,  and  an  injection  of  carprofen  (5  mg/kg)  was  given  
before   the   surgery   for   post-­‐‑operative   analgesia.   Once   a   surgical   level   of   anaesthesia  
was  reached  (measured  by  lack  of  pedal  withdrawal)  a  small  incision  was  made  at  the  
base   of   the   back   and   a   trocar   was   used   to   insert   the   implant   to   the   dorsal   skinfold  
under  aseptic  conditions.  The   incision  was  closed  with  a  Michel  clip.  The  cages  were  
placed  on  heating  pads  until  all  mice  were  recovered  fully  from  anaesthesia.    
On  day  1,  7,  14  or  21,  4  x106  CFSE  stained  CD4  and  CD8  OVA  transgenic  T  cells  from  
OT-­‐‑I  and  OT-­‐‑II   transgenic  mice  were   injected   intravenously   in  200  µμl  sterile  PBS  into  
the   immunized   C57Bl/6   mice.   Three   days   later   the   mice   were   sacrificed   by   cervical  
dislocation  and   the   spleens  were   removed.  Antigen-­‐‑specific  proliferation  of  CD4  and  






Table  3-­‐‑1:  Composition  of  the  different  formulations  used  for  the  in  vivo  experiments  and  the  
corresponding  immunisation  protocol.  
Group   Formulation   Adjuvant   Immunisation  time  point:  
  Immunology  experiments  
1   Blank  implant   No   Day  0  
2   OVA  implant   No   Day  0  
3   OVA/QA  implant   Yes   Day  0  
4   OVA  implant  liposomes   No   Day  0  
5   OVA/QA  implant  liposomes   Yes   Day  0  
6   Alum  +  OVA   Yes   Days  0,  14  
3.2.11 Immunisation  protocol  to  determine  the  quality  of  immune  response  
On  day  -­‐‑1  transgenic  OT-­‐‑I  and  OT-­‐‑II  cells  were  obtained  from  the  spleens  and  lymph  
nodes   of   transgenic  mice   as   described   in   the   previous   section.   Transgenic   cells  were  
injected   via   the   tail   vein   into   C57Bl/6   mice   at   a   concentration   of   2   x105   transgenic  
cells/mL   in  200  µμL  sterile  PBS.  On  day  0   the  C57Bl/6  mice  were   immunised  with   the  
vaccines   as   described   in   the   kinetics   experiments.   On   day   14,   mice   receiving   alum  
formulations  were  boosted.  On  day  28,  mice  were  sacrificed  using  a  lethal  overdose  of  
ketamine/xylazine  and  blood  was  collected  from  the  distal  aorta.  The  axial  and  brachial  
lymph  nodes  draining  the  site  of  vaccination  were  collected  to  assess  the  local  immune  
response   to   the   vaccination.   The   spleens   were   also   harvested   to   allow   for   the  
assessment  of  the  systemic  immune  response  to  the  vaccine.  
3.2.12 Flow  cytometry  
Aliquots  of  cells  were  washed  in  ﬂuorescence-­‐‑activated  cell  sorting  (FACS)  buffer  (PBS  
containing   1%   BSA   and   0.01%   sodium   azide)   and   were   incubated   with   anti-­‐‑
CD16/CD32  antibody  (2.4G2  Fc  block)  to  block  non-­‐‑speciﬁc  binding.  A  combination  of  
mAb  was  added  to  the  samples  and  incubated  on  ice  in  the  dark  for  10  min.  Samples  
were   then   stained  with:   anti-­‐‑CD16/CD32   antibody   (2.4G2  Fc   block),  CD4-­‐‑FITC,  CD8-­‐‑





used.  A  BD  FACSCanto   II   (Becton  Dickinson,  Franklin  Lakes,  NJ,  USA)  was  used   for  
the   acquisition   of   flow   cytometry   data.   Data   analysis   was   carried   out   using   FlowJo  
(Tree  Star,  Inc.,  Ashland,  USA).    
3.2.13 OVA-­‐‑specific  IgG  response  in  serum  of  vaccinated  mice  
Blood  samples  were  collected  from  all  animals  and  spun  for  10  minutes  at  5000  rpm  to  
separate   the   serum.   The   serum   was   stored   at   -­‐‑20°C   until   analysis   as   described  
previously.    
3.2.14 Measurement  of  OVA-­‐‑specific  Interferon-­‐‑ϒ    
Single  cell  suspensions  (2  x  106  cells/mL)  prepared  from  the  lymph  nodes  and  spleens  
of  vaccinated  mice  were  restimulated  with  α-­‐‑CD3  (10  µμg/mL)  plus  IL-­‐‑2  (2  ng/mL),  Ova  
(200  µμg/mL)  plus  IL-­‐‑2  (2  ng/mL),  or  IL-­‐‑2  (2  ng/mL)  in  triplicate.  Plates  were  incubated  
at  37°C  and  5%  CO2  for  three  days.  A  100  µμL  aliquot  of  supernatant  was  removed  from  
each  well   for  analysis  of   IFN-­‐‑γ  production  using   the  BD  Cytometric  Bead  Array   (BD  
CBA)  according  to  the  manufacturer’s  instructions.  
3.2.15 Transmission  electron  microscopy  (TEM)  
Implants  of  a  length  of  1.5  cm  were  placed  into  vials  containing  1.5  mL  MilliQ  water  in  
a   shaking   water   bath   at   37°C.   Samples   were   taken   after   1   and   8   days   by   complete  
exchange   of   the   release   media.   Carbon-­‐‑coated   copper   grids   were   glow   discharged  
(Edwards  E306A  Vacuum  Coater,  England).  10  µμL  of  each  sample  was  adsorbed  onto  a  
grid   and   the   excess   sample   was   removed   using   a   filter   paper.   The   grids   were  
negatively  stained  with  10  µμl  of  1%  phosphotungstic  acid  (pH  6.8).  
3.2.16 Statistical  analysis  
Statistical  analysis  was  carried  out  using  Prism  (GraphPad  Software  Inc.  La  Jolla,  USA).    
3.3 Results  and  discussion  
3.3.1 Preparation  of  implants  
The   mixtures   of   excipients   utilised   resulted   in   the   successful   preparation   of   lipid  





to   be   softened   and   then  uniformly   extruded   through   the   outlet   die.   Extrudates  were  
not  pasty  or  brittle  and  showed  no  deliquescence  during  handling.  The  inclusion  of  the  
preformed  liposomes  in  the  lipid  mix  had  no  impact  on  extrudate  production.    
The  release  of  liposomes  from  the  implants  was  investigated  as  the  particulate  nature  
of  the  vaccine  is  crucial  for  the  induction  of  an  immune  response  [145].  Implants  were  
incubated  in  water  and  samples  of  water  were  taken  after  one  day  and  eight  days.  All  
implants   released   large   multilamillar   liposomes,   examples   of   which   are   shown   in  
Figure  3-­‐‑1.  The  liposomes  had  a  diameter  between  125  nm  and  1000  nm.  These  images  
showed   that   the   lipids   spontaneously   form   liposomes   upon   release   independent   of  
their   formulation  or   the  presence  of  OVA  or  QA.  This   formation  of   liposomes  can  be  
explained   by   the   fact   that   liposomes   form   when   lipid   cakes   or   thin   lipid   films   are  
hydrated  and  stacks  of  lipid  bilayers  become  fluid  and  swell  [22].  
	  
Figure  3-­‐‑1:  TEM   images  of   the   release   in  purified  water   after   24  h  of   (A)   blank   implant   (55%  
Chol,  30%  D114,  15%  soybean  lecithin).  (B)  OVA  +  QA  Lip  implant  (55%  CHOL,  30%  D114,  15%  
soybean  lecithin  containing  0.13%  OVA  and  0.66%  QA).  





3.3.2 Lipid  modification  after  extrusion  and  during  storage  
The   extrusion   process   necessitates   the   melting   of   the   low  melting   lipids   during   the  
process  to  enable  the  mass  to  be  moved  forward  by  the  screws  and  be  pushed  through  
the  outlet  die.  Therefore  during  extrusion  the  lipids  are  exposed  to  mechanical  as  well  
as  thermal  stress.  These  stresses  may  induce  transitions  to  unstable  polymorphs  which  
subsequently   upon   storage   may   transform   to   a   more   stable   polymorph   [135].   Such  
rearrangements   can   be   associated   with   changes   in   the   matrix   structure   of   the   lipid  
implants  and  might  have  an   influence  on  release  behaviour  as  well  as  on  mechanical  
properties.   Therefore,   polymorphic   modifications   and   the   mechanical   stability   of  
implants,   formulated   using   CHOL:D114:soybean   lecithin   at   ratio   50:35:15,   were  
investigated   directly   after   extrusion   and   over   a   storage   period   of   3   months   and   at  
storage  temperatures  of  25°C  and  4°C.  
Firstly   the  polymorphic  behaviour  and  melting  points  of   the   individual   lipids   (D114,  
CHOL,  and  soybean  lecithin)  were  determined  as  references  (Figure  3-­‐‑2,  Figure  2-­‐‑8  A).    
  
Figure  3-­‐‑2:  DSC  thermograms  of  implants  pure  components,  D114,  CHOL  and  soybean  lecithin.  
The   thermogram  of  D114   shows   one   single   endothermic   event   at   59°C   (n=3,   SD=0.8)  
which  is  characteristic  for  the  melting  of  the  stable  β-­‐‑modification  of  pure  Dynasan  114  
at  around  56°C  [136].  The  melting  behaviour  of  CHOL  shows  a  small  melting  peak  at  





point  of  cholesterol  at  149°C  (n=3,  SD=0.5).  The  DSC  measurement  of  soybean  lecithin  
showed  no  distinct  melting  peak  but  melting  occurred  between  40  and  60°C.    
Next,  the  thermal  behaviour  of  the  lipid  blend  after  the  cryomilling  step  was  analysed,  
no   unstable   polymorph   transformation   could   be   observed.   Thermograms   of   the  
extrudates   immediately  after  extrusion  were   recorded   to   investigate   if   the   thermal  or  
mechanical  stress  caused  by  the  extrusion  induced  any  changes  to  the  polymorphism  
of   the   lipids   (Figure  3-­‐‑3  Day  0).  No  re-­‐‑crystallization  events  or   instable  modifications  
after  extrusion  could  be  detected  indicating  that  the  crystalline  state  of  the  material  was  
not   affected  by   the   extrusion  process.  The   thermogram   (Figure   3-­‐‑3)  of   the   extrudates  
shows  two  endothermic  peaks  corresponding  to  the  melting  endotherm  of  cholesterol  
and  D114.  The   location  of   the  melting  endotherm  of  D114  remained  constant  at  59°C  
therefore   it   can   be   assumed   that   D114   crystallized   in   the   stable   β-­‐‑modification.  
Interestingly,   the   shape   and   intensity   of   the   CHOL   endotherm   changed  with   a   shift  
from  149°C  to  117°C  and  a  decrease  in  the  intensity  of  the  signal.  The  same  behaviour  
was   observed   by   Vogelhuber   et   al.   (2003)   [115]   when   studying   glyceryl  
trimyristate/cholesterol   mixtures   and   this   was   interpreted   as   a   melting   point  
depression.  Vogelhuber  et  al.   furthermore  state   that   these  results  are   indicative  of   the  






Figure  3-­‐‑3:  DSC  thermograms  of  implants  (50%  CHOL,  30%  D114.  15%  soybean  lecithin)  (n=3)  
at  different  time  points  during  storage.  (A)  Stored  at  4°C.  (B)  Stored  at  25°C.  
In  order   to   evaluate   the   storage   stability  of   the   extrudates  over   a  period  of   3  month,  
thermograms   of   samples   stored   at   25°C   and   4°C  were   taken   at   different   time   points  
(Figure   3-­‐‑3).   No   polymorphic   transformations   over   a   period   of   3   month   could   be  
observed,  neither  for  samples  stored  at  4°C  nor  for  those  stored  at  25°C.  These  results  
support   the   conclusion   that   extrudates   can   be   stored   at   either   temperature.   After  
extrusion,  the  initial  handling  of  the  implants  showed  that  the  systems  were  not  pasty  
or  brittle.  The  mechanical  strength  of  the  extrudates  was  evaluated  during  the  storage  
period  of  3  months.  The  texture  analyser  measurements  (Figure  3-­‐‑4)  showed  that  there  
was  no   significant   change   in   the  hardness  of   the   implants  over   time   for   either  of   the  
storage  temperatures.  
In   addition   the   injectability   of   the   implants   through   a   trocar   was   investigated.  
Extrudates  of  a   length  of  1  cm  were   introduced   into  pig  skin  using  a   trocar.  Pig  skin  
was  used  as  it   is  more  similar  to  human  skin  in  terms  of  mechanical  properties  [146].  
Mouse  skin  is  much  thinner  and  therefore  less  force  should  be  needed  to  introduce  the  
implant   in   the  mouse  model.  After   insertion  of   the   implants   into  pig   skin,   the   tissue  
was  cut  open  and  the  extrudates  retrieved.  Visual  analysis  did  not  show  any  breakage,  






Figure   3-­‐‑4:   Texture   analyser   measurements   of   implants   (n=3)   analysed   on   days   0,   7,   14,   1  
months,  2  months  and  3  months  at  4°C  or  25°C,  respectively.  
	  
Figure   3-­‐‑5:   Application   of   an   implant   into   pig   skin   using   a   trocar.   (A)   Implant   before  
application.  (B)  Insertion  of  loaded  trocar  into  pig  skin.  (C)  Inserted  implant.  (D)  Implant  after  
application.  
3.3.3 Antigen  release  in  vitro  and  in  vivo    
Antigen  release  was  examined  directly  in  vitro  and  indirectly  in  vivo  by  assessing  T  cell  
proliferation  at  predetermined  time  points  after  immunisation.  Implants  for  the  in  vitro  





of  2  mm  and  were  2.5  cm  long,  containing  100  µμg  OVA  per  implant  +/-­‐‑  500  µμg  QA.  For  
the  in  vivo  release  studies,  the  implants  had  the  same  composition  but  were  only  0.5  cm  
long  and  contained  therefore  only  20  µμg  OVA  per  implant  +/-­‐‑  100  µμg  QA.  The  control  
implant  consisted  of  soybean  lecithin,  D114  and  cholesterol.  
The   in   vitro   investigation   of   the   release   of   FITC-­‐‑OVA   indicated   that   after   already   7  
hours  10  to  15%  of  the  OVA  is  released  (Figure  1-­‐‑6).  However  release  was  incomplete  
during   the   time   course   investigated.   Release   from   the   implants   will   likely   occur   by  
diffusion.  As  the  implants  do  not  degrade  in  vitro  OVA  could  possibly  have  remained  
inside  the  implant  not  reaching  pores  to  diffuse  out.  Therefore,   it   is  unsurprising  that  
not  all  OVA  was  released.  However,  in  the   in  vivo  situation  we  observed  that  after  28  
days   partial   breakdown   of   the   implants   had   occurred   making   it   likely   that   release  
might  be  more  complete  in  an  in  vivo  system  than  in  vitro.  
	  
Figure  3-­‐‑6:  Cumulative  release  of  FITC-­‐‑OVA  from  implants  with  and  without  QA  (55%  CHOL,  
30%   D114   and   15%   Soybean   Lecithin).   Data   is   the   mean   of   3   replicates   and   the   standard  
deviation  of  n  =  3.    
To  analyse  how  long  OVA  was  released   in   the  animals  after   implantation,  mice  were  
injected   with   CFSE   stained   OVA-­‐‑specific   T   cells   at   predetermined   times   after  
implantation.  These  cells  can  be  used  to  measure  antigen  release  as  they  will  divide  as  





to  both   cell-­‐‑surface  and   intracellular  proteins  by   reaction  with   lysine   side-­‐‑chains  and  
other  available  amine  groups  [147].  When  a  cell  divides  the  daughter  cells  will  contain  
half  the  amount  of  CFSE  which  can  be  measured  by  flow  cytometry,  thus  allowing  for  
the  investigation  of  release  in  vivo.    
One  day  following  administration  of  the  vaccines,  CD8  T  cells  from  all  groups  of  mice  
given  OVA-­‐‑containing  vaccines  showed  similar  high  levels  of  cell  division  (Figure  3-­‐‑7)  
indicating   that   antigen   was   immediately   available   for   presentation   by   antigen  
presenting  cells  to  the  CD8  T  cells.  This  shows  good  agreement  with  the  in  vitro  release  
data   which   shows   a   release   of   more   than   20%   of   the   loaded   OVA   after   24   hours.  
Interestingly  T  cell  proliferation  did  not  appear  to  be  dependent  on  the  presence  of  an  
adjuvant   in   the   vaccine.   Proliferation   by  OT-­‐‑I   cells   in   the   absence   of   a   costimulatory  
signal   has   been  previously   reported   and   it  was   found   that  while   in   the   absence   of   a  
costimulatory   signal   CD8   cells   could   undergo   proliferation   they   did   not   gain   full  
effector   function   [148].   Alternatively   it   could   be   that   the   physical   act   of   vaccine  
administration   created   sufficient   inflammatory   signals   to   drive  T   cell   proliferation   at  
this  time  point.    
At   day   7,  mice   immunised  with   implants   containing  OVA   and  QA   or  with  OVA   in  
alum  exhibited   significantly  more  CD8+  proliferation   than  did  mice   immunised  with  
implants   containing  OVA   alone   (p<0.05).   The   inclusion   of   liposomes   in   the   implants  
appeared   to   have   no   effect   on   the   level   of   CD8   proliferation.   As   alum   is   known   to  
provide  a  depot  effect,  sustained  release  from  this  formulation  was  expected  [139]  and  
it  was  encouraging  to  see  similar  results  with  the  implants.  A  possible  explanation  for  
the  higher  CD8+  T  cell  proliferation  observed  for  the  OVA/QA  implants  are  that  due  to  
the   presence   of   the   water-­‐‑soluble   component   QA,   the   release   of   OVA   may   be  
enhanced.    Indeed  the  in  vitro  release  (Figure  3-­‐‑6)  showed  that  implants  containing  QA  
release   more   OVA   than   implants   without   the   adjuvant.   It   is   also   possible   that   the  
adjuvant  QA  is  required  for  cell  division  at  day  7,  whereas  it  was  not  required  at  day  1.  
A  greater   reliance   on   costimulation  when   antigen   is   limited,   as   could   be   the   case   by  





The   results   from   day   14   revealed   no   CD8+   T   cell   division   for   any   of   the   groups  
supporting  the  conclusion  that  after  14  days  there  was  no  longer  any  OVA  present  in  
the  system.  This   is   in  accordance  with  the   in  vitro  release  data  (Figure  3-­‐‑6)  showing  a  
release  up  to  7  days.    
	  
Figure  3-­‐‑7:  Transgenic  CD8+  T  cell  proliferation,  as  a  percentage  of  divided  CD8+  T  cells.  Mice  
were  immunized  with  blank  implants  (-­‐‑  Implant),  implants  containing  OVA  or  OVA/QA  either  
incorporated  directly   into   the   lipid  mix   (OVA   Implant,  OVA/QA   Implant)  or   formulated   into  
liposomes  which  were   then   freeze-­‐‑dried  and   incorporated   into   the   lipid  mix   (Lip   Implant)  or  
with  OVA  in  alum  (Alum).  The  adoptive   transfer  of  CFSE  stained  cells  was  performed  at   (A)  
day  1,  (B)  day  7,  or  (C)  day  14.  Data  shown  are  the  individual  results  from  five  mice  per  group  
plus  the  mean  and  SEM.    
Immune   responses   generated   by   the   sustained-­‐‑release   lipid   implants   were   then  
examined   28   days   post   immunisation.   Both   CD4   and   CD8   OVA-­‐‑specific   T   cell  
responses  were  examined   (Figure  3-­‐‑8).  The   inclusion  of  QA   in   implants   resulted   in  a  
higher   percentage   of   CD4+   and   CD8+   Tg   T   cells   in   the   lymph   nodes   of   immunised  
mice.   Similar   results   confirming   the   importance   of   inclusion   of   an   adjuvant   in   the  





The  inclusion  of   liposomes  into  the   implants  did  not  make  a  significant  difference  on  
antigen   specific   CD4+   or   CD8+   T   cell   expansion.   Importantly   measurable   immune  
responses   were   detectable   28   days   after   immunization   with   implants   and   these  
responses  were  superior  to  those  generated  by  the  alum  adjuvanted  vaccine  which  was  
boosted  at  day  14.  
	  
Figure  3-­‐‑8:  OVA-­‐‑specific  expansion  of  transgenic  CD4+  (A)  and  CD8+  (B)  T  cells  isolated  from  
lymph  nodes  of  C57Bl/6  mice  on  day  28.  Mice  were  immunized  with  blank  implants  (-­‐‑  Implant),  
implants   containing   OVA   or   OVA/QA   either   incorporated   directly   into   the   lipid   mix   (OVA  
Implant,   OVA/QA   Implant)   or   formulated   into   liposomes  which  were   then   freeze-­‐‑dried   and  
incorporated  into  the  lipid  mix  (Lip  Implant)  or  with  OVA  in  alum  (Alum).  Data  shown  are  the  
individual  results  from  4  mice  per  group  from  3  independent  experiments,  plus  the  mean  and  
SEM.  Statistical  analysis  of  results  was  carried  out  by  one-­‐‑way  ANOVA  followed  by  pairwise  
Tukey’s  multiple  comparisons.    
Following  an   in  vitro   restimulation  with  OVA,  cytokine   secretion  was   investigated   to  
examine  antigen-­‐‑specific  effector  function.  The  secretion  of   IL-­‐‑4  (a  Th2  cytokine),  and  
IFN-­‐‑γ  (a  Th1  cytokine)  were  examined  (Figure  3-­‐‑9).  Higher  IFN-­‐‑γ  concentrations  in  cell  
supernatants   were   detected   for   those   groups   that   received   implants   containing   QA  
compared   to   groups   that   received   antigen   and   no   adjuvant.   The   IFN-­‐‑γ   responses  
detected   upon   restimulation   of   cells   from   mice   immunised   with   a   single   OVA/QA  
implant   were   significantly   higher   than   those   from  mice   immunised   two   times   with  
OVA   in   alum.   No   IL-­‐‑4   was   detected   in   any   samples,   regardless   of   the   presence   of  
antigen  and/or  adjuvant  (data  not  shown).  Therefore,  these  results  indicate  that  a  Th1  






Figure  3-­‐‑9:  Interferon-­‐‑γ  concentrations  for  lymph  node  samples  restimulated  in  vitro  with  OVA.  
Mice  were  immunized  with  blank  implants  (-­‐‑  Implant),  implants  containing  OVA  or  OVA/QA  
either  incorporated  directly  into  the  lipid  mix  (OVA  Implant,  OVA/QA  Implant)  or  formulated  
into  liposomes  which  were  then  freeze-­‐‑dried  and  incorporated  into  the  lipid  mix  (Lip  Implant)  
or  with  OVA  in  alum  (Alum).  Data  shown  are  the  mean  and  SEM  from  4  mice  per  group  from  3  
independent  experiments.    
Furthermore,  the  serum  from  the  immunised  C57Bl/6  mice  was  collected  at  the  end  of  
the   experiments   to  measure  OVA   specific   IgG   antibodies   in   order   to   investigate   the  
ability  of   the   implants   to  stimulate  a  humoral  response.  As  shown  in  Figure  3-­‐‑10,   the  
QA/OVA  implants   resulted   in  significantly  higher  antibody   titres   than   the  OVA  only  
implants,  indicating  once  more  the  importance  of  the  adjuvant  in  the  system.  This  also  
correlates  with  the  results  obtained  by  Myschik  et  al.  [29]  comparing  the  production  of  
OVA   IgG   antibodies   from   OVA   and   OVA/QA   implants   produced   by   direct  
compression.  No  distinction   could   be  made   in   the   antibody  production   between  QA  
implants   and   the   alum   +   OVA   injection   group.   This   is   an   interesting   result   as   the  
implants  were  administered  at  day  0  while   the  alum  +  OVA  mice   received  a  booster  
injection   at   day   14   of   the   experiment.  Moreover   no   difference   between   the   implants  
with  and  without  preformed  liposomes  could  be  identified.    

























Figure   3-­‐‑10:   OVA-­‐‑specifc   IgG   antibody   titres   determined   by   ELISA   on   day   28.   Mice   were  
immunized   with   blank   implants   (-­‐‑   Implant),   implants   containing   OVA   or   OVA/QA   either  
incorporated  directly   into   the   lipid  mix   (OVA   Implant,  OVA/QA   Implant)  or   formulated   into  
liposomes  which  were   then   freeze-­‐‑dried  and   incorporated   into   the   lipid  mix   (Lip   Implant)  or  
with  OVA  in  alum  (Alum).  Data  shown  are   the   individual  results   from  4  mice  per  group  and  
the  mean  and  SEM  from  one  representative  experiment  of  three.    
The   reason   for   including   liposomes   in   the   formulation   was   so   that   antigen   and  
adjuvant  would   be   released   in   a   particulate   form,  with   the   particles   containing   both  
antigen   and   adjuvant   and   therefore   being   able   to   induce   optimal   APC   and   T   cell  
activation.   A   concern   with   antigen   and   adjuvant   being   released   individually   and  
asynchronously  from  a  sustained  release  formulation  is  that  a  tolerogenic,  as  opposed  
to  an  effector,  response  could  be  stimulated.  Indeed  Kamath  et  al  recently  reported  that  
exposure  of  APC  to  antigen  before  adjuvant  induces  an  antigen-­‐‑positive  non-­‐‑activated  
population  of  APC  [128].  While  the  implants  used  here  appeared  to  be  able  to  stimulate  
an   effector   immune   responses   (as   demonstrated   by   increased   numbers   of   antigen  
specific  CD4  and  CD8  cells,  IFN-­‐‑γ  production  and  IgG)  this  response  could  perhaps  be  
further   improved   through   the   loading   of   antigen   and   adjuvant   into   a   suitable  
particulate  delivery  system  which  could  then  be  incorporated  into  the  implant.  Such  a  
particulate   delivery   system   would   need   to   be   able   to   efficiently   load   high   levels   of  
antigen  and  adjuvant  and  be  compatible  with  a  lipid  based  implant  and  tsc-­‐‑extrusion.  
The   liposomes  which  were   used   here  were   compatible  with   the   lipid   based  delivery  

















system  and  tsc-­‐‑extrusion  but   likely  had  only  very   low  levels  of  antigen  and  adjuvant  
associated  with  the  particles  released  [29].    
In  our  study  we  used  tsc-­‐‑extruded  implants  in  an  attempt  to  mimic  a  natural  infection  
as   regards   antigen   release;   we   will   not   be   mimicking   the   natural   route   of   infection  
which  can  be  important  in  situations  where  mucosal  immunity  is  required.  Therefore,  
the   suitability  of   these  kinds  of   implants  and   the   required   release  period  needs   to  be  
assessed  for  each  application.  
3.4 Conclusion  
This   study   showed   that   lipid   based   tsc-­‐‑implants   can   be   utilised   for   in   vivo  
immunisation  studies.  The   implants  have  suitable  physical  characteristics  and  release  
the  vaccine  over  a  period  of  between  7  and  10  days,  which  would  correspond   to   the  
duration  of  a  natural  infection.  The  results  conﬁrmed  that  the  investigated  tsc-­‐‑implants  
can  replace  a  prime-­‐‑boost  immunisation  regime.  Tsc-­‐‑implants  are  therefore  considered  
to   be   a   promising   sustained   release   delivery   system,   which   can   be   produced   by   a  
scalable  process.  Further  optimisation  of  the  extrudates  is  possible,  tuning  release  and  
decreasing   the   diameter   of   the   implants,   increasing   their   potential   applications.   The  
applicability   of   the   system   to   different   antigens   and   peptides  will   be   investigated   in  
future  studies.    
3.5 Data  additional  to  the  publication  
3.5.1 Additional  in  vivo  data  
Appendix  C  shows  additional  in  vivo  data  not  shown  in  the  publication  such  as  the  IgG  
titres   from   the   two   replicates   of   the   experiment,   the   interferon-­‐‑γ   concentrations  
measured  in  the  spleen  and  transgenic  CD8+  T  cell  proliferation.  
3.5.2 Implant  changes  after  extraction  
Figure   3-­‐‑11   shows   implants   before   administration   to   the  mice   (A)   and   after   28   days  
inside   the  mouse   (B).  During   the   time  under   the   skin   of   the  mouse,   the   implant   lost  
shape  and  turned  from  a  cylindrical  into  a  ball  formed  shape.  This  is  probably  due  to  





stress   the   implant  was  exposed   to  under   the   skin  of   the  mouse.  But   the   implant  was  
still  located  in  the  neck  of  the  mouse.  
  
Figure  3-­‐‑11:  (A)  Implant  before  administration  to  the  mouse.  (B)  Implant  after  28  days  inside  a  
mouse.  
3.5.3 Antigen  release  in  vitro  after  storage  
The  mechanical  stability  of  the  implants  stored  at  25°C  and  4°C  over  a  period  of  three  
month  was  investigated  and  showed  to  be  given  (Figure  3-­‐‑4).  Also  the  polymorph  state  
of   the   lipids   did   not   changer   over   a   storing   period   of   three   month   (Figure   3-­‐‑3).   To  
further  investigate  the  stability  of  the  implants  during  storage,  implants  were  stored  at  
25°C  over  a  period  of  six  months.  DSC  measurement  was  performed  and  also  the  OVA  
release   in  vitro   from   the   implants  was   investigated.   Figure   3-­‐‑12   shows   the   release  of  
OVA  from  implants  directly  after  extrusion,  after  one,  three  and  six  month  for  implant  
formulation  with  and  without  QA.    
  
Figure  3-­‐‑12:  Cumulative  release  of  OVA  from  implants  with  and  without  QA  (55%  CHOL,  30%  





Implants  without  QA.  (B)  Implants  with  QA.  Data  is  the  mean  of  3  replicates  and  the  standard  
deviation  of  n  =  3  
Implants   consisted   of   55%   CHOL,   30%   D114,   and   15%   soybean   lecithin.   Implants  
contained  2%  OVA  with  and  without  QA  (0.3%).  Implants  containing  QA  (Figure  3-­‐‑12  
B)   showed   a  more   complete   release   than   implants  without  QA.  The   release   gets   less  
complete   the   longer   implants   are   stored,   for   both   implants   with   and   without   QA.  
Furthermore  the  release  duration  also  decreases  with  storage  time.  Implants  stored  for  
6  months  release  OVA  over  68  hours  (2.8  days),  whereas  the  release  duration  measured  
from  implants  directly  after  extrusion  is  215  hours  (8.9  days).  These  results   indicate  a  
change   is   occurring   during   storage.   The   results   from   the   DSC   measurements   are  
illustrated  in  Table  3-­‐‑2.    
Table  3-­‐‑2:   Shows   the  melting   temperature  and   the  melting  energy  of   implants   stored  at  25°C  
over  different  time  periods.  
Implants   Day  0   1  month   3  months   6  months  
  
[°C]   [J/g]   [°C]   [J/g]   [°C]   [J/g]   [°C]   [J/g]  
Blank   59.70   49.85   60.10   54.44   59.76   48.79   59.37   54.43  
OVA   59.47   52.06   59.53   53.33   59.00   43.03   59.13   53.43  
OVA+QA   59.00   49.90   59.50   51.91   59.47   48.13   59.57   52.20  
No  shift  in  melting  temperature  or  melting  energy  is  observed  over  time.  Furthermore,  
no  unstable  polymorphs  occurred  during  storage.  Since  the  DSC  measurements  did  not  
offer   an   explanation   for  what   occurred  during   storage,   the   assumption   that   the   lipid  
matrix   is   changing  or   that   interactions  between   the  model   antigen  and   the   lipids   are  
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4 Twin-­‐‑screw  extruded   lipid   implants   containing  TRP2  peptide  
for  tumour  therapy  
In   the   previous   chapter   it  was   shown   that   implants   can   be   stored   safely   up   to   three  
months   without   changing   their   mechanical   strength   or   the   polymorph   form.   More  
importantly   the  performed   in  vivo   study  proofed   that  our   implant   systems  were  well  
tolerated   by   mice.   Furthermore,   it   was   shown   that   comparable   immune   responses  
could  be  achieved  when  comparing   the   implant   systems  with   two  booster   injections.  
The  importance  of  the  adjuvant  in  such  sustained  delivery  systems  also  emerged  from  
the  study.  Considering  these  promising  results,  in  this  chapter  the  use  of  lipid  implants  
in   tumour   treatment   is   investigated.   For   this   purpose,   a   non-­‐‑mutated   melanoma-­‐‑
associated  antigen,  namely  the  TRP2  peptide  was  incorporated  into  the  implants.  This  
peptide   is   a   very   valuable   excipient.   Therefore   the   extrusion   process   had   to   be  
transferred   to   a   small   size   extruder,   which   allowed   working   with   very   small   batch  
sizes.   Before   starting   with   the   production   of   the   TRP2   loaded   implants,   the   process  
transfer   from   one   extruder   to   another   was   analysed.   Optical   changes   of   implants  
produced   by   the   two   extruders   were   investigated   by   SEM.   Also   mechanical   and  
polymorph   differences   of   the   implants   were   examined.   After   adapting   the   lipid  
formulation   to   the   small   scale   extruder,   implants   containing   QA   and   TRP2   were  
produced.   The   in   vitro   release   of   TRP2   and  QA   from   the   implants  was   investigated.  
Also  the  use  of  vesicular  phospholipid  gels  (VPGs)  for  tumour  therapy  was  considered,  
analysing  the  in  vitro  release  of  TRP2  from  the  VPGs.  An  in  vivo  tumour  growth  study  
was   performed   comparing   lipid   implants,   VPGs   and   conventional   injection   in   a  
therapeutic   way.   Tumour   cells   were   injected   first   and   6   days   later   the   different  
formulations  were  given.  





The   discovery   that   CD8+   cytotoxic   T   lymphocytes   (CTL)   can   recognize   tumour-­‐‑
associated   antigens   has   opened   a   new   approach   to   the   development   of   specific   anti-­‐‑
tumour  immunotherapies.  During  the  last  few  years,  much  effort  has  been  put  into  the  
identification   of   tumour-­‐‑associated   antigens   [150-­‐‑152].   However,   most   of   these  
tumour-­‐‑associated   antigens   are   non-­‐‑mutated   self-­‐‑antigens   and   are   poorly  
immunogenic   [150,153,154].   Therefore,   the   induction   of   a   potent   and   specific   T   cell  
response  still  represents  a  major  challenge  [155].  The  use  of  lipid  implants  as  sustained  
delivery   systems   might   help   to   overcome   this   challenge.   A   class   of   non-­‐‑mutated  
melanoma-­‐‑associated  antigens  has  been  identified  that  are  recognized  in  an  MHC  class  
I-­‐‑restricted  fashion  by  melanoma-­‐‑reactive  CTLs  from  different  patients.  These  antigens  
include  tyrosinase-­‐‑related  protein  TRP1  and  TRP2,  melanoma  antigen  reactive  with  T  
cells  (MART)-­‐‑1,  and  gp100  [156,157].  TRP1  has  40-­‐‑50%  amino  acid  sequence  identity  to  
tyrosinase   and   TRP2   [158].   Human   TRP2   shares   84%   of   the   sequence   of   its   mouse  
counterpart   [159].   TRP2   peptide   (amino   acids   180-­‐‑188   of   the   TRP2   protein,  
SVYDFFVWL)   is   recognized   by   tumour   reactive  CTLs   from  both,  mice   and  humans.  
The  peptide   sequence   is   identical  between  mice  and  humans,  and   is   therefore  a  very  
interesting   candidate   for   tumour   studies   [156,160].   However,   short   peptides   for  
vaccinations   show   some   disadvantages.   Vaccination  with   short   peptides   can   lead   to  
immunological   tolerance   and   short   peptide   antigens   often   fail   to   induce   CD8+   T  
memory   cells   [161].  On   the   other   hand,   vaccination  with   long  peptides   (22-­‐‑45   amino  
acids)  increases  vaccine  efficacy  with  long  peptides  being  able  to  induce  robust  CD8+  T  
cell   responses   [161].   Therefore,   a   long  TRP2  peptide  was  used   in   this   study.   Peptide  
antigens  are  easy  to  manufacture,  however,  they  have  a  very  low  immunogenicity  and  
often   need   to   be   administered   together   with   immunostimulatory   adjuvants   [5].   QA  
was   used   in   this   study.   To   attempt   to   get   simultaneous   delivery,   both   adjuvant   and  
peptide   were   incorporated   into   a   lipid   matrix.   In   the   study   presented   here,   lipid  
implants  composed  of  cholesterol,  Dynasan  114,  soybean  lecithin,  TRP2  and  QA  were  




In  early   stages  of   formulation  development,  often,   extensive   formulation  screening   is  
necessary   to   achieve   optimal   implant   characterisations.   Only   after   the   optimal  
formulation   composition   has   been   achieved   using   model   compounds,   the   move   to  
expensive  drugs  or  bioactives   is  made.  At   this   stage,   a   scale-­‐‑down  of   the  production  
process  may  be  necessary.  Consequently,   it   is   important  to  investigate  the  influence  a  
change  of  the  production  device  might  have.  To  address  this  issue,  we  compared  two  
different  extruders   in   this  study  using  OVA  as  a  model  antigen.  One  extruder  allows  
the  preparation  of  lab  scale  batches  (minimum  5  g),  whereas  the  other  extruder  allows  
the  extrusion  of  extremely  small  quantities   (0.5  g),   inevitable  when  working  with   the  
expensive   drugs   such   as   the   TRP2   peptide   used   in   this   study.   Our   aim   was   to  
investigate  the  influence  of  the  processing  equipment  on  the  extrudability  of  the  lipid  
mixture,  on  the  properties  of  the  implants,  as  well  as  on  the  in  vitro  release  of  the  model  
antigen.  In  a  next  step,  the  formulation  was  adapted  for  the  release  of  the  TRP2  peptide  
and   the   extruded   implants   were   tested   in   an   in   vivo   tumour   study.   A   second   lipid  
system  was  tested  as  a  TRP2  carrier  in  the  in  vivo  study,  namely  vesicular  phospholipid  
gels   (VPGs).  Different   studies  describe   the  use  of   liposomal   systems  as  TRP2  carriers  
[160,162,163],   therefore   VPGs   were   considered   an   interesting   alternative   for   our  
experiment.  They  only  consist  of  soybean  lecithin  and  buffer  and  have  been  described  
in  literature  as  potential  delivery  systems  for  pharmaceutical  proteins  [164-­‐‑166].    
4.2 Materials  and  methods  
4.2.1 Materials  
The  TRP2  long  peptide  (SVYDFFVWLKFFHRTCKCTGNFA-­‐‑OH)  was  purchased  from  
peptides   and   elephants   (Potsdam,   Germany).   Cholesterol   (CHOL),   purity   95%,   was  
purchased   from   AlfaAesar   (Karlsruhe,   Germany).   Soybean   Lecithin   (approx.   90%  
phosphatidylcholine)   was   purchased   from   APPLICHEM   LIFESCIENCE   (Darmstadt,  
Germany).  Phosphate  buffered   saline   (PBS)   tablets   from  Oxoid  Limited   (Basingstoke,  
England).    Puriﬁed  Quil-­‐‑A  (QA)  was  sourced  from  Brenntag  Biosector  (Frederikssund,  
Denmark)  as  lyophilised  powder  and  was  used  as  supplied.  trimyristin  (Dynasan  114  
(D114))   was   kindly   provided   by   SASOL   Germany   GmbH   (Witten,   Germany).  




water   having   a   conductivity   of   less   than   0.055   µμS/cm   (Milli-­‐‑Q   Water   systems,  
Millipore,   MA,   USA)   was   used   throughout   the   study.   All   other   chemicals   were   of  
analytical  grade.  
4.2.2 Preparation  of  lipid  implants  by  twin  screw  extrusion  
Implants   were   prepared   from   mixtures   of   soybean   lecithin,   CHOL,   D114,   with   and  
without   OVA/TRP2   and/or   QA   as   described   previously   (Chapter   Three)   [127].   The  
ﬁnal  mixture  was  subsequently  fed  into  a  twin-­‐‑screw  extruder  (small  size  extruder  ZE  
5,   Three-­‐‑Tec,   Seon,   Switzerland   or   Haake   MiniLab®   Micro   Rheology   Compounder,  
Thermo   Haake,   Germany).   The   ZE   5   extruder   is   equipped   with   three   different  
individual   heating   zones.   Each   individual   heating   zone   has   a   length   of   1.2   cm  
separated  by  a  gap  of  0.3  cm.  Heating  zones  were  operated  at  different  temperature  as  
described  in  Table  1,  a  rotation  speed  of  55  rpm  was  applied.  Implants  extruded  with  
the  Haake  extruder  were  produced  at  45°C  and  40  rpm.  The  resulting  implants  had  a  
diameter  of  2  mm  and  were  subsequently  cut  into  lengths  of  2.5  resp.  0.5  cm,  resulting  
in   an   implant  mass   of   about   80  mg   resp.   16  mg.   Implants  were   produced  under   the  
laminar   flow   (Hera   Safe,   Kendro   Laboratory   Products   GmbH,   Germany)   and  
equipment  was  heat  sterilized  at  160°C  for  2  hours  before  use.    
4.2.3 Preparation  of  vesicular  phospholipid  gels  (VPGs)  
Vesicular   phospholipid   gels   were   formulated   by   dual   asymmetric   centrifugation  
(SpeedMixer,  Hauschild  &   co  KG,  Hamm,  Germany).   For   homogenization   a   process  
speed  of  3500  rpm  was  used  for  30  minutes.  QA  and  TRP2  peptide  were  incorporated  
into   the  VPGs  by  direct   loading.  QA  (0.5  mg/ml)  and  TRP2   (0.28  mg/ml)  solutions   in  
sterile  filtered  PBS  buffer  were  added  to  the  accurately  weighed  soybean  lecithin  and  
homogenized  by  means  of  the  dual  asymmetric  centrifuge  in  a  25  ml  sterile  cylindrical  
plastic   container   (25   ml,   aponorm,   Germany).   VPGs   contained   300  mg/g   lipids.   The  
PBS  buffer  was  sterile   filtrated  and  the  containers  were  autoclaved.  All  other  utensils  
were   autoclaved   or   head   sterilized   if   possible.   The   VPG´s   were   prepared   under   the  




4.2.4 Density  measurements  of  implants  
To  determine   the   true   density   of   the   produced   implants,   defined   as   the   density   of   a  
material   excluding   pores   and   inter-­‐‑particle   spaces,   an   AccuPyc   1330   helium  
pycnometer  (Micromeritics,  Aachen,  Germany)  was  used  at  a  sample  holder  volume  of  
0.718507   cm3.   Prior   analysis   the   instrument   was   calibrated   using   a   metal   sphere   of  
known   volume.   10   cleaning   cycles   were   performed   using   analytical   grade   helium.  
Implants   were   cut   into   small   pieces,   approximately   150-­‐‑200   mg   of   the   sample   was  
analysed  and  the  true  density  was  calculated  as  an  average  of  six  measurements.    
4.2.5 Scanning  electron  microscopy  (SEM)  
A  Jeol  JSM-­‐‑6500  F  (Jeol  JSM-­‐‑6500F,  Tokyo,  Japan)  was  used  at  an  acceleration  voltage  
of   2   kV   and   a   magnification   of   150.   Implants   were   cut   and   attached   to   aluminium  
blocks  with  double  adhesive  tape  and  were  analysed  without  further  treatment.    
4.2.6 In  vitro  release  of  OVA  from  implants  
The  release  of  the  model  antigen  OVA  was  investigated  over  a  period  of  up  to  7  days.  
Lipid  implants  of  a  length  of  2.5  cm  (n=3)  were  incubated  at  37  °C  in  a  Heidolph  1000  
shaking   incubator   (10   rpm/min)   in   vials   containing   1.8  ml  phosphate   buffered   saline  
(PBS)   (pH   7.4,   0.01  M,   0.05%  NaN3).   Lipid   implants   contained   55%   cholesterol,   15%  
soybean   lecithin,   30%   D114,   1.6   mg   OVA   and   0.24   mg   QA.   At   defined   time   points  
samples  were   taken  and   the  release  medium  was  exchanged  completely.  All   samples  
were   centrifuged   at   14000   rpm   (Mikroliterzentrifuge  Z   160  M,  Hermle   Labortechnik,  
Wehingen,   Germany)   for   5   minutes   to   remove   lipid   particulates.   OVA   in   the  
supernatant  was  measured  by  UV  (Agilent  Technologies  8453)  at  a  wavelength  of  280  
nm.  For  each  tested  mixture  an  implant  containing  neither  OVA  nor  QA  was  used  as  a  
blank  for  the  UV  measurements.  Each  implant  was  weighted  before  incubation  and  the  
total   amount   of   protein   present   in   each   implant  was   calculated   individually   using   a  
standard  curve  of  OVA  in  PBS.  All  measured  samples  lay  within  the  linear  part  of  the  




4.2.7 In  vitro  release  of  Quil  A  from  implants  
Implants   were   cut   in   3   cm   lengths   and   weighed.   All   implants   contained   65%  
cholesterol,  600  µμg  of  QA  and  336  µμg  TRP2.  Implants  were  placed  into  2  mL  Eppendorf  
tubes   filled  with   1  mL   PBS   buffer   (pH   7.3)   and   incubated   at   37°C   (Clayson   shaking  
incubator,   New   Zealand)   at   10   rpm/min.   At   defined   time   points   300   µμl   of   release  
medium  was  taken  out  and  replaced  with  fresh  PBS  buffer.  Samples  were  centrifuged  
for  10  minutes  at  14000  rpm  in  a  bench   top  centrifuge   (Prism  R,  Labnet   International  
Inc.,  Edison,  USA)  to  pellet  the  lipid  fractions.  The  supernatant  was  transferred  into  an  
Eppendorf   tube   and   stored   at   -­‐‑20°C   until   high   performance   liquid   chromatography  
with  evaporating  light  scattering  detector  (HPLC-­‐‑ELSD)  analysis  was  carried  out.  
4.2.8 High  performance   liquid   chromatography  with   evaporating   light   scattering  
detector  (HPLC-­‐‑ELSD)  
The  HPLC  system  consisted  of  1200  Series  evaporating  light  scattering  detector  (ELSD)  
system   from   Agilent   Technologies   (Santa   Clara,   USA)   equipped   with   a   ZORBAX  
Eclipse  XDB-­‐‑C8  Column  (2.1  x  50  mm;  3.5  µμm,  Agilent  Technologies).  The  column  was  
maintained   at   a   temperature   of   25°C.   A   guard   column   (2.1x12.5mm,   Agilent  
Technologies)   was   used   to   prevent   contamination   of   the   column   and   was   also  
maintained   at   25°C.   The   injection   volume  was   20  µμL.   The  mobile   phase   consisted   of  
water/acetonitrile  (75:25%  v/v)  containing  0.01%  v/v  formic  acid.  A  flow  rate  of  0.25  mL  
per  minute  was  used.  The  ELSD   settings  were   as   follows:   nebulizing   temperature   of  
30°C,  nitrogen  gas  pressure  at  3.5  bar,  gain  at  10.    
4.2.9 In  vitro  release  of  TRP2  from  implants  and  VPGs  
Release   from  implants  was  performed   in  2ml  Eppendorf  vials  containing  1.8  mL  PBS  
(pH  7.4,   0.01  M,   0.05%  NaN3,   0.25%  SDS).  Release   from  VPGs  was  analysed   in   2  mL  
Eppendorf  vials  containing  1  mL  PBS  (pH  7.4,  0.01  M)  supplemented  with  0.05%  NaN3,  
0.25%   SDS.   Release   experiments   were   performed   by   complete   buffer   exchange   in   a  
Heidolph   1000   shaking   incubator   at   37   °C   and   10   rpm/min.   All   samples   were  
centrifuged   at   14000   rpm   (Mikroliterzentrifuge   Z   160   M,   Hermle   Labortechnik,  
Wehingen,  Germany)  for  10  minutes  to  remove  lipid  particulates.  TRP2  concentration  




4.2.10 Reverse-­‐‑phase  HPLC  (RP-­‐‑HPLC)  for  TRP2  quantification  
TRP2  peptide  release  was  quantified  by  RP-­‐‑HPLC  using  a  Dionex  Ultimate  3000  HPLC  
system  (Dionex,  Softron  GmbH,  Germering,  Germany).  A  Phenomenex   Jupiter  5u  C4  
300   Å   column   (250   mm   x   4.60   mm,   Phenomenex,   Achaffenburg,   Germany)   and   an  
injection  volume  of  150  µμL  of  each  sample  were  used.  The  running  buffer  consisted  of  
acetonitrile  (0.1%  TFA)  and  H2O  (10%  acetonitrile  and  0.1%  Trifluoroacetic  acid  (TFA)),  
with  a  flow  rate  set  to  0.75  mL/min.    
4.2.11 Differential  scanning  calorimetry  (DSC)  
A      Phoenix   204   (Netsch,   Selb,   Germany)   DSC   was   used   to   record   thermograms   of  
implants  directly  after   the  extrusion.  Samples  of  about  4  mg  each  were  weighed   into  
aluminium   crucibles.   5   K/min  were   used   as   heating   and   cooling   rates   and  were   set  
between  20°C  and  160°C.  An  empty  crucible  served  as  reference.  
4.2.12 Texture  analysis  of  implants  
A   TA.XT   Plus   Texture   Analyser   (Stable   Micro   Systems)   was   used   to   determine   the  
mechanical  stability  of  the  implants.  Implants  were  compressed  using  a  stainless  steel  
cylinder  having  a  diameter  of  5  mm  (compression  speed  0.5  mm/s,  compression  force  
30  N).  For  each  measurement,  three  replicates  were  analysed.    
4.2.13 Tumour  cells  
B16-­‐‑F10-­‐‑luc2   melanoma   cells   (Thermofisher   Scientific   New   Zealand,   Auckland,   NZ)  
were  cultured   in  cRPMI   in  BD  Falcon  tissue  flasks   (BD,  Biosciences,  MA,  USA).  Cells  
were  passaged  when  confluent.  On  the  day  of  the  tumour  injection  cells  were  washed  
with   10   mL   of   PBS,   the   adherent   cells   were   dissociated   by   incubation   with   2   mL  
TrypLE  Exress  (Life  Technologies,  Auckland,  NZ)  for  10  minutes  at  room  temperature.  
To  ensure  that  the  cells  are  dissociated  the  flasks  were  tapped  by  hand  from  all  sides.  
Cells  were  then  washed  with  8  mL  media  and  centrifuged  at  11000  rpm  for  8  minutes  
(Heraeus   Multifuge   3   S-­‐‑R,   Thermo   Scientific).   The   supernatant   was   discarded,   cells  
were  resuspended  and  washed  with  10  mL  PBS.  Subsequently,  cells  were  counted  and  





Male   C57Bl/6   mice   (n=72)   were   bred   and   maintained   under   specific   pathogen-­‐‑free  
(SPF)   conditions   at   the  HTRU,  Dunedin,  New  Zealand.  Mice  had   access   to   food   and  
water   ad   libitum.  All   experiments  were   approved  by   the  University   of  Otago  Animal  
Ethics  Committee,  AEC-­‐‑Code:  D64/12.  
4.2.15 Immunisation  protocol  
6  days  prior  to  immunisation  each  mouse  was  injected  s.c.   into  the  left  flank  with  1  x  
105  B16-­‐‑F10-­‐‑luc2  melanoma  cells   in   100  µμl  PBS.  The   formulations   (implants,  VPGs  or  
aqueous   control   formulation)   were   given   subcutaneously   into   the   neck   of   the   mice.  
Aqueous   formulations   as  well   as  VPGs  were   injected   in   a   volume   of   200  µμl.   For   the  
insertion  of  the  implants  mice  were  injected  subcutaneously  with  carprofen  (5  mg/kg)  
for   post-­‐‑operative   analgesia   and  were   anaesthetised  with   inhaled   isoflurane.   Once   a  
surgical   level   of   anaesthesia  was   reached   (measured   by   lack   of   pedal  withdrawal)   a  
small   incision  was  made   at   the   base   of   the   back   and   a   trocar  was   used   to   insert   the  
implant  to  the  dorsal  skinfold  under  aseptic  conditions.  The  incision  was  closed  with  a  
Michel  clip.  The  cages  were  placed  on  heating  pads  until  all  mice  fully  recovered  from  
anaesthesia.  Mice  were  weighed   and   physically   checked   for   tumour   growth   every   2  
days.  Once  tumours  were  palpable  they  were  monitored  daily  (including  tumour  size  
measurements).   Tumour   size   was   monitored   with   a   digital   calliper.   Mice   were  
sacrificed  if  the  tumour  reached  a  size  of  150  mm2.  
4.2.16 Statistical  analysis  
Statistical  analysis  was  carried  out  using  Prism  (GraphPad  Software  Inc.  La  Jolla,  USA).  
4.3 Results  and  discussion  
4.3.1 Differences   between   implants   prepared   using   larger   and   small   scale  
extruders  
We  were   able   to   show   in   a  previous   study   that   implants   for   antigen  delivery   can  be  
successfully   produced   by   twin-­‐‑screw   extrusion   (Chapter   Three)[127].   The   lipid  
mixtures   as   well   as   the   extrusion   temperature   are   important   parameters   in   the  




stress,   but   we   were   able   to   show   that   the   extrusion   process   did   not   change   the  
polymorphic   state   of   the   lipids.   Furthermore,   we   showed   that   storing   did   not  
compromise   the  physical   stability   or   the  polymorphic   state   of   the   implants   (Chapter  
Three)   [127].   Implants   described   in   those   studies   were   produced   using   a   Haake  
MiniLab   extruder   which   requires   a  minimum   of   5   g   of  material.   As   the   aim   of   this  
study  was   to  perform  a   tumour  experiment  using   implants  containing  TRP2  peptide,  
an  expensive  active  ingredient,  it  was  necessary  to  transfer  the  production  process  to  a  
different  device.   In  order   to  determine   if   changing   the  extruder   impacted  on   implant  
production  and  on   the   implants  produced,   implants   containing  55%  cholesterol,   15%  
soybean   lecithin   and   30%   D114   were   extruded   using   two   different   extruders;   all  
formulations   contained   2%   OVA   as   model   antigen   and/or   0.3%   QA.   The   Haake  
extruder  has  screws  of  a  length  of  11  cm  with  a  conical  form  going  from  a  diameter  of  
10  mm   to   4  mm.   The   ZE   extruder,  which   enables   batch   sizes   of   0.5   g   of   lipid   to   be  
formulated,  was  used  for  comparison.  The  ZE  5  extruder  has  a  screw  length  of  only  7.5  
cm  and  a  diameter  of  5  mm  (Figure  4-­‐‑1).  This  difference  in  size  consequently  results  in  
a  change  of   the  extrusion  parameters  such  as   the   through-­‐‑put   time  and  heat   transfer.  
An  additional  advantage  of  the  ZE  5  extruder  is  that  it  allows  the  use  of  three  different  
heating  zones  during  manufacturing.  Each  individual  heating  zone  has  a  length  of  1.2  
cm  separated  by  a  gap  of  0.3  cm  and  can  be  tempered  between  room  temperature  and  
230°C.  
  
Figure  4-­‐‑1:  Image  of  the  screws  from  the  Haake  MiniLab  extruder  (top)  and  the  ZE  5  extruder  
(bottom)  
In  the  first  set  of  experiments,  the  extrusion  temperature  of  the  three  heating  zones  was  
kept  at  45°C  (Table  4-­‐‑1,  run  1),  as  this  was  the  extrusion  temperature  used  in  previous  




Table  4-­‐‑1:  Temperature  chosen  for  the  three  individual  heating  zones  of  the  ZE  5  extruder  for  
the  different  runs,  all  carried  out  at  55  rpm.  
Run   Heating  Zone  1  [°C]   Heating  Zone  2  [°C]   Heating  Zone  3  [°C]  
1   45   45   45  
2   48   48   48  
3   45   48   50  
OVA   release   in   vitro   from   implants   produced   by   the   two   different   extruders   was  
compared   (Figure   4-­‐‑2).   It   became   clear   that   it   is   not   possible   to   transfer   the   process  
from   one   extruder   device   to   another   while   maintaining   the   same   extrusion  
temperature.   OVA   release   from   implants   produced   by   the   ZE   5   extruder   was   less  
complete  compared  to  OVA  release  observed  from  implants  produced  using  the  Haake  
extruder.  The   release   from   implants  produced  by   the  ZE  5   extruder   stopped  after   75  
hours,   whereas   the   release   from   the   implants   produced   by   the   Haake   extruder  
continued   for  up   to   200  hours.   Implants   containing  QA  produced  by   either   extruder  





Figure  4-­‐‑2:  Cumulative  release  of  OVA  from  implants  produced  at  45°C  containing  55%  CHOL  
with  and  without  QA  produced  by  the  Haake  (squares)  and  the  ZE  5  extruder  (circles).  Data  are  
the  mean  and  SD  of  3  independent  replicates.  
SEM  micrographs   of   the   surface   and   the   cross   section   of   implants   produced   at   45°C  
using   the   Haake   and   the   ZE5   extruder   were   compared   in   order   to   investigate   if  
differences   in   the   structure   correlated   with   different   release   behaviour   from   the  
implants.   The   surface   of   implants   extruded   by   the   ZE   5   extruder   (Figure   4-­‐‑3   D)  
appeared   to   be   smoother   compared   to   implants   produced   by   the   Haake   extruder  
(Figure  4-­‐‑3  A).  The  cross-­‐‑section  cut  of  the  implants  produced  by  the  Haake  extruder  
(Figure   4-­‐‑3   B   and   C)   revealed   that   these   implants   have   pores   and   cracks   inside   the  
implants.   The   implants   produced   by   the   ZE   5   showed   no   cracks   and   only   very   few  
pores  (Figure  4-­‐‑3  E  and  F).  On  the  cross-­‐‑section  of  implants  from  the  ZE  5  (Figure  4-­‐‑3  
E)   the   right   upper   half   of   the   section   appeared   very   smooth,   but   this   is   due   to   the  
cutting  of  the  implant.  The  higher  magnification  (Figure  4-­‐‑3  F)  was  taken  from  the  left  
part  of  the  cross-­‐‑section.  The  network  of  pores  and  cracks  in  the  implants  produced  by  
the  Haake  extruder  could  explain  why  the  release  of  OVA  from  these  implants  is  more  
complete  compared  to  implants  produced  by  the  ZE  5.  This  is   in  accordance  with  the  






Figure   4-­‐‑3:   Scanning   electron   micrographs   obtained   from   lipid   implants   after   extrusion  
produced  with  the  Haake  and  the  ZE  extruder  (Run  1  Table  4-­‐‑1).  Formulations  contained  55%  
CHOL,   15%  soybean   lecithin  and  30%  D114.  Haake   extruder:   (A)   surface  of   the   implants,   (B)  
cross   section   magnification   40   X,   (C)   cross-­‐‑section   magnification   300   X.   ZE5   extruder:   (D)  
surface  of  the  implants,  (E)  cross  section  magnification  40  X,  (F)  cross-­‐‑section  magnification  300  
X.  
Reitz  and  Kleinebudde  (2007)  [167,168]  showed  that  the  extrusion  temperature  affects  
the   inner  morphology   of   the   obtained   system   and   also   has   a   great   influence   on   the  
porosity   of   the   extrudates.   In   an   attempt   to   prolong   the   antigen   release   from   the  
implants,   the   temperatures   of   the   different   heating   zones   of   the   ZE   5   extruder  were  
increased   (Table   4-­‐‑1   run  2   and  3).  Changing   the   temperature   in   the  different  heating  
zones   had   a   considerable   influence   on   the   resulting   antigen   release   (Figure   4-­‐‑4).  
Increasing   the   temperature   in   all   heating   zones   to   48°C   instead   of   45°C   reduced   the  
burst   release   at   the   beginning,   but   did   not   prolong   the   OVA   release,   which   still  




temperature   from  45   to  50°C   (Table  1,   run  3)  greatly  prolonged   the   release  up   to  200  
hours   (Figure   4-­‐‑4)   with   sustained   release   of   75%   OVA   for   implants   containing   QA.  
These   results   are   in   accordance   with   literature,   indicating   that   the   extrusion  
temperature   plays   an   important   role   [167,168].   Using   these   parameters,   a   release  
duration   of   200   hours   (corresponding   to   8   days)   comparable   to   the   one   from   the  
implants  produced  by   the  Haake  extruder  could  be  achieved.  However,  compared  to  
the  implants  from  the  Haake  extruder,   the  release  is  still   less  complete  from  implants  
produced  by  the  ZE  5  extruder  (Figure  4-­‐‑4).  
  
Figure  4-­‐‑4:  Cumulative  release  of  OVA  from  implants  containing  55%  CHOL,  with  and  without  
QA,   produced   at   different   temperatures   by   the  ZE   5   extruder.   Squares:   implants   extruded   at  
48°C  (Table  4-­‐‑1  run  2);  Circles:  implants  extruded  using  different  temperature  for  the  heat  zones  
(45/48/50°C)  (Table  4-­‐‑1  run  3).  Data  are  the  mean  and  SD  of  3  independent  replicates.  
To   further   investigate  where   these  differences  arose   from,  analysis  of   the  mechanical  
properties  of  the  implants,  density  measurements  as  well  as  DSC  measurements  were  
performed.  The  thermograms  obtained  from  implants  produced  using  the  ZE  extruder  
indicate  no   changes   to  unstable  polymorphs,   even   at   extrusion   temperatures   of   50°C  
(Figure  4-­‐‑5  A).  Texture  analyser  measurements  (Figure  4-­‐‑5  B)  confirmed  that  implants  
produced  by  the  ZE  5  extruder  are  slightly  more  brittle  than  implants  produced  by  the  
Haake  extruder,  which  was  also  observed  when  handling  the  implants.  The  density  of  
implants  produced  by  the  ZE  5  extruder  was  1037.2  +/-­‐‑  4.0E-­‐‑10  mg/cm3  (n=  6),  slightly  




(1013.5  +/-­‐‑  4.0E-­‐‑10  mg/cm3,  n=  6).  These  physical  differences  between  the  two  implants  
further   emphasize   the   distinction   between   the   implants   produced   by   the   two  
extruders.   The   higher   density   of   implants   produced   by   the   ZE   5   extruder   correlates  
with   the   SEM  micrographs,   showing   fewer  pores   than   for   implants  produced  by   the  
Haake   extruder.   We   assume   that   the   lipids   in   the   ZE   5   extruder   are   melted   more  
completely,   due   to   the   higher   contact   surface   between   the   lipids   inside   the   extruder  
and   the   heating   walls   of   the   extruder.   Whereas   in   the   Haake   extruder,   lipids  
presumably   undergo   higher   mechanical   stress   than   in   the   ZE   5   extruder.   These  
differences  would  explain  the  difference  in  release.    
  
Figure  4-­‐‑5:  (A)  Thermogram  of  implants  extruded  with  the  Haake  extruder  (45°C)  compared  to  
implants   produced   by   the   ZE   5   extruder   (45/48/50°C).   (B)   Texture   Analyser   measurements  
implants  from  the  Haake  extruder  (45°C)  compared  to  implants  produced  by  the  ZE  5  extruder  
(45/48/50°C).  
4.3.2 In  vitro  release  of  TRP2  peptide  and  QA  from  implants    
Implants   produced   by   the   ZE   5   extruder   using   parameters   shown   in   Table   1   run   3  
show  a  promising  release  profile  for  the  model  antigen  OVA.  Also  DSC  measurements  
showed   that   no   unstable   polymorph   modifications   appeared   after   the   extrusion  
process.  Therefore,  these  production  parameters  were  applied  for  the  implants  used  in  
tumour   growth   study.   A   mixture   containing   65%   CHOL,   15%   soybean   lecithin   and  
20%  D114  was   used,   the   implants   contained   0.53  mg  QA,   0.28  mg   TRP2   and   12  mg  
trehalose.  This  corresponds  for  an  implant  of  a  length  of  0.5  cm  to  100  µμg  QA  and  56  µμg  
TRP2,  which  was   the  dose   required   for   the   in   vivo   tumour   study.  The   extrusion  was  




production  stage.  TRP2  was  first  admixed  with  12  mg  of  trehalose,  before  blending  it  
with  the  lipids.  This  step  was  necessary  in  order  to  obtain  an  appropriate  TRP2  release  
from   the   implants.   When   admixing   TRP2   directly   with   the   lipid   mixture,   without  
trehalose,   a   very   slow   release  was   observed   stopping   at   3.5%   released  TRP2   after   10  
days   (Appendix  D).  Figure  4-­‐‑6   shows   the   in  vitro   release  of  TRP2   from   the  produced  
implants.   The   release   of  TRP2   from   the   implants   is   very   slow,  with  up   to   40%  TRP2  
released  after  58  days.  
  
Figure  4-­‐‑6:  Cumulative  release  of  TRP2  from  implants  produced  by  the  ZE  5  extruder  and  from  
VPGs.  Data  are  the  mean  and  SD  of  3  independent  replicates.    
In   addition   to   the  peptide   release   from   the   implants,   the   release   of   the   adjuvant  QA  
was   investigated.   Implants   were   of   the   same   composition   as   described   previously,  
except   that  also  a  batch  of   implants  without  TRP2  was  produced.   In  contrast   to  what  
was   observed   for   the   peptide,   a   QA   release   duration   of   14   days   was   achieved   for  
implants   containing   the   TRP2   peptide   (Figure   4-­‐‑7).   The   presence   of   TRP2   in   the  
implants   seemed   to   increase   the   release   rate   of   QA   compared   to   implants   without  
TRP2.   After   7   days,   implants   containing   TRP2   have   released   already   87%   of   QA  
compared   to  49%  when  no  TRP2  was   in   the   implant.  These  results  correspond  to   the  
QA  release  behaviour  observed  from  implants  with  and  without  OVA  (Chapter  Two),  
where  it  was  shown  that  the  presence  of  OVA  in  the  implant  formulations  resulted  in  




the   TRP2   peptide   and   the   adjuvant   leads   to   the   conclusion   that   not   only   the  
composition  of  the  implant,  as  often  indicated  in  literature  [28,120],  has  an  influence  on  
the  release  behaviour  but  also  the  molecule  itself.  Interactions  between  the  peptide  and  
the  lipid  matrix  play  a  key  role  and  have  to  be  further  investigated.  
  
Figure  4-­‐‑7:  Cumulative  release  of  QA  from  implants  produced  by  the  ZE  5  extruder  with  and  
without  TRP2  in  the  formulation.  Data  are  the  mean  and  SD  of  three  independent  replicates.    
4.3.3 In  vitro  release  of  TRP2  peptide  from  VPGs  
In   addition   to   lipid   implants,   TRP2   loaded  VPGs  were   produced   to   investigate   their  
efficiency  in  the  in  vivo  tumour  experiment.  VPGs  represent  a  semi-­‐‑solid  phospholipid  
dispersion   and   are   suited   to   carry   both   lipophilic,   amphiphilic   and   lipophilic   drugs  
[166].  VPGs  used   in   this   study  were   composed  of   soybean   lecithin   and  PBS   (300  mg  
lipid/  g  PBS).  TRP2  and  QA  were  added  such  that  200  µμl  of  VPG  contained  100  µμg  QA  
and  56  µμg  TRP2.  Figure  4-­‐‑6  shows  the  TRP2  release  from  this  system.  Only  5%  of  TRP2  
were   released   before   the   release   comes   to   an   end   and   the   remaining   peptide   stays  
inside  the  VPG.  As  mentioned  already,  also   interactions  between  the  peptide  and  the  
lipids  can  be  the  reason  for  this  slow  and  incomplete  release.  




4.3.4 In  vivo  tumour  study  
The   previously   described   TRP2   implants   and   VPGs   were   then   used   in   an   in   vivo  
tumour  study.  Table  4-­‐‑2  shows  the  immunisation  groups  and  the  number  of  mice  used  
in  each  study.  In  the  first  study,  we  observed  some  adverse  reaction  in  the  VPG  groups  
three   days   after   the   formulations   were   given   to   the   mice,   therefore   VPGs   were  
excluded  from  further  experiments.  It  is  likely  that  the  adverse  reactions  are  due  to  the  
QA,   as  QA   is   known   to  be  have  undesirable   side   effects   [169].  Rönnberg   et   al   (1995)  
stated   that   QA   exhibits   lytic   activities,   by   reacting   with   the   cholesterol   in   the   cell  
membrane   that   can   cause   adverse   reactions   [170].   Interestingly   they   found   that   a  
dramatic   decrease   of   the   hemoltytic   activity   of  QA  when   incorporated   into   ISCOMs.  
They   assumed   that   the   CHOL   present   in   the   ISCOMs   interacts   with   QA   thereby  
blocking  QA  to  interact  with  CHOL  in  the  cell  membranes.     This  also  is  in  agreement  
with  a  study  by  Walduck  et  al  (1998)  immunizing  sheep  with  CHOL-­‐‑lecithin  implants  
[82].  The  study  showed  that  QA  was  better  tolerated  in  implants  than  in  the  injections,  
leading   to   minor   skin   irritation   in   the   sheep.   In   our   study   the   VPG   contained   no  
cholesterol  while  the  implants,  which  contain  cholesterol,  were  well  tolerated  with  no  
swelling,   redness   or   skin   irritation   observed.   However,   no   endotoxin   values   of   the  
implants  nor  the  VPGs  were  measured,  which  would  be  necessary  for  a  substantiated  
conclusion  on  the  adverse  reactions  provoked  by  the  VPGS.    
Table  4-­‐‑2:  Immunisation  groups  of  the  in  vivo  study  for  the  two  performed  experiments.  
Group   Description   No.  of  mice  
Study  1  
No.  of  mice  
Study  2  
1   QA  Implant   4   6  
2   TRP2  +  QA  Implant   8   10  
3   QA  VPG   4   -­‐‑  
4   TRP2  +  QA  VPG   8   -­‐‑  
5   TRP2  in  PBS   8   8  





We  found  no  statistically  significant  difference  between  the  results  of  the  no  treatment  
groups  of  the  two  studies,  therefore  data  from  the  two  experiments  were  combined.  Six  
days  after  tumour  cell  injection,  the  different  formulations  described  in  Table  4-­‐‑2  were  
administered.   Tumour   size   was   monitored   with   a   digital   calliper   and   mice   were  
sacrificed   when   tumour   size   exceeded   150   mm2.   Table   4-­‐‑3   indicates   the   median  
survival  time  for  each  group  corresponding  to  the  time  at  which  half  the  animals  had  
tumours  greater   than  150  mm2   in   size.  Survival   of   treated  mice  was  not   significantly  
different   from  untreated  mice,  however   there  was  a   trend   that  mice   in   the  TRP2+QA  
implant  group  survived  the  longest.  The  numbers  show  that  for  mice  in  the  TRP2+QA  
implant  group  the  median  survival   time   is   four  days   longer   than   in   the  no-­‐‑treatment  
group.   According   to   these   numbers,   mice   in   the   TRP2+QA   implant   group   have   the  
longest  median  survival  time.    
Table  4-­‐‑3:  Median  survival  times  for  each  group  in  days.  
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Figure  4-­‐‑8  shows  the  survival  curves  for  each  group  of  mice  after  tumour  inoculation  
(day  0)  and  Figure  4-­‐‑9  shows  tumour  growth  in  individual  mice.  Statistical  analysis  of  
the   survival   curves   showed   that   there   is   a   significant   difference   between   the   group  
without  treatment  and  the  group  having  received  TRP2+QA  implants  (p=0.009)  as  well  
as   between   the   group   without   treatment   and   the   group   having   received   TRP2+PBS  
injections  (p=0.035).  On  the  other  hand,  there  was  no  significant  difference  between  the  






Figure  4-­‐‑8:  Tumour  development  in  mice  immunized  with  the  TRP2-­‐‑long  peptide.  Groups  were  
inoculated  on  day  0  with  B16-­‐‑F10-­‐‑luc2  tumour  cells.  On  day  six,  groups  were  administered  with  
formulations  listed  in  Table  2.  Tumour  size  was  monitored  with  a  digital  calliper  and  mice  were  
sacrificed  when  tumour  size  exceeded  150  mm2.  
The  in  vitro  release  of  TRP2  from  the  implants  showed  that  after  10  days,  less  than  2  %  
of  TRP2  were  released  (Figure  4-­‐‑6).  In  the  in  vivo  experimental  setup,  animals  were  first  
injected   with   the   B16F10luc2   melanoma   cells   s.c.   into   the   flank.   Six   days   later   the  
formulations  (implants,  injections,  VPGs)  were  given.  Each  animal,  administered  with  
a   TRP2   formulation,   received   in   total   a   dose   of   56   µμg   TRP2.   It   appears   that   the  
TRP2+QA  implants  as  well  as  the  PBS+TRP2  injection  group  delayed  the  appearance  of  
the  tumour  (Figure  4-­‐‑9).  Whether  the  mice  received  56  µμg  TRP2  at  once  in  the  injection  
group   or   much   lower   amounts   of   TRP2   were   released   from   the   implants   in  
combination  with  QA,  seemed  to  have  the  same  effect  on  the  delay  of  tumour  growth.  
In   the  TRP2+QA   implant   group   tumours   started   to   grow  17  days   (mean  value   of   all  
mice  in  this  group)  after  tumour  cells  were  injected,  this   is  11  days  after  the  implants  
were  given  to  the  mice  for  experiment  1.  For  experiment  2,  tumours  started  to  grow  21  
days  (mean  value  of  all  mice  in  this  group)  after  tumour  cell  injection  in  the  TRP2+QA  
group,  respectively  15  after  the  implants  were  given.  The  in  vitro  release  of  TRP2  out  of  
the   implants   showed   that   after   11   days   only   1.89%   of   the   peptide   was   released  





Figure   4-­‐‑9:   Size   of   tumours   in  mice   given:   (A)   no   treatment,   (B)  QA   implants,   (C)   TRP2+QA  
implant  or  (D)TRP  in  PBS.  Data  are  from  individual  mice.    
This  raises  the  question  of  the  usefulness  of  the  implants  as  a  therapeutic  vaccine  or  if  a  
more  appropriate  use  would  be  a  prophylactic  vaccine  e.g.  to  prevent  from  metastases.  
As  the  in  vitro  data  showed  that  the  peptide  release  from  the  lipid  implant  is  very  slow,  
a   prophylactic   infectious   disease   model   might   be   more   appropriate.   In   the   cancer  
setting  TRP2+QA  implants  might  be  able  to  inhibit  the  growth  of  a  tumour  when  a  low  
tumour  burden   is  present   as   an   adjuvant   therapy.   For   example  patients  having  been  
treated  with  radiation  or  chemotherapy  might  be  treated  with  TRP2+QA  implants  after  
this  treatment  to  prevent  the  recurrence  of  tumours.    
	     















































The  process  transfer  from  one  extruder  to  another  changed  the  physical  properties  as  
well  as  the  release  behaviour  of  the  implants.  A  scale-­‐‑down  of  an  extrusion  process  by  
using   a   different   device   can   be   realized   but   only  with   engineering   efforts.   The   lipid  
mixtures  as  well  as  the  extrusion  parameters  have  to  be  adapted  to  each  extruder.  The  
in  vivo  study  showed  that   lipid  implants  containing  TRP2  and  QA  were  able  to  delay  
tumour  growth  for  a  short  period  of  time,  but  the  same  retardation  of  tumour  growth  
was  observed  for  the  TRP2+PBS  injection  group.  However,  the  slow  in  vitro  release  of  














5 Lipid-­‐‑Peptide  Interactions  
The  aim  of  Chapter  Four  was  the  preparation  and  the  execution  of  an   in  vivo   tumour  
study.  Therefore,  the  TRP2  peptide,  consisting  of  23  amino  acids,  was  incorporated  into  
the   implants   followed   by   an   in   vitro   investigation   of   the   release   from   the   implants.  
Against  expectation,  the  TRP2  peptide  showed  a  very  slow  release  from  the  implants.  
Whereas  in  Chapter  Two,  the  much  bigger  molecule  OVA,  showed  a  release  duration  
of  no  more  than  nine  days.  The  results  of  these  two  release  studies  let  to  the  research  
performed   in   this   Chapter.   The   assumption   was   that   larger   molecules   should   have  
more  difficulties  to  diffuse  out  of  the  lipid  matrix  than  small  molecules,  consequently  
showing  a  slower  release  than  small  molecules.  But  data  collected  in  Chapter  Two  and  
Chapter   Four   indicate   the   opposite.   Therefore   Chapter   Five   aims   to   find   an  
explanation   for   this,   investigating   possible   lipid-­‐‑peptide   interactions,   to   be   able   to  
better  predict  drug  release  from  lipid  matrixes  in  the  future.    






The  previous  chapter  showed  that  the  release  of  the  TRP2  peptide  from  lipid  implants  
is  very   slow.  Compared   to   the  model  antigen  OVA  used   for  preliminary   studies,   the  
TRP2  peptide  is  a  much  smaller  molecule  (5  kDa  compared  to  44  kDa).  As  it  should  be  
easier   for   small  molecules   to   diffuse   out   of   the   lipid   implant   through   the   pores   and  
channels  inside  the  lipid  matrix,  a  faster  TRP2  release  compared  to  OVA  was  expected.  
Kreye  et  al  (2011)  showed  that  diffusion  plays  a  major  role  in  the  release  of  molecules  
from  lipid  implants  [171].  This  chapter  investigates  the  influence  molecular  weight  of  a  
molecule  has  on  the  release  behaviour  from  lipid  implants.  Furthermore,  the  influence  
of   the   hydrophobicity   of   the   molecule   on   the   release   behaviour   was   studied.   These  
investigations  were  conducted  in  order  to  determine  if  peptide-­‐‑lipid  interactions  were  
taking   place   and   have   an   influence   on   the   release   behaviour   from   the   lipid   matrix.  
Reithmeier  et  al  (2001)  stated  that  the  adsorption  of  peptides  or  proteins  to  the  matrix  
material   can  be  a   critical   factor   in  controlling   the   release  kinetics   [77].  Another   factor  
influencing   the   release   behaviour   is   peptide   or   protein   aggregation   inside   of   the  
controlled   release  device   [172],   caused  by   the   interaction  of   the  dissolving  protein  or  
peptide  with   the   hydrophobic  matrix,   that  might   lead   to   unfolding   of   the   protein   or  
peptide   [173].   Therefore,   Reithmeier   et   al   (2001)   measured   the   adsorption   of   the  
peptides   on   the   lipid   matrix   of   their   microparticles   and   connected   an   incomplete  
release   to   an   absorption   of   the   peptide   on   the   matrix   [77].   The   interaction   between  
proteins  or  peptides  and   solid   lipid  matrixes  are  poorly   investigated   so   far,  however  
many   investigations   on   the   interaction   of   peptides   and   lipid   membranes   have   been  
conducted  [174-­‐‑176].  Almeida  and  Souto  (2007)  [15]  stated  that   the   interactions  of   the  
lipid   matrix   with   lysozyme   might   have   induced   conformational   changes   of   the  
lysozyme.   In   our   study   peptides   of   different   molecular   weight   and   hydrophobicity  
were   incorporated   into   lipid   implants.   Their   release   was   measured   in   vitro   and   a  
correlation   between   the   release   behaviour,   their   molecular   weight   and   their  
hydrophobicity  was   tried   to   identify.   Furthermore,   the   interaction   between   the   lipid  
matrix   and   the  peptides  was   investigated   to   conclude   if   they   could  be   related   to   the  





5.2 Materials  and  methods  
5.2.1 Materials  
The  TRP2  long  peptide  (SVYDFFVWLKFFHRTCKCTGNFA-­‐‑OH)  was  purchased  from  
peptides   and   elephants   (Potsdam,   Germany).   Cholesterol   (CHOL),   purity   95%,   was  
purchased   from   AlfaAesar   (Karlsruhe,   Germany).   Soybean   Lecithin   (approx.   90%  
phosphatidylcholin)   was   purchased   from   APPLICHEM   LIFESCIENCE   (Darmstadt,  
Germany).   Trp-­‐‑Lys,   Trp-­‐‑Lys-­‐‑Lys,   Trp-­‐‑Lys-­‐‑Lys-­‐‑Lys,   Trp-­‐‑Phe   and   Trp-­‐‑Phe-­‐‑Phe   were  
purchased   from  Biomatik   (Cambridge,  Canada).   Insulin  was   purchased   from   Sigma-­‐‑
Aldrich   (Germany).   Peptide   1   (P1)   (SVYDFFVWLKFFHITCLCTGNFA–OH)   and  
peptide   2   (P2)   (SRYDKKRWLKKKHRTCKCTGNRA-­‐‑OH)   were   purchased   from  
GenScript   USA   Inc.   (Piscataway,   USA).   Puriﬁed   Quil-­‐‑A   (QA)   was   sourced   from  
Brenntag   Biosector   (Frederikssund,   Denmark),   a   lyophilised   powder,   was   used   as  
supplied.   Dynasan   114   (D114)   was   kindly   provided   by   SASOL   Germany   GmbH  
(Witten,   Germany).   Acetonitrile   was   purchased   from   VWR   (France).   Ultrapure  
deionised  water  having  a  conductivity  of  less  than  0.055  µμS/cm  (Milli-­‐‑Q  Water  systems,  
Millipore,   MA,   USA)   was   used   throughout   the   study.   All   other   chemicals   were   of  
analytical  grade.  
5.2.2 Preparation  of  lipid  implants  by  twin  screw  extrusion  
Implants   were   prepared   from   mixtures   of   soybean   lecithin,   CHOL,   D114,   with   and  
without   active   ingredient   and/or  QA  as  described   in  Chapter   Four.   Shortly,   soybean  
lecithin  and  D114  were  transferred  into  a  high-­‐‑grade  stainless  steel  beaker  for  milling  
in   a   swing   mill   Retsch   CryoMill   (Retsch   Technology,   Haan,   Germany).   After  
precooling   the   system  with   liquid   nitrogen   for   10  min   at   5  Hz,   soybean   lecithin   and  
D114  were  ground  for  1  min  at  25  Hz.  The  obtained  powder  was  mixed  by  hand,  using  
a  plastic  mortar  and  pestle,  with  the  remaining  ingredients.  The  ﬁnal  mixture  was  then  
gradually  blended  with  a  mix  of  Active  ingredient  and  QA  and  subsequently  fed  into  a  
twin-­‐‑screw   extruder   (small   size   extruder   ZE   5,   Three-­‐‑Tec,   Seon,   Switzerland).   The  
resulting  implants  had  a  diameter  of  2  mm  and  were  subsequently  cut  into  lengths  of  





5.2.3 In  vitro  release  from  implants    
Implants  were  cut  into  lengths  of  2.5  cm  and  incubated  at  37°C.  Release  from  implants  
was  performed  in  2  mL  Eppendorf  vials  containing  1.8  mL  PBS  (pH  7.4  or  pH  4,  0.01  
M,   0.05%   NaN3,   0.25%   SDS)   and   was   performed   by   complete   buffer   exchange   in   a  
Heidolph   1000   shaking   incubator   at   37   °C   and   10   rpm/min.   All   samples   were  
centrifuged   at   14000   rpm   (Mikroliterzentrifuge   Z   160   M,   Hermle   Labortechnik,  
Wehingen,   Germany)   for   10   minutes   to   remove   lipid   particulates.   Peptide  
concentrations   were   then   quantified   by   Reversed-­‐‑Phase   HPLC   (RP-­‐‑HPLC)   or   UV  
metrically.  
5.2.4 Adsorption  Test  
Peptides  were  incubated  in  1.8  ml  PBS  (pH  7.4,  0.01  M,  0.05%  NaN3,  0.25%  SDS)  at  37°C  
with  and  without  blank  implants  (implants  containing  only  lipids).  Four  pieces  of  0.5  
cm  long  implants  in  each  vial  were  used  in  this  study.  The  peptide  concentration  was  
measured  at  pre-­‐‑set  time  points  by  RP-­‐‑HPLC.    
5.2.5 Reversed-­‐‑Phase  HPLC  (RP-­‐‑HPLC)  for  peptide  quantification  
Peptides   were   quantified   by   RP-­‐‑HPLC   using   a   Dinoex   Ultimate   3000   HPLC   system  
(Dionex,   Softron  GmbH,  Germering,  Germany).  A   Phenomenex   Jupiter   5u  C4   300  Å  
column   (250  mm  x  4.60  mm,  Phenomenex,  Achaffenburg,  Germany)  and  an   injection  
volume  of   25   to   150  µμL  of   sample  was  used  depending  on   the  peptide.  The   running  
buffer  consisted  of  Acetonitrile  (0.1%  TFA)  and  H2O  (10%  Acetonitrile  and  0.1%  TFA),  
with  a  flow  rate  set  to  0.75  mL/min.    
5.2.6 UV-­‐‑Metric  quantification  
OVA,  lysozyme  and  insulin  were  detected  by  UV.  The  supernatant  was  measured  by  
UV  (Agilent  Technologies  8453)  at  a  wavelength  of  280  nm.  For  each  tested  mixture  an  
implant   containing   only   lipids  was   used   as   a   blank   for   the  UV  measurements.   Each  
implant  was  weighted   before   the   release   and   the   total   amount   of   protein   present   in  
each   implant  was   calculated   individually  using  a   standard   curve  prepared  by  an  11-­‐‑





1  mL  PBS.  All  measured   samples   lay  within   the   linear   part   of   the   standard   curve   (3  
mg/mL  –  5  µμg/mL).  
5.3 Results  and  discussion  
5.3.1 Release  of  molecules  with  different  molecular  weight  from  lipid  implants    
Chapter   Four   showed   that   the   TRP2   long  peptide,   having   a  molecular  weight   of   2.8  
kDa,  has   a  very   slow  and   incomplete   release  behaviour.   In   this  Chapter,   interactions  
between  peptide  and  lipid  implants  are  investigated  in  order  to  try  to  better  predict  the  
release   of   a   drug   out   of   the   lipid   matrix.   In  Chapter   Two   and  Chapter   Three,   the  
model   antigen   OVA,   having   a   molecular   weight   of   44   kDa,   was   used   for   different  
studies.   Initially,   molecules   of   different   molecular   weight   were   chosen   to   study   the  
influence  molecular  weight  has  on  the  release  out  of  the  lipid  systems.  Table  5-­‐‑1  shows  
the   molecular   weight   of   the   chosen   molecules   for   this   study,   lying   in   between   the  
molecular  weight  of  OVA  and  the  TRP2  long  peptide.  
Table  5-­‐‑1:  Molecules  with  their  molecular  weight,  hydropathy,  and  isoelectric  point.  
Molecule   Molecular  weight  
[kDa]  
Isoelectric  point   Hydropathy  –  Kyte  
Doolittle  
Ovalbumin   44   4.54   0  
Lysozyme   14.3   11.35   -­‐‑0.43  
Insulin   5.7   5.4   A  Chain:  0.18  
B  Chain:  0.22  
Figure   5-­‐‑1   shows   the   release   of   OVA,   lysozyme   and   insulin   from   lipid   implants  
composed  of  65%  CHOL,  15%  soybean  lecithin  and  20%  D114.  Implants  contained  2%  
of  OVA,  lysozyme  or  insulin  respectively,  with  and  without  0.3%  of  the  adjuvant  QA.  
The   first   assumption   implies   that   the   diffusion   of   the  molecule   out   of   the   pore   and  
channel   system   insight   the   implant,   plays   a   dominant   role   in   the   release   kinetics   as  
suggested  by  literature  [171].  Therefore,  it  was  assumed  that  molecules  with  a  smaller  
molecular  weight  should  diffuse  faster  out  of  the  implant  than  molecules  with  a  larger  
molecular   weight.   Opposite   to   the   assumption   made,   insulin,   having   the   smallest  
molecular  weight,   showed   the  slowest   release  behaviour,  with  a  nearly   linear   release  





insulin,  showed  a  much  faster  release,  of  merely  five  days,  half  as  long  as  the  release  of  
insulin   (Figure   5-­‐‑1).   OVA  was   released   over   a   period   of   ten   days,   showing   a   faster  
release  than  insulin  during  the  first  150  hours.  Even  though  insulin  and  OVA  are  both  
released  over  a  duration  of  ten  days,  the  release  profile  is  different.  Where  for  insulin  
we   observed   a   nearly   linear   release,   OVA   showed   a   burst   release  which   than   slows  
than  down  after  approximately  100  hours.    
  
Figure   5-­‐‑1:   Cumulative   release   of   molecules   with   different   molecular   weight   from   lipid  
implants  (OVA,  lysozyme  and  insulin  are  released).  (A)  without  QA.  (B)  with  QA.  Data  are  the  
mean  and  SD  of  3  independent  replicates.  
Chapter  Two   showed   that   the  presence  of  QA   in   the   implant   formulation   leads   to   a  
faster  and  more  complete  release  of  the  model  antigen  OVA.  This  result  was  confirmed  
for  OVA  as  well  as  for  insulin.  However,  QA  seems  to  have  no  influence  on  the  release  
of   lysozyme.   In  Chapter   Two   it   was   revealed   that   QA   forms   pores   on   the   implant  
surface  during  release.  This  led  to  the  assumption  that  the  presence  of  these  pores  was  
responsible   for   a   more   complete   OVA   release   when   QA   was   in   the   formulation.  
Considering  the  fact   that   this   is  not   true  for   lysozyme,   the  assumption  arises   that  not  
only   the   pore   formation,   but   also   some   interactions   between   QA   and   the   released  
molecule   are   influencing   the   release   behaviour   of   the   latter.   This   could   also   be   the  
reason  why  adverse   reactions   to  QA  VPGs   in   the   in   vivo   study  described   in  Chapter  
Four  were  more  extensive  than  to  QA+TRP2  VPGs.  QA  is  known  to  have  undesirable  
side  effects  [169].  It  exhibits   lytic  activities,  by  reacting  with  the  cholesterol   in  the  cell  





of  QA  was  observed  in  the  presence  of  CHOL  blocking  QA  to  interact  with  CHOL  in  
the  cell  membranes.  Possibly  similar  interactions  took  place  between  the  TRP2  peptide  
and   the   QA,   decreasing   the   toxicity   of   QA   in   the   TRP2+QA   VPGs.   These   results  
indicate   that   the   chemical   and   physical   characteristics   of   a   molecule   influence   the  
diffusion  out  of  the  implants  rather  than  their  size.    
Since  no  direct  relation  between  the  size  and  the  release  behaviour  could  be  identified,  
the   isoelectric  point   (IEP),  hence  the  net  charge,  of   the  molecules  at   the  release  buffer  
pH   7.4   was   taken   into   consideration   (Table   5-­‐‑1).   OVA   and   insulin   are   negatively  
charged,   lysozyme   positively.   At   first   sight,   it   appears   that   the   negatively   charged  
molecules  are  released  over  a  longer  period  of  time.  However,  to  confirm  or  refute  this,  
further  molecules  have  to  be  considered.    
5.3.2 Interaction  of  peptides  of  different  hydropathy  and  molecular  weight  with  
lipid  implants  
Since   the   size   gave   no   indication   about   the   release   behaviour   out   of   lipid   implants,  
peptides   with   different   hydropathy  were   chosen   to   investigate   the   relation   between  
release  rate  and  hydropathy  (Table  5-­‐‑2).  The  Kyte-­‐‑Doolittle  hydropathy  scale  was  used,  
taking  into  consideration  the  hydrophilic  and  hydrophobic  properties  of  each  of  the  20  
amino  acid  side-­‐‑chains  [177].  A  hydropathy  <  0  corresponds  to  hydrophilic  molecules,  
a  hydropathy  >  0  to  hydrophobic  molecules.  In  a  first  step,  the  release  of  small  peptides  
was  analysed  (Table  5-­‐‑2,  peptides  1  to  5)  to  comprehend  if  there  is  a  relation  between  
the  release  behaviour  and  the  hydropathy  of  the  peptide.  
Table  5-­‐‑2:  Peptides,  their  hydropathy,  molecular  weight  and  isoelectric  point.  





1   Trp-­‐‑Lys-­‐‑Lys-­‐‑Lys   -­‐‑3.16   588.73   10.84  
2   Trp  –Lys-­‐‑Lys   -­‐‑2.9   460.56   10.1  
3   Trp  –Lys   -­‐‑2.4   332.39   10.1  
4   Trp  –Phe   0.95   351.4   6.01  
5   Trp  –Phe-­‐‑Phe   1.56   498.5   6.01  
6   P2   -­‐‑1.99   28882.4   11.15  
7   TRP2  long  
peptide  
0.25   2834.31   9.02  





Figure  5-­‐‑2   shows   the   release  of   these  peptides   from   lipid   implants   composed  of   65%  
CHOL,  15%  soybean  lecithin  and  20%  D114.  Implants  contained  2%  peptide  and  0.3%  
of   QA.   The   release   rate   from   the   implants   did   not   show   a   correlation   with   the  
hydropathy  of  the  peptide.  However,  Figure  5-­‐‑2  shows  that  there  is  a  difference  in  the  
shape   of   the   release   curves   comparing   hydrophobic   and   hydrophilic  molecules.   The  
release  curve  of  Trp-­‐‑Phe  and  Trp-­‐‑Phe-­‐‑Phe  showed  steep  slopes  at  the  beginning  of  the  
release,  flattening  down  after  two  to  three  days.  The  curves  of  the  hydrophilic  peptides  
(Trp-­‐‑Lys,  Trp-­‐‑Lys-­‐‑Lys  and  Trp-­‐‑Lys-­‐‑Lys-­‐‑Lys)  on  the  other  hand  showed  a  steep  slope  at  
the   beginning   and   nearly   all   the   peptide   was   already   released   after   two   days.   This  
might  be  an  indication  that  the  hydropathy  does  not  influence  the  amount  of  peptide  
that  is  released  but  the  way  it  comes  out  of  the  implant  (i.e.  with  a  burst,  linear…).  Trp-­‐‑
Phe  and  Trp-­‐‑Phe-­‐‑Phe  present  the  same  release  speed  and  duration,  however,  after  nine  
days  a  complete  Trp-­‐‑Phe  was  observed,  but  merely  50%  of  Trp-­‐‑Phe-­‐‑Phe  was  released.    
  
Figure  5-­‐‑2:  Cumulative  release  of  peptide  with  different  hydropathy  from  lipid  implants  (at  pH  
7.4).  Data  are  the  mean  and  SD  of  3  independent  replicates.  
In   a   next   step,   the   adsorption   of   the   different   peptides   onto   lipid   implants   was  
investigated.  Protein  aggregation  inside  the  controlled  release  device  as  well  as  peptide  
interactions  with   the   hydrophobic   lipid  matrix   can   have   an   influence   on   the   release  





different   time   frames,   with   and   without   blank   implants   (implants   containing   only  
lipids).  
Figure   5-­‐‑3   presents   the   changes   in   peptide   concentration   over   time   for   the   different  
samples.  Figure  5-­‐‑3  confirms  that  when  blank  implants  were  present  in  the  sample,  the  
decrease   in   peptide   concentration   over   time   was   greater   than   in   the   absence   of  
implants.   By   comparing  Figure   5-­‐‑3  A   and  B,   it   becomes   clear   that   in   the  presence   of  
implants,   the  concentration  of  peptides  with  a  hydropathy  >  0  decreased  much  faster  
than   for   peptides   having   a   hydropathy   <   0.   As   expected,   hydrophobic   peptides  
adsorbed  much   faster   to   the   implants,   showing   the   important   role  hydropathy  plays.  
The  concentration  of  Trp-­‐‑Phe  decreased   to  73%  after  seven  days.  For  Trp-­‐‑Phe-­‐‑Phe  an  
even   more   substantial   alter   in   concentration   could   be   observed,   after   seven   days  
merely  40%  of  the  peptide´s  initial  concentration  were  measurable  in  the  PBS  buffer.  In  
samples  containing  no  lipid  implants,  the  concentration  decreased  no  more  than  12%,  
even  after  7  days  incubation,  whether  the  peptide  was  hydrophilic  or  hydrophobic  did  
not  make  a  difference.  
  
Figure  5-­‐‑3:  Indicates  the  percentage  of  peptide  present  in  PBS  for  different  peptides  (Table  5-­‐‑2,  
peptides  1  to  5)  after  different  incubation  durations  with  and  without  blank  implant  present  in  
the  sample.  (A)  Peptides  with  a  hydropathy  <  0.  (B)  Peptides  with  a  hydropathy  >  0.  Data  are  
the  mean  and  standard  deviation  (SD)  of  3  independent  replicates.  
All   peptides   used   in   the   previous   study   were   short   peptides,   but   all   of   different  
molecular  weight.  Therefore,   two  peptides  of  the  same  molecular  weight  as  the  TRP2  





more   hydrophobic   and   P2   more   hydrophilic   than   the   TRP2   peptide.   The   same  
experiment   as   described   previously  was   performed;   peptides  were   incubated   in   PBS  
with  and  without  blank  implants.  Figure  5-­‐‑4  shows  the  results  of  this  study.  After  only  
one  day  incubation,  there  was  no  more  TRP2  measurable  in  the  sample  containing  the  
blank   implant.   The   same   holds   true   for   the   P2   peptide.   A   different   behaviour   was  
observed   for   the   P1   peptide,   the   concentration   decreased   gradually,   showing   a  
decrease  of  30%  after  one  day,  going  further  down  to  a  remaining  concentration  of  14%  
P1  after  seven  days  incubation  with  lipid  implant  in  the  sample.  This  was  the  opposite  
of  what  was  expected  considering  the  results  from  the  previous  study  (Figure  5-­‐‑3),  as  
P2  is  more  hydrophilic  than  P1.  The  concentrations  in  the  samples  containing  only  PBS  
on  the  other  hand  decreased  only  slightly  (no  more  than  10%  over  seven  days)  for  the  
three   studied  peptides.  This   result   is   consistent  with   the   results   from   the   experiment  
performed  with  the  short  peptides.  
  
Figure  5-­‐‑4:  Percentage  of  peptide  present  in  PBS  for  different  peptides  (Table  5-­‐‑2,  peptide  P1,  P2  
and  TRP2)   after   incubation   up   to   seven   days  with   and  without   blank   implant   present   in   the  
sample.  Data  are  the  mean  and  SD  of  3  independent  replicates.  
Since   the   two   studies   led   to   conflicting   results   concerning   the   absorption   behaviour  
onto   the   implants   in   relation  with   the   hydropathy,   peptides   of   the   two   studies  were  
compared.  Considering  the  hydropathy  of  peptide  P1  and  P2,  it  can  be  noticed  that  the  





P2   and   Trp-­‐‑Lys.   The   main   difference   between   the   two   peptides   in   each   pair   is   the  
molecular  weight.  Figure  5-­‐‑5  shows  the  data  for  those  four  peptides.  Even  though  the  
hydropathy   is   the   same,   the   behaviour   of   the   peptides   was   different.   These   results  
indicate  that  neither  the  hydropathy  nor  the  size  alone  influenced  the  behaviour  of  the  
peptides  when  incubated  together  with  lipid  implants.  The  fact  of  how  fast  a  peptide  
adsorbs   on   the   lipid   implants   correlated   well   with   the   hydropathy   value   for   short  
peptides   (two  to   four  amino  acids).  This  correlation  could  not  be  observed  for   longer  
peptides.  The  folding  of  the  peptide  might  also  play  a  role,  and  should  be  investigated.  
Conformational  changes  of  lysozyme  due  to  interactions  with  a  lipid  matrix  have  been  
stated  by  Almeida  and  Souto   (2007)   [15].  Therefore,   the  conformation  of   the  peptides  
should  be  further  analysed.  The  correlation  for  shorter  peptides  was  maybe  very  good  
because   there  are  not  many  possible  ways   for   them  to   fold,  which   is  not   the  case   for  
lager  peptides.    
  
Figure  5-­‐‑5:  Indicates  the  percentage  of  peptide  present  in  PBS  for  different  peptides  (Table  5-­‐‑2,  
peptides   3,4,6   and   8)   after   different   incubation   durations   with   and   without   blank   implant  
present  in  the  sample.  (A)  Peptides  with  a  hydropathy  >  0.  (B)  Peptides  with  a  hydropathy  <  0.  
Data  are  the  mean  and  SD  of  3  independent  replicates.  
5.3.3 Interaction  of  peptides  with  pure  lipids  
As   the   implants   consist   of   a  mixture   of   CHOL,  D114   and   soybean   lecithin,   peptides  
TRP2,  P1  and  P2  were  incubated  with  each  of  the  lipids  individually,  in  order  to  see  the  
effect   each   lipid   has   on   peptide   concentration.   Figure   5-­‐‑6   shows   the   change   in  





data  clearly  showed  that  all   three  peptides  strongly   interacted  with  cholesterol.  After  
one  day,  an  important  concentration  decrease  was  noticed  for  all  three  peptides.    
  
Figure  5-­‐‑6:   Indicates   the  percentage  of  peptide   incubated   in  PBS  at  37°C   together  with  either,  
D114,  soybean  lecithin  or  CHOL,  for  different  peptides  (TRP2,  P1  and  P2)  at  day  0,  after  1  day  






Incubated  together  with  cholesterol,  already  after  one  day,  there  was  no  P2  measurable  
in  the  sample  anymore.  The  same  was  observed  for  P1  after  seven  days.  TRP2  reacted  
least   with   cholesterol,   after   seven   days   there   were   still   50%   of   the   initial   TRP2  
concentration  measurable.    
All   three   peptides   interacted   also   with   soybean   lecithin,   already   after   day   one,   a  
decrease  in  concentration  could  be  determined.  According  to  the  results  of  this  study,  
peptides   interacted   least   with   the   D114.   One   assumption   is   that   as   cholesterol   and  
lecithin   are   amphiphilic  molecules,   there   is  more   room   for   interaction   than  with   the  
D114.   Furthermore,   lecithin   is   known   to   form   lamellar   structures,   and   some   of   the  
peptide   could   be   enclosed   into   micelles   or   liposomal   structures   when   incorporated  
together   with   lecithin.   The   interaction   with   all   three   lipids   was   strongest   for   the  
peptide   P2,   even   though   P2   is   the  most   hydrophilic   of   the   three   analysed   peptides.  
These  results  confirmed  the  data  obtained  from  the  previous  study,  showing  that   the  
interaction  between  the  lipids  and  the  larger  peptides  is  not  in  direct  correlation  with  
the  hydropathy  of  the  considered  peptide.  
5.4 Conclusion  
This  chapter  aimed  to  investigate  the  potential  influence  size  and  hydropathy  have  on  
the  release  out  of  lipid  implants.  It  was  demonstrated  that  not  size  alone  plays  a  role  in  
the  release  rate  of  a  molecule  from  the  lipid  matrix.  Besides  the  size,  the  hydropathy  of  
a  peptide  in  relation  with  its  release  was  also  analysed.  No  direct  relation  between  the  
hydropathy  and  the  release  rate  was  identified  for  peptides.  Merely  the  release  profile  
showed   similarities   for   peptides   of   the   same   hydropathy   whether   they   were  
hydrophilic   or   hydrophobic.   Furthermore,   the   role   that   the   adjuvant   plays   in   the  
release  has  been  reweighed.   It  appeared   that  not  only   the  pore   former  quality  of  QA  
has   to  be  considered,  but  also   the  possibility  of   interactions  between   the  peptide  and  
the  adjuvant  should  be  considered.  When  examining   the  adsorption  of  peptides  onto  
the   lipid   implants,   there  was  a  nice  correlation,   indicating   that  hydrophobic  peptides  
adsorbed   faster   than   hydrophilic   peptides.   However,   this   was   only   true   for   short  
peptides.  When  analysing  peptides  of  higher  molecular  weight  (P1,  P2  and  TRP2)  the  





hydropathy  of   the  peptides  allow   to  predict   the   release  behaviour  or   the   interactions  
with   the   implant.   It   is   assumed   that   the   folding   of   the   molecules   might   play   an  
important   role  and  should  be   investigate.  Furthermore,  a  broader   range  of  molecules  
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6 Summary  and  future  work  
As  discussed  in  Chapter  One,   the  delivery  of  subunit  vaccines  in  a  sustained  manner  
results   in   most   cases   in   a   better   immune   response   than   given   by   one   or   multiple  
booster   injections.   Furthermore,   sustained   delivery   systems   allow   to   reduce   the  
number   of   immunisations   and   thereby   make   the   need   for   multiple   administrations  
redundant.   Different   delivery   systems,   consisting   of   different   materials,   have   been  
discussed,   each   presenting   its   own   advantages   and   disadvantages.   However,   an  
optimal   system  has  not  been   found   jet,   showing   the  need   to   carry  on   the   research   in  
this   area,   as   new,   optimized   delivery   systems   are   essential   for   the   successful   use   of  
subunit  vaccines  in  the  future.  
The  work  presented  in  this  thesis  investigated  the  use  of  lipid  implants  as  systems  for  
the  sustained  delivery  of  subunit  vaccines.  They  appear  to  be  well  tolerated  in  a  mouse  
model   and  were  able   stimulate  antibody  production  as  well   as  T   cell   expansion.  The  
production   of   these   lipid   systems   by   twin-­‐‑screw   extrusion  makes   the   production   of  
large   batch   sizes   possible   within   a   small   amount   of   time.   These   lipid   systems   are  
promising  candidates  for  the  future  of  sustained  vaccine  delivery.  
The  successful  preparation  by  direct  compression  and  the  immune  response  stimulated  
by  such  lipid  implants  was  described  in  literature  [28,29].  However,  the  preparation  of  
lipid  implants  for  vaccine  delivery  by  twin-­‐‑screw  extrusion  has  not  been  investigated  
before.  In  Chapter  Two  the  search  for  an  extrudable  mixture  was  described  as  well  as  
the  important  parameters  for  the  extrusion  process.  Different  extrudable  mixture  were  
identified   and   the   release   behaviour   of   the  model   antigen  OVA  was   investigated.   It  
was   shown   that   the   composition   of   the   lipid   formulation   influenced   the   release   of  
OVA.  Particularly  the  amount  of  cholesterol  in  the  mixture  affected  the  release  of  OVA,  
showing   that   higher   amounts   of   cholesterol   in   the   formulation   led   to   a   slower  OVA  
release.   In   the   investigated   implant   systems,   the   adjuvant  QA  was  used,   as  previous  
studies   indicated   that   it   proves   to   be   the   most   effective   adjuvant   for   these   systems  
[29,178].  In  Chapter  Two  it  was  shown  that  the  presence  of  the  QA  in  the  formulation  
influenced  the  release  of  OVA  from  the  implants.  When  QA  was  present,  OVA  release  





forms  pores  on  the  implant  surface,  explaining  why  the  OVA  release  is  more  complete  
when   there   is   QA   in   the   system.  Moreover,   the   treatment   of   implants   by   heat   after  
extrusion  made  it  possible  to  slow  down  the  OVA  release  from  the  implants  up  to  14  
days,   compared   to   a   release   duration   of   seven   days   without   the   curing   step.  
Furthermore,   the   release   of   QA   from   the   implants   was   investigated,   as   literatures  
showed   that   an   optimal   immune   response   could   be   achieved  when   the   antigen   and  
adjuvant   are   released   together   [128].   Results   indicated   that   QA   is   released   over   a  
period   of   12   days   from   our   implants,   thereby   longer   than   OVA   was   released.   This  
implies   that   as   long   as   OVA   is   released,   there   is   also   adjuvant   released   from   the  
implants,   increasing   the  chance   that  a  strong   immune  response  can  be   trigged  by   the  
investigated   implants.  What  was  observed   for   the   release  of  OVA   in  presence  of  QA  
holds  also  true  for  the  release  of  the  adjuvant.  The  presence  of  OVA  in  the  formulation  
enhances   the   release  of  QA   from   the   implants.  Thus,  Chapter  Two  proved   that   lipid  
implants  can  be  produced  by  twin-­‐‑screw  extrusion  and  that  a  reasonable  antigen  and  
adjuvant  release   from  the   implants  could  be  obtained.  As   the   lipids  undergo   thermal  
and  mechanical  stress  during  the  extrusion  process,   the  polymorph  state  of   the   lipids  
was   investigated   in   Chapter   Three.   Neither   the   extrusion   process,   nor   storing   the  
implants  did  change  the  polymorphism  of   the   lipids.  Also  the  mechanical  strength  of  
the  implants  stayed  stable  during  storage.  However,  when  investigating  the  release  of  
implants   stored   over   several  months,   a   change   in   the   release   of  OVA  was   observed.  
The  longer  the  implants  were  stored,  the  shorter  and  less  complete  OVA  was  released.  
This   observation   could   not   be   correlated  with   changes   in   polymorphism   or  melting  
energy   in   the   implants.  The  assumption   that   interactions  between  OVA  and  the   lipid  
matrix   takes   place   occurred.   This   should   be   further   investigated   by   trying   to  
investigate  the  state  OVA  is  in  when  released  from  the  implants.  Another  explanation  
could  be  the  rearrangement  of  the  lipid  matrix  during  storage.    
To   investigate   the   compatibility   of   the   produced   implants,   an   in   vivo   study   was  
conducted   in   a   mouse   model.   The   in   vivo   release   of   OVA   was   studied   and   the  
advantage   of   depot   versus   double   shot   was   investigated.  Chapter   Three   shows   the  
data   of   these   studies.  The   in   vivo   release   correlated  nicely  with   the   in   vitro   data,   and  





was   comparable   for   implants   containing   QA   and   the   injection   group.   These   results  
indicate   the   importance   of   the   adjuvant   in   such   vaccine   delivery   systems.   Implants  
showing   an  OVA   release   of   seven   days   resulted   in   the   same   immune   response   than  
two  injections  given  at  day  one  and  day  14.  An  interesting  future  approach  would  be  to  
test   the   cured   implants   in  vivo   and  compare   them   to  double  OVA  shots,   as   the  OVA  
release   in   vitro   from   the   cured   implants   is   double   as   long   as   from   the   implants  
investigated   in   the   in   vivo   study   presented   in  Chapter   Three.   Furthermore,   cytokine  
secretion   was   analysed   to   examine   antigen-­‐‑specific   effector   function.   The   results  
indicated   that   a   Th1   response  was   observed   for   the   groups   receiving  QA   containing  
implants.  
Considering   the   promising   results   obtained   from   the   in   vivo   studies  while   using   the  
model   antigen  OVA,  Chapter   Four   investigated   the   use   of   these   implant   systems   in  
tumour   therapy   in   a   mouse   model.   For   this   purpose   a   non-­‐‑mutated   melanoma-­‐‑
associated  antigen,  namely  the  TRP2  peptide  was  incorporated  into  the  implants.  First  
the   production   device   had   to   be   changed   to   a   small   size   extruder,   enabling   the  
production  of   small  batch   sizes.  The   characteristics  of   implants  produced  by   the   two  
different   extruders   were   compared.   Results   clearly   showed   that   a   transfer   from   one  
extruder   device   to   another   couldn’t   be   performed   without   adjusting   the   extrusion  
parameters   and   lipid   formulation,   if   the   same   implant   characteristics   are   to   be  
maintained.   Implants  and  VPGs  containing  QA  and  TRP2  were  produced   to  perform  
an   in  vivo   tumour  growth  study.  VPGs  were  considered  an   interesting  alternative   for  
our   experiment   as   numerous   studies   describe   the   use   of   liposomal   systems   as   TRP2  
carriers   [160,162,163].   In   vitro   release   of   TRP2   turned   out   to   be   slow   and   incomplete  
from  both  systems,  VPGs  and   implants.   In  vivo,   the   two  systems  were  compared  to  a  
no-­‐‑treatment  group  and  one  group  of  mice  receiving  TRP2  in  PBS  injections.  There  was  
a  statistical  difference  between  the  TRP2+QA  implants  and  the  no  treatment  group.  On  
the  other  hand,   the  TRP2   in  PBS   injection  achieved  the  same  results  as   the  TRP2+QA  
implants.  VPGs  were  not  well  tolerated  by  the  mice  and  were  therefore  considered  as  a  
non-­‐‑suitable   system.  Most   likely   the   adverse   reactions   are   due   to   the   QA,   as   QA   is  
known   to  be  have  undesirable   side  effects   [169].   In  our   study,   the  VPG  contained  no  





swelling,   redness   or   skin   irritation   observed.   The   CHOL   present   in   the   implants  
probably   interacts  with   the  QA,   thereby  withdrawing   the   toxicity  of  QA.  To   confirm  
this  assumption,  VPGs  containing  no  QA  would  have  to  be  administered  to  the  mice.  
Furthermore,   adverse   reactions  were   less   severe   for  VPGs   containing  TRP2+QA   than  
for  VPGs  containing  only  QA.  We  suppose  that  some  interactions  between  the  peptide  
and   the   QA  might   take   place,   thereby   decreasing   the   toxicity   of   QA.   Therefore,   the  
interaction  between  the  peptide  and  QA  should  also  be   investigated.  Also   testing  the  
VPGs   for   their   endotoxin   level   should   be   considered   before   deciding   if   VPGs   are  
adequate  delivery  systems  or  not.  Another  interesting  question  arising  from  this  in  vivo  
study  is  related  to  the  results  showing  that  TRP2+QA  implants  have  the  same  effect  as  
the  TRP2+PBS  injections.  Both  formulations  were  able  to  delay  tumour  growth.  A  total  
dose   of   56   µμg   TRP2   was   administered   to   each   animal.   In   the   injection   group   mice  
received  56  µμg  TRP2  at  once  whereas  much  lower  amounts  of  TRP2  were  released  from  
the  TRP2+QA  implants.  The  in  vitro  release  of  TRP2  out  of  the  implants  showed  that  at  
the  moment   tumours  were  starting   to  grow;  only  1.89%  of   the  peptide  were   released  
(approximately   1.12   µμg   TRP2).   This   brings   us   to   reconsider   the   implants   as   a  
therapeutic   vaccine   system.   A   prophylactic   use   of   the   implants   as   tumour   vaccine  
might  be  more  appropriate.  In  the  cancer  setting  TRP2+QA  implants  might  be  able  to  
inhibit   the  growth  of  a   tumour  when  a   low  tumour  burden   is  present.  To   investigate  
the  future  use  of  these  implants,  first  the  release  of  TRP2  in  vivo  should  be  analysed.  In  
a  next  step,  a  prophylactic  in  vivo  study  would  have  to  be  performed,  administering  the  
implants  first  and  afterwards  the  tumour  cells.    
In  Chapter   Five   the   interactions   of   peptides   and   lipid   implants  were   investigated   in  
order   to   better   predict   the   release   of   a   drug   from   the   lipid   matrix.   The   slow   and  
incomplete  release  observed  for  TRP2  raised  questions  about  what  drug  characteristics  
influence   the   release   out   of   the   lipid  matrix.  Up   to   present,   the   common   knowledge  
was   that  diffusion  plays   a  major   role   in   the   release  of  molecules   from   lipid   implants  
[171].   Consequently,   larger   molecules   should   be   released   slower   than   smaller   ones.  
Though  our  results  showed  that  OVA  was  released  much  faster  than  TRP2,  which  is  a  
much   smaller   molecule.   This   observation   led   to   the   assumption   that   maybe   some  





release   of   a   molecule,   rather   that   the   size   of   the   molecule.   Literature   suggests   that  
another   factor   influencing   the   release   behaviour   is   peptide   or   protein   aggregation  
inside  of  the  controlled  release  device  [172],  caused  by  the  interaction  of  the  dissolving  
protein   or   peptide  with   the   hydrophobic  matrix   that  might   lead   to   unfolding   of   the  
protein  or  peptide  [173].  This  is  a  really  important  point,  which  should  be  investigated,  
in  order   to   try  and  predict   the   release  of  a  molecule   from  a   lipid   implant   system.  To  
learn  more  about  the  interactions  between  lipid  implants  and  peptides,  we  investigated  
the  adsorption  behaviour  of  peptides,  characterized  by  different  hydropathies,  on  the  
lipid  matrix.  No  direct  correlation  between  size,  hydropathy  and  the  release  behaviour  
could  be   identified.  Only  when  considering  short  peptides,  a  correlation  between   the  
hydropathy   and   the   adsorption   behaviour   on   lipid   implants   could   be   identified.   But  
this  was  not  true  for  larger  peptides.  We  assume  that  the  interactions  between  peptides  
and   the   lipid   implants   are  dependent   on   the   folding   of   the  peptides.   This   should   be  
investigated  by  analysing  the  folding  of  peptides  of  different  hydropathie  and  different  
size  before  and  during  incubation  with  and  without  lipid  implants  present.  Including  
peptide   folding   could  offer   valuable   clues  on   the   release  behaviour  of  peptides   from  
lipid  implants.    
Another   controversial   subject   is   the   size   of   the   implants.   The   implants   used   in   our  
studies  had  a   cylindrical   shape  with  a  diameter  of  2  mm.  The   length  of   the   implants  
was   varying,   using   for   example   a   size   of   5  mm   for   the   in   vivo   studies.   The   question  
arises  if  a  smaller  size  should  be  used  for  further  investigations.  Table  6.1  shows  some  
of  the  implants  approved  for  human  use  as  well  as  their  size.  Implanon®  and  Zoladex®,  
implants   applied   s.c.,   they   are   both   longer   than   the   implants   used   in   our   in   vivo  
study,except   for   Zoladex®   having   a   smaller   diameter   than   implants   in   our   study.  
Intravitreal   implants   seem   to   be   smaller   in   size   than   our   systems,   but   Retisert®   for  
example   is   also   5  mm   long   and   has   a  width   of   2  mm.   Compared   to  what   is   on   the  
market,   the   implants   analysed   in   this   work   seem   to   have   a   reasonable   size   for   s.c.  
application.  However,   smaller   sized   implants,   resulting   in   the  use  of  a   smaller   trocar  
for   application,  would  of   course   increase  patience   compliance  and  make   implants  an  
even   more   attractive   delivery   system.   Therefore,   the   investigation   of   smaller   sized  





delivery  systems.  In  case  that  the  implants  would  be  used  at  some  point  in  veterinary  
medicine,  these  size  considerations  would  be  of  less  importance.    
Table  6-­‐‑1:  Examples  of  implants  approved  for  human  use  and  their  size    
Name   Active  component   Application   Size  
Implanon®(Nourypharma  GmbH)   etonogestrel   s.c.   d:  2  mm  
l:  4  cm  
Zoladex®  (Zeneca)   goserelinacetate   s.c.   d:  1  mm  
l:  1.5  cm  
Retisert®(Bausch  and  Lomb)   fluocinolone  acetonide   intravitreal   l:  5  mm  
w:  2  mm  
h:  1.5  mm  
Ozurdex®  (Allergan)   dexamethasone   intravitreal   d:  0.45  mm  
l:  6.5  mm  
Iluvien®  (Alimera)   fluocinolone  acetonide   intravitreal   d:  0.37  mm  
l:  3.5  mm  
  
*  d:  diameter,  l:  length,  w:  width,  h:  height    
The   work   conducted   in   this   thesis   showed   that   lipid   implants   are   an   interesting  
candidate   for   sustained   vaccine   delivery.   But   the   results   also   indicated   that   at   the  
moment   there  are  no  reliable  criteria   to  predict   the  release  behaviour   from  such   lipid  
systems.   Lipid-­‐‑peptide   interactions   seem   to   play   a   major   roll.   It   would   be   of   great  
interest  to  further  investigate  these  interactions  to  gain  better  understanding  of  the  role  
they  play  in  the  peptide  release  behaviour  from  lipid  implants.    
In   conclusion,   biodegradable   lipid   implants   produced   by   twin-­‐‑screw   extrusion   show  
great   promise   as   sustained   vaccine   delivery   systems.   They   show   good  
biocompatibility,  good  biodegradability  and  producing  them  by  twin-­‐‑screw  extrusion  
easily  enables  the  production  of  large  batch  sizes,  therefore  their  development  should  
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8.1 Appendix  A  
Solutions  used  in  this  thesis  
Solutions  for  in  vitro  release  studies  
  
PBS  pH  7.4  
Na2HPO4  *  H2O                    1.44  g  
KH2PO4                       0.2  g  
NaCl                          8  g  
KCl                          0.2  g  
NaN3                          0.5  g  
Distilled  water  to                    1000  mL  
  
Solutions  used  for  Enzyme-­‐‑linked  Immunosorbent  Assays  (ELISAs)    
  
0.1  M  Carbonate-­‐‑Bicarbonate  buffer  pH  9.6    
Sodium  carbonate  (Na2CO3)                 0.318  g    
Sodium  hydrogen  carbonate  (NaHCO3)           0.586  g    
Milli-­‐‑Q  water  qs  to                    200  mL    
Adjust  pH  to  9.6    
(This  buffer  was  also  used  for  coating  of  plates  with  anti-­‐‑CD3)    
  
Wash  Buffer    
Phosphate  buffered  saline                 1000  mL    
Tween  20                       500  µμL    
Adjust  pH  to  7.4    
    





Blocking  Buffer    
Phosphate  buffered  saline                 200  mL    
Bovine  serum  albumin  (BSA)              4  g    
Adjust  pH  to  7.4    
    
Assay  Buffer    
Wash  Buffer                       200  mL    
Bovine  serum  albumin  (BSA)              1  g    
Adjust  pH  to  7.4      
  
Cell  culture  work  
Lysis  Buffer    
(A)  0.16  M  Ammonium  chloride  (NH4Cl)  solution    
Ammonium  chloride                   8.29  g    
Milli-­‐‑Q  water  to                    1000  mL    
Adjust  pH  to  7.4    
(B)  0.17  M  Tris  hydrochloride  (Tris-­‐‑HCl)  solution    
Tris-­‐‑HCl                       20.6  g    
Milli-­‐‑Q  water  to                    1000  mL    
Adjust  pH  to  7.65    
Mix  9  parts  of  solution  A  with  1  part  of  solution  B,  filter  sterilise  through  a  0.22    
µμm  filter  prior  to  use.  
  
Fluorescence-­‐‑activated  cell  sorting  (FACS)  buffer    
Sodium  azide  (NaN3)                   0.1  g    
Bovine  serum  albumin  (BSA)              10.0  g    
PBS  (pH  7.5)  to                    1000  mL    
  
Complete  Iscove'ʹs  Modified  Dulbecco'ʹs  Medium  (cIMDM)    
Penicillin/Streptomycin  solution              10.0  mL    





Foetal  calf  serum  (FCS)                   50.0  mL    
Glutamax                       10.0  mL    
IMDM  to                       1000  mL    
  
Complete  RPMI  Medium  
Sodium  carbonate  (Na2CO3)                 2  g  
D-­‐‑glucose                       4.5  g  
Penicillin/Streptomycin  solution              10.0  mL    
Foetal  calf  serum  (FCS)                   100.0  mL    
Glutamax                       10.0  mL    
Sodium  Pyruvate                    10  mL  
RPMI  to                       1000  mL  





8.2 Appendix  B  
Scanning  electron  micrographs  of  the  surface  of  cured  implants.  
  
Figure  B  -­‐‑  1:  Scanning  electron  micrographs  obtained  from  lipid  implants  after  curing.  at  40°C,  
45°C,  50°C  respectively  55°C.  Scale  bar  =  10  µμm.  Magnification  500  x.  
  
Figure  B  -­‐‑  2:  Scanning  electron  micrographs  obtained  from  blank  lipid  implants  after  14  days  in  
PBS  buffer   (pH  7.4)  at  37°C.   Implants  were  cured  at  40°C,  45°C,  50°C  respectively  55°C.  Scale  






Figure   B   -­‐‑   3:   Scanning   electron  micrographs   obtained   from  OVA+QA   lipid   implants   after   14  
days  in  PBS  buffer  (pH  7.4)  at  37°C.  Implants  were  cured  at  40°C,  45°C,  50°C  respectively  55°C.  
Scale  bar  =  10  µμm.  Magnification  500  x.  





8.3 Appendix  C  
Additional  data  from  the  in  vivo  study  described  in  Chapter  Three  
  
Figure   C   -­‐‑   1:   OVA-­‐‑specifc   IgG   antibody   titres   determined   by   ELISA   on   day   28.   Mice   were  
immunized   with   blank   implants   (-­‐‑   Implant),   implants   containing   OVA   or   OVA/QA   either  
incorporated  directly   into   the   lipid  mix   (OVA   Implant,  OVA/QA   Implant)  or   formulated   into  
liposomes  which  were   then   freeze-­‐‑dried  and   incorporated   into   the   lipid  mix   (Lip   Implant)  or  
with  OVA  in  alum  (Alum).  Data  shown  are   the   individual  results   from  4  mice  per  group  and  








Figure   C   -­‐‑   2:   OVA-­‐‑specifc   IgG   antibody   titres   determined   by   ELISA   on   day   28.   Mice   were  
immunized   with   blank   implants   (-­‐‑   Implant),   implants   containing   OVA   or   OVA/QA   either  
incorporated  directly   into   the   lipid  mix   (OVA   Implant,  OVA/QA   Implant)  or   formulated   into  
liposomes  which  were   then   freeze-­‐‑dried  and   incorporated   into   the   lipid  mix   (Lip   Implant)  or  
with  OVA  in  alum  (Alum).  Data  shown  are   the   individual  results   from  4  mice  per  group  and  
the  mean  and  SEM.    
  
  
Figure  C   -­‐‑   3:   Interferon-­‐‑γ   concentrations   for   spleen   samples   restimulated   in   vitro  with  OVA.  
Mice  were  immunized  with  blank  implants  (-­‐‑  Implant),  implants  containing  OVA  or  OVA/QA  
either  incorporated  directly  into  the  lipid  mix  (OVA  Implant,  OVA/QA  Implant)  or  formulated  
into  liposomes  which  were  then  freeze-­‐‑dried  and  incorporated  into  the  lipid  mix  (Lip  Implant)  







Figure  C  -­‐‑  4:  Transgenic  CD4+  T  cell  proliferation,  as  a  percentage  of  divided  CD4+  T  cells.  Mice  
were  immunized  with  blank  implants  (-­‐‑  Implant),  implants  containing  OVA  or  OVA/QA  either  
incorporated  directly   into   the   lipid  mix   (OVA   Implant,  OVA/QA   Implant)  or   formulated   into  
liposomes  which  were   then   freeze-­‐‑dried  and   incorporated   into   the   lipid  mix   (Lip   Implant)  or  
with  OVA  in  alum  (Alum).  The  adoptive   transfer  of  CFSE  stained  cells  was  performed  at   (A)  
day  1,  (B)  day  7,  or  (C)  day  14.  Data  shown  are  the  individual  results  from  five  mice  per  group  
plus  the  mean  and  SEM  





8.4 Appendix  D  
TRP2  release  from  lipid  implants  
  
Figure   D   -­‐‑   1:   Cumulative   release   of   TRP2   from   implants   produced   by   the   ZE   5   extruder.  
Implants   consist  of  65%  CHOL,  15%  soybean   lecithin  and  20%  D114,   containing  0.53  mg  QA,  
0.28  mg  TRP2  Data  are  the  mean  and  SD  of  3  independent  replicates.  
  
  
